WO2011020033A2 - Engineered proteins including mutant fibronectin domains - Google Patents
Engineered proteins including mutant fibronectin domains Download PDFInfo
- Publication number
- WO2011020033A2 WO2011020033A2 PCT/US2010/045490 US2010045490W WO2011020033A2 WO 2011020033 A2 WO2011020033 A2 WO 2011020033A2 US 2010045490 W US2010045490 W US 2010045490W WO 2011020033 A2 WO2011020033 A2 WO 2011020033A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- engineered protein
- engineered
- domain
- cells
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 339
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 325
- 108010067306 Fibronectins Proteins 0.000 title claims description 65
- 102000016359 Fibronectins Human genes 0.000 title claims description 33
- 238000000034 method Methods 0.000 claims abstract description 63
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 36
- 201000011510 cancer Diseases 0.000 claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims description 271
- 108060006698 EGF receptor Proteins 0.000 claims description 131
- 102000001301 EGF receptor Human genes 0.000 claims description 130
- 102000005962 receptors Human genes 0.000 claims description 95
- 108020003175 receptors Proteins 0.000 claims description 95
- 150000001413 amino acids Chemical class 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 49
- 108060003951 Immunoglobulin Proteins 0.000 claims description 48
- 102000018358 immunoglobulin Human genes 0.000 claims description 48
- 238000011282 treatment Methods 0.000 claims description 46
- 150000007523 nucleic acids Chemical class 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 210000004899 c-terminal region Anatomy 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
- -1 PDGF Proteins 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 230000001413 cellular effect Effects 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 229960005395 cetuximab Drugs 0.000 claims description 11
- 239000013612 plasmid Substances 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 9
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 8
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 8
- 229960001972 panitumumab Drugs 0.000 claims description 8
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 239000005090 green fluorescent protein Substances 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 7
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims description 5
- 239000012216 imaging agent Substances 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 231100000331 toxic Toxicity 0.000 claims description 5
- 230000002588 toxic effect Effects 0.000 claims description 5
- 108010070675 Glutathione transferase Proteins 0.000 claims description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 101001004623 Homo sapiens Lactase-like protein Proteins 0.000 claims description 3
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 108091008553 MuSK receptors Proteins 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 108091008552 RYK receptors Proteins 0.000 claims description 3
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims description 3
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 101710154606 Hemagglutinin Proteins 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 101710176177 Protein A56 Proteins 0.000 claims description 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 239000000185 hemagglutinin Substances 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 102000005720 Glutathione transferase Human genes 0.000 claims 2
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 223
- 230000027455 binding Effects 0.000 description 88
- 235000001014 amino acid Nutrition 0.000 description 67
- 239000011230 binding agent Substances 0.000 description 66
- 229940024606 amino acid Drugs 0.000 description 65
- 230000003828 downregulation Effects 0.000 description 62
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 57
- 101800003838 Epidermal growth factor Proteins 0.000 description 56
- 229940116977 epidermal growth factor Drugs 0.000 description 56
- 102400001368 Epidermal growth factor Human genes 0.000 description 55
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 49
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 47
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 34
- 230000004927 fusion Effects 0.000 description 34
- 102100037362 Fibronectin Human genes 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 30
- 238000000684 flow cytometry Methods 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 238000009826 distribution Methods 0.000 description 27
- 230000005012 migration Effects 0.000 description 27
- 238000013508 migration Methods 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 26
- 230000026731 phosphorylation Effects 0.000 description 25
- 238000006366 phosphorylation reaction Methods 0.000 description 25
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 23
- 235000002374 tyrosine Nutrition 0.000 description 23
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 22
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 22
- 229940027941 immunoglobulin g Drugs 0.000 description 22
- 239000002609 medium Substances 0.000 description 22
- 235000004400 serine Nutrition 0.000 description 22
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 22
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 21
- 238000002898 library design Methods 0.000 description 21
- 229920009537 polybutylene succinate adipate Polymers 0.000 description 21
- 238000013461 design Methods 0.000 description 20
- 230000035772 mutation Effects 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 239000004471 Glycine Substances 0.000 description 17
- 239000011324 bead Substances 0.000 description 17
- 229960002449 glycine Drugs 0.000 description 17
- 235000018417 cysteine Nutrition 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 230000035755 proliferation Effects 0.000 description 15
- 239000012103 Alexa Fluor 488 Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000036963 noncompetitive effect Effects 0.000 description 14
- 108020004705 Codon Proteins 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 230000001976 improved effect Effects 0.000 description 13
- 238000012300 Sequence Analysis Methods 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 241000283707 Capra Species 0.000 description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 108010090804 Streptavidin Proteins 0.000 description 10
- 230000008484 agonism Effects 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 108010004729 Phycoerythrin Proteins 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 108091006905 Human Serum Albumin Proteins 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 8
- 238000001042 affinity chromatography Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000002860 competitive effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002222 downregulating effect Effects 0.000 description 8
- 238000013507 mapping Methods 0.000 description 8
- 238000004064 recycling Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 7
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 7
- 102000007982 Phosphoproteins Human genes 0.000 description 7
- 108010089430 Phosphoproteins Proteins 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000003305 autocrine Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 230000012743 protein tagging Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 239000012114 Alexa Fluor 647 Substances 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 229920002873 Polyethylenimine Polymers 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 229940072221 immunoglobulins Drugs 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000011284 combination treatment Methods 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 150000001945 cysteines Chemical class 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000033300 receptor internalization Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 210000005253 yeast cell Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 4
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000007413 biotinylation Methods 0.000 description 4
- 230000006287 biotinylation Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010232 migration assay Methods 0.000 description 4
- 238000007857 nested PCR Methods 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 241000289427 Didelphidae Species 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- 102000009490 IgG Receptors Human genes 0.000 description 3
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 3
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000289371 Ornithorhynchus anatinus Species 0.000 description 3
- 241000282577 Pan troglodytes Species 0.000 description 3
- 108010001441 Phosphopeptides Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001687 destabilization Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000007783 downstream signaling Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 231100000065 noncytotoxic Toxicity 0.000 description 3
- 230000002020 noncytotoxic effect Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical group C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102220473730 Ras-related protein Rab-5A_A56E_mutation Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008267 autocrine signaling Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 102000045108 human EGFR Human genes 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 238000003121 in-cell western assay Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 238000002824 mRNA display Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
- NTEDOEBWPRVVSG-FQUUOJAGSA-N (2s)-1-[(2r)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CO)C(=O)N1CCC[C@H]1C(O)=O NTEDOEBWPRVVSG-FQUUOJAGSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- WIIZWVCIJKGZOK-IUCAKERBSA-N 2,2-dichloro-n-[(1s,2s)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide Chemical compound ClC(Cl)C(=O)N[C@@H](CO)[C@@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-IUCAKERBSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 229920002157 Cellulin Polymers 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100058504 Drosophila melanogaster Muted gene Proteins 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 229940122558 EGFR antagonist Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101800000155 Epiregulin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 238000001327 Förster resonance energy transfer Methods 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000004422 Phospholipase C gamma Human genes 0.000 description 1
- 108010056751 Phospholipase C gamma Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102220630778 Presenilin-1_L14H_mutation Human genes 0.000 description 1
- 102100025498 Proepiregulin Human genes 0.000 description 1
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 101150086827 bloc1s5 gene Proteins 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 108091006050 fluorescent recombinant proteins Proteins 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010053299 glycyl-arginyl-glycyl-aspartyl-seryl-proline Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000012562 protein A resin Substances 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102220091606 rs148701985 Human genes 0.000 description 1
- 102220320750 rs748521485 Human genes 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Definitions
- This invention relates to engineered proteins, and more particularly to engineered proteins that include at least one genetically modified fibronectin (Fn) domain.
- the proteins can specifically bind target molecules, such as cell surface receptors, and thereby affect cellular physiology (e.g., cellular proliferation, differentiation, or migration).
- an engineered protein that include at least one genetically modified fibronectin (Fn) domain (e.g., a type III fibronectin domain (Fn3)). Where more than one domain is included, each domain may bind a different epitope on a given molecular target.
- an engineered protein can include (a) a first genetically modified Fn domain that binds a first epitope on a molecular target (e.g., a cellular receptor) and (b) a second genetically modified Fn domain that binds a second epitope on the same target (e.g., the same cellular receptor).
- the engineered protein can include (a) one or more genetically modified Fn domains and (b) one or more heterologous amino acid sequences, which may contribute to the therapeutic activity of the engineered protein by, for example, binding an epitope on the molecular target.
- heterologous amino acid sequences as target- specific protein scaffolds. While heterologous sequences (or target- specific protein scaffolds) are described further below, we note here that they can constitute an immunoglobulin or a biologically active fragment or other variant thereof (e.g., an scFv). More broadly, we use the term "heterologous" to indicate that the amino acid sequences that may contribute to therapeutic activity are distinct (e.g., distinct in their sequence or structure) from the genetically modified Fn domain to which they are joined.
- any of the engineered proteins can further include an amino acid sequence that: prolongs the circulating half-life of the engineered protein; facilitates its purification; facilitates conjugation; is a label, marker or tag (including an imaging agent) or serves as a linker (e.g., between a first and second genetically modified Fn domain or between a genetically modified Fn domain and a heterologous amino acid sequence such as an immunoglobulin).
- a label, marker or tag including an imaging agent
- serves as a linker e.g., between a first and second genetically modified Fn domain or between a genetically modified Fn domain and a heterologous amino acid sequence such as an immunoglobulin.
- the engineered protein can be: a genetically modified Fn domain; two or more such domains joined to one another; or at least one genetically modified Fn domain joined to a target-specific protein scaffold.
- One or more accessory sequences can be included in or added to any of these configurations. While we discuss these proteins further below, we note here that where at least one genetically modified Fn domain is joined to a target-specific protein scaffold, the protein scaffold can be an
- immunoglobulin e.g., an IgG
- the Fn domains can be identical to one another or distinct, and they can be joined to either the amino or carboxy terminus of the target-specific protein scaffold.
- the protein scaffold is an IgG
- one or more genetically modified Fn domains can be joined (e.g., fused) to the amino or carboxy terminus of a light chain (or chains), to the amino or carboxy terminal of a heavy chain (or chains), or to any combination of these positions.
- a first genetically modified Fn domain can be joined to the amino terminus of one or both heavy chains and a second genetically modified Fn domain can be fused to the carboxy terminus of one or both light chains.
- the first and second Fn domains can be the same in their sequence and/or binding specificity (e.g., they may bind the same epitope on a molecular target) or they may differ from one another in their sequence and/or binding specificity (e.g., they may bind two different epitopes on the same or different molecular targets).
- an engineered protein binds more than one epitope
- we may refer to the engineered protein as "heterovalent” e.g., heterobivalent where two different epitopes are bound; heterotrivaent where three different epitopes are bound; and so forth.
- an engineered protein binds two of the same epitope, we may refer to it as homobivalent.
- engineered proteins described herein can include, consist of, or consist essentially of the recited sequences.
- the engineered proteins, compositions containing them pharmaceutically acceptable preparations, stock solutions, kits, and the like), nucleic acids encoding them, and cells in which they are expressed are all within the scope of the present invention.
- Methods of making and methods of isolating or purifying the engineered proteins are also within the scope of the present invention.
- an engineered protein can be isolated or purified following chemical synthesis or expression in cell culture.
- Methods of using the engineered proteins to assess cells in vitro and to treat patients are also within the scope of the present invention. Production, isolation, formulation, screening, diagnostic and treatment methods are discussed further below.
- the genetically modified Fn domains, heterologous sequences, and accessory sequences can be joined by various means, including by covalent bonds.
- these sequences can be joined as a fusion protein (e.g., where amino acid residues are joined by peptide bonds) or as a chemical conjugate.
- the accessory sequence can be a polypeptide linker between two Fn domains or between a Fn domain and a heterologous sequence.
- the engineered protein can consist of or include two genetically modified Fn domains that are fused to one another or conjugated to one another.
- the engineered protein can consist of or include one or more genetically modified Fn domains that are fused to or conjugated with an antibody targeting the same molecular target (or antigen) such as Erbitux® (cetuximab;
- a genetically modified Fn domain and a target-specific protein scaffold target the same molecular target (or antigen) when they specifically bind the same molecular target (or antigen).
- a target-specific protein scaffold to which it is joined can specifically bind the same cell-surface protein (e.g., a tyrosine kinase receptor).
- the genetically modified Fn domain and the target-specific protein scaffold may bind distinct (e.g. , non-overlapping) epitopes on the molecular target.
- Fn domains can be joined to (e.g., fused to or conjugated with) a whole, complete, or full-length protein scaffold
- the Fn domain(s) can also be joined to a biologically or therapeutically active fragment or other variant of a protein scaffold (e.g., an antibody or another target-specific protein scaffold, examples of which are provided below).
- a biologically or therapeutically active fragment or other variant of a protein scaffold e.g., an antibody or another target-specific protein scaffold, examples of which are provided below.
- fragments or other variants of the currently available antibodies listed above can also be incorporated into the engineered proteins of the present invention and are useful in the present methods so long as they retain biological activity (e.g., sufficient and selective binding to the molecular target).
- compositions in which two or more of the amino acid sequences described herein are included but not physically joined are also within the scope of the present invention.
- the composition can be a pharmaceutically acceptable preparation including, in admixture, a genetically modified fibronectin domain and a heterologous amino acid sequence.
- the composition can be a solution suitable for intravenous administration.
- a pharmaceutical formulation can include, as separate entities, a genetically modified Fn domain and an immunoglobulin, including any of the currently available immunoglobulins that specifically bind a molecular target as described herein (e.g., cetuximab).
- the invention features methods of making the engineered proteins described herein and compositions containing them (e.g. , stock solutions or pharmaceutically acceptable formulations). The methods of generating engineered proteins can be carried out using standard techniques known in the art.
- chemical synthesis can also be used. These methods can be used alone or in combination to produce engineered proteins having one or more of the sequences described in detail herein as well as engineered proteins that differ from those proteins but that have the structure and one or more functions of an engineered protein as described herein (e.g., the configuration and components described herein and an ability to specifically bind a molecular target).
- the invention features screening methods in which one or more epitopes on a target are used to identify or construct engineered proteins (or domains thereof) that specifically bind that epitope or epitopes.
- the libraries may include clones in which one or more of the amino acid residues in the otherwise diversified binding loops of a Fn domain are maintained as wild-type sequence or as preferentially biased toward wild-type sequence. The selection of these conserved or biased amino acid positions can be aided through identification of clones that stabilize the domain or are accessible to solvent based on structural analysis.
- the clones may also be present preferentially in Fn domains of various species, and the present methods can include a step in which an alignment is carried out as described in the Examples below.
- the library may be biased toward clones having amino acids that are better suited for molecular recognition (e.g., tyrosine, serine, and glycine).
- amino acids observed in natural binding repertoires may be used.
- These combinatorial libraries may be constructed from degenerate nucleotides that produce the desired amino acid bias. These libraries may contain a higher fraction of functional sequences than results from fully random library generation.
- Libraries made by the methods described herein are within the scope of the present invention as are methods of screening such libraries to identify clones that can be incorporated in an engineered protein.
- Fn domains To identify genetically modified Fn domains, one can diversify a domain by mutating the DNA encoding one or more residues in the BC, DE, and/or FG loops (as defined in the art; see, e.g., Ruoslahti, Ann. Rev. Biochem. 57:375-413, 1988). While useful Fn domains are described further below, we note here that they can be variants (e.g. , mutants) of a type III domain and, more specifically, of the tenth type III domain. Virtually any Fn domain may serve as the original source of the genetically modified Fn domain that becomes incorporated into the present proteins.
- the Fn domain may have a sequence modified from a mammalian (e.g., human) Fn domain.
- the diversification process may also be combined with homologous recombination of mutated loop gene fragments in which the constant portion of the Fn gene is used as a homologous region for recombination.
- This approach may be used in parallel with mutation of the entire Fn gene including the constant region.
- the engineered proteins are not limited to those that affect cellular physiology by any particular mechanism. Our work to date indicates that antibody-Fn fusions are able to cluster cellular receptors on the cell surface. For example, we have fused the clinically approved human monoclonal antibody (mAb) 225 (cetuximab) with variants of the tenth type III domain of human fibronectin that recognize the EGF receptor (EGFR) to establish multispecif ⁇ c antibody- fibronectin fusions capable of clustering EGFR. These constructs induce receptor clustering and effectively downregulate EGFR in a number of cancerous cell lines without agonizing signaling. The engineered proteins of the present invention may, therefore, bring about this same downregulation.
- mAb human monoclonal antibody
- cetuximab cetuximab
- EGFR EGF receptor
- the antibody constant domain can aid in the persistence of the proteins in the bloodstream and enhance immune cell recruitment.
- the amino acid sequence that prolongs the circulating half-life may be a part of the immunoglobulin portion of immunoglobulin- fibronectin fusions.
- the modular structure and design of the present proteins forms the basis for a new generation of therapeutics, including antibody-based therapeutics, that can bind to different (e.g., nonoverlapping) regions on molecular targets, including cell-surface targets (e.g., cellular receptors such as a receptor tyrosine kinase).
- the engineered protein may cause a substantial decrease in the amount of the target (e.g., an EGFR or other receptor tyrosine kinase) on the surface of the cell.
- the target e.g., an EGFR or other receptor tyrosine kinase
- the engineered protein can downregulate the receptor without activating the receptor's signaling cascade. As a result, one can bring about a desired change in cellular physiology.
- an engineered protein targeting the EGFR may inhibit cellular proliferation or migration.
- these proteins are therapeutically useful (e.g., in treating cancers involving EGF receptor-positive cells).
- Engineered proteins that target an EGFR can be used in treating any of the same cancers presently treated with EGFR antagonists.
- Specific cancers amenable to treatment with proteins that target the EGFR include breast cancer, bladder cancer, non-small-cell lung cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, ovarian cancer, cervical cancer, lung cancer, esophageal cancer, glioblastomas, and pancreatic cancer.
- By targeting other cell-surface proteins one can treat other types of cancers.
- Those of ordinary skill in the art will appreciate which molecular targets are associated with which cancers or other diseases, disorders, or conditions.
- the engineered proteins can be used, due to their target specificity, to deliver cargo (e.g., a therapeutic agent) to a cell that expresses the target molecule.
- the target may or may not be a receptor; any cell-surface, cancer-specific protein can be targeted.
- the proteins can be internalized, the delivery can encompass an intracellular delivery of the cargo.
- the cargo can vary widely and includes nucleic acids (e.g., antisense
- RNAi e.g., an siRNA or shRNA
- the cargo can also be a conventional small molecule therapeutic agent, such as a chemotherapeutic agent or any agent that is toxic to the cell to which it is delivered (e.g., a radioisotope).
- the subject can be a human and the method can include a step of identifying a patient for treatment (e.g., by performing a diagnostic assay for a cancer). Further, one may obtain a biological sample from a patient and expose cancerous cells within the sample to one or more engineered proteins ex vivo to determine whether or to what extent the engineered protein downregulates a target expressed by the cells or inhibits their proliferation or capacity for metastasis. Similarly, one may obtain a biological sample from a patient and expose cancerous cells within the sample to one or more of the present proteins that have been engineered to carry toxic cargo. Evaluating cell survival or other parameters (e.g., cellular proliferation or migration) can yield information that reflects how well a patient's cancer may respond to in vivo treatment with the engineered protein tested in culture.
- a diagnostic assay for a cancer e.g., by performing a diagnostic assay for a cancer.
- engineered proteins can contain naturally occurring amino acid residues (and may consist of only naturally occurring amino acid residues), the invention is not so limited.
- the proteins can also include non-naturally occurring residues.
- Any of the engineered proteins may also vary (either from each other or from a wild-type protein from which they were derived) due to post-translational modif ⁇ cation(s). For example, the glycosylation pattern may vary or there may be differences in amidation or phosphorylation.
- the sequence of the first Fn domain and the sequence of the second Fn domain can vary from one another in the regions that confer epitope binding specificity but be otherwise identical or nearly identical (e.g., at least 90% identical).
- the first domain and the second domain can be generated from a type III Fn domain (e.g. , a tenth type III Fn domain) and can vary from either one another or from the wild type sequence from which they were derived in one or more of the regions defining the BC loop, the DE loop, and the FG loop.
- the first Fn domain and the second Fn domain can be identical to one another or nearly identical (e.g., at least 90%, 95%, or 98% identical).
- the Fn domain engineered e.g., mutated
- the variability (i.e., variability between one genetically modified Fn domain and another or between such a domain and the wild type sequence from which it was derived) can be generated by the addition, deletion or substitution of amino acid residues.
- a first genetically modified Fn domain and a second genetically modified Fn domain can be at least or about 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical.
- a genetically modified Fn domain and the wild-type sequence from which it was derived can be at least or about 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical.
- a Fn domain included in an engineered protein can be generated from the following wild-type fibronectin domain, where residues 23-31 (underlined) represent the BC loop, residues 52-56 (also underlined) represent the DE loop, and residues 77-86 (also underlined) represent the FG loop. Residues within one or more of the loops can be engineered, and the remaining residues, which constitute the constant region, can be also varied or invariant: VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKSTATIS GLKPGVDYTITVYAVTGRGDSPASSKPISINYRT (SEQ ID NO:1)
- loop regions can be altered to effect a change in epitope- binding specificity (specific mutations are described further below), and the constant region can remain unchanged or vary from one Fn domain to another as described herein.
- receptor downregulation has been achieved using multiple receptor-targeted antibodies, but the current technology enables downregulation with a single agent. This may be advantageous for clinical development and efficacy.
- the present invention is exemplified by our work with the EGF receptor. As two EGFR-targeted antibodies are approved for clinical use in oncology, the EGFR has been validated as a therapeutic target.
- the present invention features the use of the engineered proteins described herein in the treatment of cancer or in the manufacture of a medicament for the treatment of cancer.
- Figure l(A) and Figure l(B) depict the results of analyses of sequences within wild-type Fn3 domains (Panel A) and genetically modified Fn domains (Panel B).
- the "x" in the BC loop corresponds to an amino acid present in other domains that is not present in the human tenth type III domain.
- the outline around S81-S84 represents rare positions as most type III domains contain shorter FG loops.
- the amino acid frequency at each position was compared to the frequency in the composite na ⁇ ve libraries.
- Figure 2 is a bar graph mapping amino acid distributions. The frequencies of each amino acid in multiple distributions are presented.
- NNB refers to a degenerate codon with 25% of each nucleotide at the first two positions and 33% of C, T, and G at the third position.
- Tyr/Ser refers to an even mix of tyrosine and serine.
- CDR-H3 refers to the expressed human and mouse CDR- H3 sequences.
- Skewed Design refers to the theoretical distribution attainable using skewed oligonucleotides.
- Skewed Sequence refers to the distribution attained experimentally using skewed nucleotides.
- Figure 3 is a plot depicting library source probability. For each binding clone sequence, the probability of origination from each library was calculated based on library design. The relative preferences for G4 versus NNB (o) or G4 versus YS (x) are presented for each loop as well as the total domain. Each symbol indicates a sequenced clone.
- Figure 4 illustrates the results of a binding competition performed with the indicated Fn clones, the antibody 225, and EGF for the EGFR expressed on A431 cells.
- Figures 5(A), 5(B), and 5(C) are a series of schematics and graphical results related to EGFR downregulation.
- Panel (A) shows an Fn3-Fn3 heterobivalent protein with the wild-type FN3 structure from PDB ID ITTG and a flexible linker drawn approximately to scale (in cartoon form).
- Panel (B) is a representation of surface EGFR expression.
- Panel (C) is a bar graph depicting data from the expression study shown in Panel (B) for select constructs with A431 cells. Error bars indicate standard deviation of triplicate samples.
- Figure 6 is a series of sequences including a portion of the pETh-Fn3-Fn3 vector. This construct is used for bacterial expression of Fn3-Fn3 bivalent domains with a C-terminal His6 tag.
- the Fn3 sequences shown in this vector construct can be replaced by any other genetically modified Fn3 domain, including clones A, B, C, D, and E.
- the nucleic acid sequence is shown as SEQ ID NO:
- the amino acid sequence, translated from the ATG in Ndel site onward is shown as SEQ ID NO: .
- Figure 6 also includes nucleic acid and protein sequences for Fn3 domains engineered for binding to the indicated target. Sequence data is provided from Nhel to BamHl in both the nucleotide and amino acid formats.
- the engineered binders are designated as clones A-E, FG5, and U5.
- Figure 7 is a bar graph illustrating the results of receptor downregulation studies in various cell lines (HT29, U87, HeLa, HMEC, CHO, and A431) with PBSA as a control, EGF, and the contructs D-C, D-B, and D-E. Values and error bars indicate the mean and standard deviation of triplicate samples. Parenthetical notations (e.g., (0.1 IM)) indicate the number of EGFR per cell in million (M).
- Figure 8 is a schematic depicting the results of a global phorphorylation analysis. The top portion (above the bold line) represents the fifteen highest responders to EGF treatment, and the bottom portion represents the fifteen highest responders to heterobivalent treatment.
- Figure 9 is a bar graph depicting the results of a study of relative viability of hMEC cells treated with the proteins and constructs indicated for 48 or 96 hours. Column and error bars represent mean and standard deviation of triplicate samples. * indicates data from a single sample.
- Figure 10 is a diagram showing EGFR downregulation by the Fn3-Fn3 constructs indicated in A431, HeLa, and HT29 cells. The mean of triplicate samples is presented.
- Figures H(A) and H(B) are a pair of bar graphs depicting the results of a study of cellular migration following treatment of the cell types indicated with the proteins indicated. + indicates addition of 225 antibody. * indicates that PBSA "wound” was completely healed, thus measurable migration was limited. Column and error bars represent mean and standard deviation of triplicate samples.
- Figure 12 is a schematic of various engineered proteins comprising a genetically modified Fn domain and an immunoglobulin.
- the constant regions of the heavy chain are labeled CHl, CH2, and CH3, and the constant region of the light chain is labeled CL.
- the variable domains of the heavy and light chains are labeled VH and VL, respectively, and the genetically modified Fn3 domain is labled Fn3.
- the amino (N) and carboxy (C) termini of the heavy and light chains are also indicated.
- the immunoglobulins are assembled in vitro in two- to-two complexes of heavy and light chain moieties, linked by three disulfide bonds.
- Fn3 is fused to the heavy or light chain at the N or C terminus with a flexible linker and the fusion constructs are named as indicated (HN where the Fn3 domain is fused to the N terminus of the heavy chain; HC where the Fn3 domain is fused to the C terminus of the heavy chain; LN where the Fn3 comain is fused to the N terminus of the light chain; and LC where the Fn3 domain is fused to the C terminus of the light chain).
- Figure 13 is a series of sequences of representing Ab-Fn3 fusions.
- Figure 14 is a line graph depicting the results of a study of multispecific antibody binding kinetics. Closed symbols represent the unconjugated 225 antibody and open symbols represent the Ab-Fn3 fusion HN-D. Nonlinear least squares regression fits are shown for 225 (solid lines) and HN-D (dashed lines) at pH 6.0 (darker solid and dashed lines) and pH 7.4 (lighter solid and dashed lines).
- Figure 15 is a schematic of multispecific antibody-induced clustering.
- Engineered proteins that are multispecific and bind two non-competitive epitopes on a target receptor may induce linear or circular chains of crosslinked receptor on the cell surface.
- Figures 17(A) and (B) are schematics representing the extent of EGFR downregulation in the cell types indicated with engineered proteins indicated.
- Figure 18 is a line graph plotting surface EGFR (% untreated) over time following Ab- Fn3 treatment in A431 cells.
- the lighter line tracks receptor downregulation following treatment with the Ab-Fn3 fusion FIN-D, and the darker line tracks receptor downregulation following treatment with the mAb combination 225 + Hl 1.
- First-order kinetic curves were fit using nonlinear least squares regression.
- Figures 19(A), (B), and (C) are a series of plots demonstrating that EGFR and its downstream effectors are not agonized by combination mAb treatment.
- activation profiles are shown for EGF ( ⁇ ), 225 (o), Hl 1 (D), and 225 + Hl 1 (•).
- serum-starved A431 cells were incubated with 225, Hl 1, the 225 + Hl 1 combination, and EGF at 37 0 C for 15 minutes (top) or 60 minutes (bottom).
- Figure 21 is a Table summarizing Fn3 library design.
- “Pos.” and “WT” are the amino acid position and residue in the human wild-type tenth type III domain.
- “Access.” is the ratio of solvent accessible surface area for the residue in the f ⁇ bronectin domain compared to the residue in a random coiled peptide.
- “Stability” is the relative increase in yeast surface display level of a library with wild-type conservation at the position of interest.
- “Native” indicates the frequencies of the indicated amino acids in type III f ⁇ bronectin domains often species.
- “Binders” indicates the enrichment of wild-type (or homo log as indicated) in engineered binders relative to the na ⁇ ve frequency.
- “Library Design” indicates the intended amino acid distribution in the new library.
- “Ab div.” is the designed amino acid distribution that mimics antibody CDR-H3. * indicates the location of loop length variability.
- Figure 22 is a Table summarizing engineered binder sequences.
- Name is the name of each clone.
- Tiget is the cognate protein bound by the Fn3 clone.
- 23 refers to the amino acid present at position 23, which is aspartic acid (D) in wild-type Fn3; all positions diversified in the na ⁇ ve library are likewise presented.
- Framework refers to amino acid mutations outside of the diversified loops. A dash (-) indicates no amino acid.
- Figure 23 is a Table summarizing a stability analysis.
- the NNB and G4 libraries were independently sorted for clones of low stability and high stability. Sequences of about 50 clones from each sorted population were analyzed. "AA” indicates the wild-type amino acid at positions with wild-type bias or amino acids of elevated frequency at positions without wild-type bias. "G4 Design” indicates the designed frequency of the indicated amino acid. "NNB” and “G4" indicate the difference in amino acid frequency between the high and low stability populations from the indicated library.
- Figure 24 is a Table regarding codon design. The nucleotide mixture used in synthesis at each diversified position is indicated.
- Figure 25 is a Table regarding EGFR binders. "Kd” indicates equilibrium dissociation constant for binding to A431 cells on ice or yeast at 22 0 C. "nb” indicates no detectable binding. A dash (-) indicates data not collected.
- the present invention is based, in part, on our discovery of engineered proteins that include at least one genetically modified Fn domain. Where more than one domain is included, each domain may bind a different epitope on a molecular target, and the two epitopes may be non-overlapping.
- the engineered protein includes a first genetically modified Fn domain that specifically binds a first epitope on a molecular target (e.g., a cellular receptor) and a second genetically modified Fn domain that specifically binds a second epitope on the same target or a distinct target.
- the engineered protein includes a genetically modified Fn domain that specifically binds a first epitope on a molecular target and a heterologous protein that specifically binds a second epitope on the same target or a distinct target.
- engineered protein(s) as (a) "binding reagent(s)” and, on occasion these terms may be abbreviated to simply “protein(s)” or “binder(s).” It is to be understood that the engineered proteins of the present invention are not naturally occurring proteins.
- proteins generally or to a portion thereof (e.g., a Fn domain) as "genetically modified" to indicate that the protein is non-naturally occurring or is a mutant of a wild-type sequence.
- an engineered protein (or a portion thereof (e.g., a genetically modified Fn domain or target-specific protein scaffold)) may be purified or isolated, in which case it has been substantially separated from materials with which it was previously associated.
- an engineered protein can be isolated or purified following chemical synthesis or expression in cell culture; the engineered proteins can be separated from the synthesis reagents or the cellular material of the expression system.
- An isolated or purified engineered protein (or a portion or domain thereof) may be at least or about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% pure.
- the engineered proteins may be present at high concentrations (in which case the compositions may be useful as stock solutions or in in vitro analysis) or at physiologically acceptable concentrations (in which case the compositions would be suitable for administration to a patient).
- the Fn domains included in the present proteins can be based on a type III Fn domain (Fn3), such as the tenth type III domain of human fibronectin.
- the Fn3 domain occurs in ⁇ 2% of animal proteins (Bork and Doolittle, Proc. Natl. Acad. Sci. USA, 89:8990-8994, 1992). In addition, both solution (Main et al, Cell, 71:671-688, 1992) and crystal (Dickinson et al, Journal of Molecular Biology, 236:1079-1092, 1994) structures of Fn3 have been determined, thus enabling rational elements of design.
- the scaffold contains three solvent-exposed loops on either side of parallel ⁇ -sheets, somewhat akin to the immunoglobulin fold.
- NMR spectroscopy indicates significant flexibility of the FG loop as well as moderate flexibility of the BC loop (Carr et al., Structure, 5_:949-959, 1997). Moreover, elongation by insertion of four glycine residues is moderately well tolerated (1.2, 2.3, and 0.4 kcal/mol destabilization of BC, DE, and FG) (Batori et al, Protein Eng., 15:1015-1020, 2002)).
- the opposing loops, AB, CD, and EF offer potential for a bispecific scaffold but are neither as well arranged nor as tolerable of insertion as the other loops.
- engineered proteins that include genetically modified Fn3 domains may have several biophysical advantages over antibodies, and we consider them an attractive scaffold for use in the proteins described herein.
- Naturally occurring Fn3 domains can bind integrins, as the FG loop contains the Arg- Gly-Asp tripeptide (Pierschbacher et al, J. Cell Biochem., 28:115-126, 1985).
- randomization of the BC loop and a shortened FG loop yielded micromolar binders to ubiquitin (Koide et al, The Journal of
- Fn3 could accommodate mutations in loop residues without notable structural change and could acquire novel binding function, a reduced stability, reduced solubility, and non-specific, low affinity binding was also observed.
- Screening of a library with more extensive randomization of the BC, DE, and FG loops yielded binders to tumor necrosis factor ⁇ and vascular endothelial growth factor receptor 2 (VEGF-R2) of nanomolar affinity (Parker et al, Protein Engineering Design and Selection, 18:435-444, 2005; Xu et al, Chemistry & Biology, 9:933-942, 2002). Further maturation produced binders of sub-nanomolar affinity, demonstrating the potential for high affinity binding with Fn3.
- VEGF-R2 vascular endothelial growth factor receptor 2
- Engineered Fn3 variants have been used intracellularly (Koide et al, Proc. Natl. Acad. Sci.
- the orientation of the domains with respect to one another can be varied.
- the first and second Fn domains can be arranged in a head-to-tail, head-to-head, or tail-to-tail configuration.
- the engineered proteins include a linker or a heterologous amino acid sequence.
- the first and second fibronectin domains can be fused, via a linker, in a head-to-tail orientation.
- the first and second fibronectin domains can be fused to one another in a head-to-tail configuration (with or without a linker) and fused to the heterologous sequence (with or without a linker).
- a linker can be included between the Fn domains and the heterologous sequence, and the Fn domain(s) can be fused to the heterologous sequence at an amino-terminus, carboxy-terminus, or both.
- the orientation of the genetically modified Fn domain with respect to the heterologous amino acid sequence is discussed further below.
- the genetically modified Fn domains used in the engineered proteins of the present invention can be characterized in several ways, including by the extent to which their amino acid sequence is identical to the amino acid sequence of a reference protein. We may refer to this similarity as "percent identity," and it can be readily determined by comparison of two sequences by eye and simple calculation or by submitting the two sequences (e.g. , a modified Fn3 sequence and a reference sequence to a sequence analysis program with the default parameters as defined therein.
- the reference sequence can be, for example, a corresponding wild-type sequence or a "parent" sequence into which one or more additional mutations were introduced.
- the reference sequence for a genetically modified tenth Fn3 domain of human fibronectin can be the wild-type tenth Fn3 domain of human fibronectin.
- a first genetically modified Fn domain and a second genetically modified Fn domain can be at least or about 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical.
- a genetically modified Fn domain and a wild-type Fn domain can be at least or about 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical.
- the engineered proteins of the present invention can include a mutant of the tenth type III fibronectin domain that is at least 40% identical to the corresponding wild-type tenth type III fibronectin domain (e.g., a mammalian (e.g., human) Fn domain).
- Figures l(A) and l(B) show the results of this analysis.
- Various sequences were aligned, and amino acid frequency at each position was evaluated. The results are presented based on an intensity scale; the more frequently a residue appears at a given position in the aligned sequences, the darker the box representing that residue in the plot.
- To analyze wild-type Fn3 domains we aligned sequences from chimpanzee, cow, dog, horse, homan, mouse, opossum, platypus, rat, and rhesus monkey.
- the genetically modified Fn3 domains used in the present engineered proteins include those in which the wild-type residues corresponding to positions 22, 32, 51, 57, and 87 are not modified (e.g., deleted or replaced) but the residue at position 76 is mutated (e.g., deleted or replaced).
- amino acid residues that are highly conserved may be substituted conservatively.
- a genetically modified Fn domain used in the engineered proteins of the present invention can be characterized is by their affinity for the molecular target they were designed to specifically bind.
- a genetically modified Fn domain (or one of the target-specific protein scaffolds described below) can bind a molecular target with an affinity in the pM to nM range (e.g., an affinity of less than or about 1 pM, 10 pM, 25 pM, 50 pM, 100 pM, 250 pM, 500 pM, 1 nM, 5 nM, 10 nM, 15 nM, 20 nM, 25 nM, 30 nM, 40 nM or 50 nM).
- Fn domains can also be classified as having or lacking
- conformational sensitivity is present when the genetically modified Fn domain specifically binds its molecular target in a naturally folded configuration but fails to do so (or does so with a greatly reduced affinity) when the target is denatured.
- any given genetically modified Fn domain (or any given heterologous sequence) can be characterized in terms of its ability to modify cell behavior (e.g. , cellular proliferation or migration) or to positively impact a symptom of a disease, disorder, condition, syndrome, or the like, associated with the expression or activity of the molecular target.
- the genetically modified Fn domain can be one that inhibits the ability of cancerous cells to proliferate or migrate and/or improves a symptom in a patient having a cancer associated with aberrent expression of the molecular target.
- the EGFR is associated with numerous cancers
- the modified Fn domain included in an engineered protein can be one that specifically binds the EGFR and inhibits cellular proliferation or migration in the bound EGFR-expressing cells.
- the modified Fn domain included in an engineered protein can be one that specifically binds EGFR-expressing cancer cells in a patient and improves a symptom the patient is experiencing or provides some other clinical benefit.
- the modified Fn domain and an engineered protein of which it is a part can be used to treat a patient who is suffering from a disease (e.g., cancer) that is associated with aberrent expression of a molecule targeted by the modified Fn domain or engineered protein.
- compositions and methods of the invention are not limited to those that elicit any particular cellular response or work through any particular mechanism of action.
- binding, proliferation, and migration assays can be carried out using A431 epidermoid carcinoma cells, HeLa cervical carcinoma cells, and/or HT29 colorectal carcinoma cells. Other useful cells and cell lines will be known to those of ordinary skill in the art.
- genetically modified Fn3 domains can be analyzed using U87 glioblastoma cells, hMEC cells (human mammary epithelial cells), or Chinese hamster ovary (CHO) cells.
- the molecular target can be expressed as a fluorescently tagged protein to facilitate analysis of an engineered protein's effect on the target.
- the assays of the present invention can be carried out using a cell type as described above transfected with a construct expressing an EGFR-green fluorescent protein fusion.
- An engineered protein may inhibit cellular proliferation or migration by at least or about 30% ⁇ e.g., by at least or about 30%, 40%, 50%, 65%, 75%, 85%, 90%, 95% or more) relative to a control (e.g., relative to proliferation or migration in the absence of the engineered protein or a scrambled engineered protein).
- genetically modified Fn domains may be described as having a
- a genetically modified Fn domain that exhibits a certain percentage of sequence identity to a reference sequence can also be a domain that exhibits an affinity for the target molecule in the pM to nM range and/or exhibits conformational sensitivity.
- the genetically modified Fn domain can be at least or about 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to a reference sequence (e.g., the naturally occurring domain from which it was derived) and can inhibit the proliferation or migration of a cell expressing a molecular target to which the modified Fn domain specifically binds.
- a genetically modified Fn domain can have or can include the amino acid sequence of a Fn3 domain described herein as clone A, clone B, clone C, clone D, or clone E (see Figure 6).
- an engineered protein can be or can include a pair of these clones, which may be fused to one another via a linker.
- the engineered proteins can include a pair of genetically modified Fn domains that have or that include the sequence of clone A, clone B, clone C, clone D, or clone E.
- downregulating an EGFR include D-B, D-C, D-D, D-E, A-D, B-D, C-D, and E-D.
- the domains may be linked in the order indicated.
- genetically modified Fn domains including the bivalents described here, can be fused, directly or via a linker, to a heterologous amino acid sequence such as an immunoglobulin.
- the amino terminal, carboxy terminal, or both, of either the heavy or light chain e.g., in an IgG
- specf ⁇ c configurations are discussed further below.
- the engineered proteins of the invention can include, in addition to a genetically modified Fn domain: (a) a target-specific protein scaffold, and/or (b) an accessory amino acid sequence.
- the affinity of the target-specific protein scaffold for its target may be increased when the scaffold is joined to one or more genetically modified fibronectin domains (as described herein).
- the affinity of an antibody for its molecular target may be at least or about an order of magnitude greater than the affinity of the antibody alone at either endosomal pH (6.0), physiological pH (7.4), or both.
- the target-specific protein scaffold can be an immunoglobulin (e.g., an IgG or a biologically active (e.g., antigen-binding) portion or variant thereof (e.g., an scFv)), a designed ankyrin repeat protein, an anticalin, or an affibody.
- immunoglobulin e.g., an IgG or a biologically active (e.g., antigen-binding) portion or variant thereof (e.g., an scFv)
- ankyrin repeat protein e.g., an scFv
- the engineered proteins include a heterologous amino acid sequence
- that sequence can be (or can be derived from; a mutant of) an ankyrin repeat protein, an anticalin, an affibody, or an immunoglobulin, including a fragment or other variant therof (e.g., an scFv).
- an scFv an immunoglobulin, including a fragment or other variant therof.
- One can also subject these protein scaffolds to directed evolution as described herein for Fn domains in order to generate binders with improved specificity and affinity for a given molecular target.
- immunoglobulin synonymously with “antibody.”
- immunoglobulin can be a tetramer (e.g., an antibody having two heavy chains and two light chains) or a single-chain immunoglobulin. Further, the immunoglobulin may be an intact immunoglobulin of type IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof (e.g. , IgGi, IgG 2 , IgG 3 , and IgG 4 )).
- antigen-binding portions or fragments or other immunoglobulin variants that can be used in the present proteins include: (i) an Fab fragment, a monovalent fragment consisting of the VLC, VHC, CL and CHl domains; (ii) a F(ab') 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VHC and CHl domains; (iv) a Fv fragment consisting of the VLC and VHC domains of a single arm of an antibody, (v) a dAb fragment (Ward et al, Nature 341 :544- 546, 1989), which consists of a VHC domain; and (vi) an isolated complementarity determining region (CDR) having sufficient framework to specifically bind, e.g.
- CDR complementarity determining region
- an antigen binding portion of a variable region an antigen binding portion of a variable region.
- An antigen-binding portion of a light chain variable region and an antigen binding portion of a heavy chain variable region, e.g., the two domains of the Fv fragment, VLC and VHC, can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VLC and VHC regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al, Science 242:423-426, 1988; and Huston et al., Proc. Natl. Acad. ScL USA 85:5879-5883, 1988).
- Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody or as "a variant" of an antibody.
- antibody portions or fragments are obtained using conventional techniques known to those of ordinary skill in the art, and the portions are screened for utility in the same manner as are intact antibodies.
- An Fab fragment can result from cleavage of a tetrameric antibody with papain; Fab' and F(ab')2 fragments can be generated by cleavage with pepsin.
- single chain immunoglobulins and chimeric, humanized or CDR-grafted immunoglobulins, including those having polypeptides derived from different species, can be incorporated into the engineered proteins.
- immunoglobulins can be joined together chemically by conventional techniques, or can be prepared as contiguous polypeptides using genetic
- nucleic acids encoding a chimeric or humanized chain can be expressed to produce a contiguous polypeptide. See, e.g., Cabilly et al., U.S. Patent
- the accessory sequence can be one that prolongs the circulating half-life of the genetically modified Fn domain or an engineered protein of which it is a part, a polypeptide that facilitates isolation or purification of the engineered protein, an amino acid sequence that facilitates the bond (e.g., fusion or conjugation) between one part of the engineered protein and another or between the engineered protein and another moiety (e.g. , a therapeutic compound) , an amino acid sequence that serves as a label, marker, or tag (including imaging agents), or an amino acid sequence that is toxic.
- the amino acid sequence that increases the circulating half- life can be an Fc region of an immunoglobulin, including an immunoglobulin that has a reduced binding affinity for an Fc receptor (such as those described in U.S. Patent Application No. 20090088561, the content of which is hereby incorporated by reference in its entirety).
- the engineered proteins of the present invention can include immunoglobulin sequences, and as the Fc region can increase circulating half-life, where the engineered proteins include an immunoglobulin as the
- heterologous, target-specific protein scaffold the Fc region of the immunoglobulin can also serve to increase the protein's circulating half-life; the accessory sequence can be a part of the heterologous amino acid sequence.
- Half- life can also be increased by the inclusion of an albumin (or a portion or other variant thereof that is large enough to have a desired effect on half- life).
- the albumin can be a serum albumin, such as a human or bovine serum albumin.
- the Fn domain or another portion of the engineered protein can also be "pegylated” using standard procedures with poly(ethylene glycol). Engineered proteins that are pegylated may have an improved circulating half-life.
- the engineered protein includes an accessory protein that facilitates isolation or purification
- that protein can be a tag sequence designed to facilitate subsequent manipulations of the expressed nucleic acid sequence (e.g., purification or localization).
- Tag sequences such as green fluorescent protein (GFP), glutathione S-transferase (GST), c-myc, hemagglutinin, ⁇ galactosidase, or FlagTM tag (Kodak) sequences are typically expressed as a fusion with the polypeptide encoded by the nucleic acid sequence.
- GFP green fluorescent protein
- GST glutathione S-transferase
- c-myc hemagglutinin
- ⁇ galactosidase ⁇ galactosidase
- FlagTM tag FlagTM tag
- Such tags can be inserted in a nucleic acid sequence such that they are expressed anywhere along an encoded polypeptide including, for example, at either the carboxyl or amino termini.
- the engineered proteins can include linkers at various positions (e.g., between two genetically modified Fn domains or between a genetically modified Fn domain and a heterologous amino acid sequence).
- the linker can be an amino acid sequence that is joined by standard peptide bonds to the engineered protein.
- the length of the linker can vary including an essentially absent linker in which the proteins are directly fused and, where it is an amino acid sequence, can be at least three and up to about 300 amino acids long (e.g., about 4, 8, 12, 15, 20, 25, 50, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250 or 300 amino acids long).
- a non-peptide linker such as polyethylene glycol or an alternative polymer could be used.
- the amino acid residues of the linker may be naturally occurring or non-naturally occurring.
- a polypeptide linker having the sequence GSGGGSGGGKGGGGT SEQ ID NO:
- linkers comprising this sequence or functional variants thereof can be incorporated in the engineered proteins of the present invention.
- the linkers can be gly cine-rich (e.g., more than 50% of the residues in the linker can be glycine residues).
- the amino acid sequence that serves as a label, marker, or tag can be essentially any detectable protein. It may be detectable by virtue of an intrinsic property, such as fluorescence, or because it mediates an enzymatic reaction that gives rise to a detectable product.
- the detectable protein may be one that is recognized by an antibody or other binding protein.
- the engineered proteins can also be configured to carry imaging or contrast agents, many of which are known in the art and can be connected to an engineered protein using standard techniques.
- the proteins can include 1-16 (e.g., 1, 2, 4, 8, 12, or 16) genetically modified Fn domains.
- the Fn domains can be identical to one another or distinct; they can bind the same, similar, or distinct epitopes, including non-overlapping epitopes; and they can be joined to the amino terminus, the carboxy terminus, or both termini of the target-specific protein scaffold. At a given terminus, one can include a single genetically modified Fn domain or a pair of these domains.
- the protein scaffold is an IgG
- one or more genetically modified Fn domains can be joined (e.g., fused) to the amino or carboxy terminus of a light chain (or chains), to the amino or carboxy terminal of a heavy chain (or chains), or to any combination of these positions.
- the engineered protein can include, as a heterologous sequence, an immunoglobulin (e.g., an IgG) and multiple genetically modified fibronectin domains fused, directly or via a linker, to the amino terminus of a heavy chain or an amino terminus of a light chain of the immunoglobulin.
- the engineered protein can include, as a heterologous sequence, an immunoglobulin (e.g.
- the engineered protein can include, as a heterologous sequence, an immunoglobulin (e.g.
- an IgG an IgG and one or more genetically modified fibronectin domains fused, directly or via a linker, to the amino terminus of a light chain and one or more genetically modified fibronectin domains fused, directly or via a linker, to the carboxy terminus of the light chain of the immunoglobulin.
- the engineered protein can include, as a heterologous sequence, an immunoglobulin (e.g., an IgG) and one or more genetically modified fibronectin domains fused, directly or via a linker, to either the amino or carboxy terminus or to both termini of a heavy chain and one or more genetically modified fibronectin domains fused, directly or via a linker, to either the amino or carboxy terminus or to both termini of the light chain of the immunoglobulin.
- an immunoglobulin e.g., an IgG
- one or more genetically modified fibronectin domains fused, directly or via a linker, to either the amino or carboxy terminus or to both termini of a heavy chain and one or more genetically modified fibronectin domains fused, directly or via a linker, to either the amino or carboxy terminus or to both termini of the light chain of the immunoglobulin.
- Protein engineering Screening and evolution of combinatorial libraries, using methods both known in the art and described in the Examples below, provides an effective way to generate binding proteins that can be used in the engineered proteins of the invention.
- the process can be described as involving three key elements: na ⁇ ve library design, selection of functional clones, and sequence diversification of lead clones.
- the present invention features methods of generating an engineered protein (or a domain thereof) by directed evolution.
- the steps of such methods can include providing a na ⁇ ve combinatorial library of protein clones, selecting or screening the library to identify lead clones, and diversifying the identified clones (e.g., by mutagenesis or informed library synthesis) to produce a next generation library.
- the cycle of selection and diversification can be repeated (e.g., two to ten times) until the desired functionality (e.g. , selective binding to an identified target) is achieved.
- Clones with the desired functionality can be identified from the library of protein variants with high throughput selection via linkage of genotype and phenotype. Though this linkage can be achieved through a multitude of display formats (Hoogenboom, Nat. Biotechnol, 23:1105- 1116, 2005) such as phage display and mRNA display, yeast surface display is preferred (Hackel and Wittrup, In Protein Engineering Handbook (Bronscheuer, Ed.), Vol. 1. Wiley- VCH, 2009). In vitro technologies tout high theoretical library sizes because of the absence of cellular transformation, which can limit library size.
- yeast surface display identified three times more clones than did phage display and did not miss a single phage clone revealing that constructed size and functional size can differ substantially (Bowley et al, Protein Engineering Design and Selection, 20:81-90, 2007). Yeast surface display may also enable selection of stable clones because of the quality control apparatus of the eukaryotic secretory system (Shusta et al, Journal of Molecular Biology, 292:949-956, 1999).
- Fluorescence-activated cell sorting of yeast allows quantitative discrimination of clone functionality (VanAntwerp and Wittrup, Biotechnol, Prog., 16:31-37, 2000).
- yeast surface display tens of thousands of copies of Fn3 are tethered to the exterior of an individual Saccharomyces cerevisiae yeast cell while the genetic information for the Fn3 clone is maintained in the cell interior.
- the cell-protein linkage begins with the Agalp subunit of a-agglutinin, which anchors in the cell wall periphery via ⁇ -glucan covalent linkage (Lu et al, J. Cell. Biol., 128:333-340, 1995).
- the Aga2p subunit, secreted from the yeast cell as a fusion to Fn3, attaches to Agalp via two disulfide bonds.
- the peptide bond in the fusion protein thus completes the linkage resulting in "display" of Fn3 on the yeast cell.
- Aga2p and Fn3, linked by a (G 4 S) 3 peptide are followed by HA and c-myc epitopes, respectively, to enable analysis of the display of Aga2p and the full-length protein fusion.
- Display is achieved through transformation of DNA encoding for the Aga2p-Fn3 fusion followed by cell growth and induction of both Agalp and Aga2p-Fn3 protein expression using a galactose-inducible GAL promoter.
- the displayed clones can be screened for their ability to bind to a target of interest, including any of those described herein, using flow cytometry or captured by immobilized antigen.
- Selected clones can be evolved through partial diversification of their sequence followed by selection for mutants that exhibit improved functionality. Error-prone PCR to introduce random mutations throughout the gene is the most common method of diversification.
- Yeast surface display also enables gene shuffling via homologous recombination (Swers et al, Nucleic Acids Research, 32:e36, 2004).
- a protein can be incorporated into the engineered proteins described herein using standard recombinant techniques. These techniquies are well known in the art and are discussed further below.
- a wide variety of molecular targets can be specifically bound and these include molecules expressed on the cell surface, such as receptors for growth factors, neurotransmitters, and the like.
- the receptor can be a tyrosine kinase receptor, and much of the work with the constructs described in the Examples has focused on the epidermal growth factor (EGF) receptor (EGFR).
- This receptor is a receptor tyrosine kinase in the ErbB family that comprises three regions: an extracellular region, a transmembrane domain, and an intracellular region that includes a juxtamembrane domain, kinase domain, and a C-terminal tail containing
- the extracellular region consists of four domains of which domains I and III are leucine rich repeat folds and domains II and IV are cysteine-rich domains.
- the receptor is predominantly present in a tethered conformation on the cell surface. Binding of ligand, including epidermal growth factor, transforming growth factor ⁇ , epiregulin, amphiregulin, ⁇ -cellulin, and heparin-binding epidermal growth factor, stabilizes an open conformation of the receptor. Resultant dimerization enables kinase activation and phosphorylation of the intracellular domain.
- Phosphorylation sites enable docking of adaptor proteins that initiate signaling cascades such as the mitogen-activated protein kinase pathway activated by Ras and She, the Akt pathway activated by
- phosphatidylinositol-3-OH kinase and the protein kinase C pathway activated by phospho lipase C ⁇ . These pathways form a complex signaling network that impacts multiple cellular processes including differentiation, migration, and growth (Yarden and Sliwkowski, Nat. Rev. MoI. Cell. Biol., 2:127-137, 2001).
- Activated EGFR is endocytosed within several minutes and a fraction undergoes fast recycling from the early endosome. The alternate fraction persists to the late endosome resulting in slower recycling or degradation (Sorkin and Goh, Experimental Cell Research., 315:683-696, 2009).
- Dysregulation of EGFR-mediated signalling is observed in breast, bladder, head and neck, and non-small cell lung cancers (Yarden and Sliwkowski, Nat. Rev. MoI. Cell. Biol, 2:127- 137, 2001). Accordingly, engineered proteins that target the EGFR can be used to treat these cancers.
- EGFRvIII which lacks amino acids 6-273, is observed in glioblastoma, non- small cell lung cancer, and cancers of the breast and ovary (Pedersen et al., Ann. Oncol, 12:745-760, 2001). This mutant is unable to bind ligand yet is constitutively active, posing a unique therapeutic challenge, particularly for ligand blocking agents.
- Ectodomain point mutants in glioblastoma yield tumorigenicity (Lee et al, PLoS. Med., I:e485, 2006).
- Kinase domain mutations observed in non-small cell lung cancer hyperactivate kinase (Sharma et al, Nat. Rev. Cancer, 7:169-181, 2007).
- Cetuximab (Erbitux, Bristol-Myers Squibb), approved for colorectal and head and neck cancer, and panitumumab (Vectibix, Amgen), approved for colorectal cancer, are antibodies that compete with EGF for receptor binding.
- panitumumab is an immunoglobulin G (IgG) 2a molecule and thus incapable of triggering cellular cytotoxicity). Both antibodies exhibit modest efficacy.
- panitumumab extends progression-free survival from 64 days to 90 days; yet the overall response rate was only 8% and there was no improvement in overall survival (Messersmith and Hidalgo, Clinical Cancer Research, 13:664- 4666, 2007).
- the binding reagents can be directed to A33 (e.g., human A33 or mouse A33), and mouse CD276.
- Other cancer-specific or receptor tyrosine kinase-specific targets include receptors of the ErbB, insulin, PDGF, FGF, VEGF, HGF, Trk, Eph, AXL, LTK, TIE, ROR, DDR, RET, KLG, RYK, and MuSK receptor families.
- VEGF receptor ⁇ e.g., VEGF -R2
- Immunological targets include the Fc ⁇ receptors Ha and Ilia, and biotechnological targets include mouse IgG and human serum albumin (HSA).
- Fc ⁇ receptors Ha and Ilia include the Fc ⁇ receptors Ha and Ilia
- biotechnological targets include mouse IgG and human serum albumin (HSA).
- HSA human serum albumin
- Biotechnological targets In addition, binders to lysozyme, carcinoembryonic antigen, goat IgG, and rabbit IgG were engineered during platform development.
- Nucleic acid sequences coding for any of the polypeptides within the present engineered proteins are also within the scope of the present invention as are methods of making the engineered proteins.
- variable regions can be constructed using PCR mutagenesis methods to alter DNA sequences encoding an immunoglobulin chain, e.g., using methods employed to generate humanized immunoglobulins (see e.g., Kanunan, et al, Nucl. Acids Res. 12:5404,1989; Sato, et al, Cancer Research 53:851-856, 1993; Daugherty, et al, Nucleic Acids Res.
- variants can also be readily produced.
- cloned variable regions can be mutagenized, and sequences encoding variants with the desired specificity can be selected (e.g., from a phage library; see e.g., Krebber et al, U.S. Patent No. 5,514,548; Hoogenboom et al, WO 93/06213, published April 1, 1993)).
- nucleic acid sequences encoding the engineered protein or a portion thereof can be ligated into an expression vector and used to transform a prokaryotic cell (e.g., bacteria) or transfect a eukaryotic (e.g., insect, yeast, or mammal) host cell.
- a prokaryotic cell e.g., bacteria
- a eukaryotic e.g., insect, yeast, or mammal
- nucleic acid constructs can include a regulatory sequence operably linked to a nucleic acid encoding the engineered protein or a protion thereof (see, e.g., Figures 6 and 13).
- Regulatory sequences e.g., promoters, enhancers, polyadenylation signals, or terminators
- the transformed or transfected cells can then be used, for example, for large or small scale production of the engineered protein by methods well known in the art. In essence, such methods involve culturing the cells under conditions suitable for production of the engineered protein and isolating the protein from the cells or from the culture medium. Additional guidance can be obtained from the Examples presented below.
- the engineered proteins described herein can be administered directly to a mammal.
- the engineered proteins can be suspended in a pharmaceutically acceptable carrier (e.g. , physiological saline or a buffered saline solution) to facilitate their delivery.
- a pharmaceutically acceptable carrier e.g. , physiological saline or a buffered saline solution
- Encapsulation of the polypeptides in a suitable delivery vehicle e.g., polymeric microparticles or implantable devices
- a composition can be made by combining any of the peptides provided herein with a pharmaceutically acceptable carrier.
- Such carriers can include, without limitation, sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents include mineral oil, propylene glycol, polyethylene glycol, vegetable oils, and injectable organic esters.
- Aqueous carriers include, without limitation, water, alcohol, saline, and buffered solutions. Preservatives, flavorings, and other additives such as, for example, antimicrobials, anti-oxidants (e.g., propyl gallate), chelating agents, inert gases, and the like may also be present. It will be appreciated that any material described herein that is to be administered to a mammal can contain one or more pharmaceutically acceptable carriers.
- compositions described herein can be administered to any part of the host's body for subsequent delivery to a target cell.
- a composition can be delivered to, without limitation, the brain, the cerebrospinal fluid, joints, nasal mucosa, blood, lungs, intestines, muscle tissues, skin, or the peritoneal cavity of a mammal.
- routes of delivery a composition can be administered by intravenous, intracranial, intraperitoneal, intramuscular, subcutaneous, intramuscular, intrarectal, intravaginal, intrathecal, intratracheal, intradermal, or transdermal injection, by oral or nasal administration, or by gradual perfusion over time.
- an aerosol preparation of a composition can be given to a host by inhalation.
- the dosage required will depend on the route of administration, the nature of the formulation, the nature of the patient's illness, the patient's size, weight, surface area, age, and sex, other drugs being administered, and the judgment of the attending clinician. Suitable dosages are in the range of 0.01-1,000 ⁇ g/kg. Wide variations in the needed dosage are to be expected in view of the variety of cellular targets and the differing efficiencies of various routes of administration. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art. Administrations can be single or multiple (e.g., 2- or 3-, 4-, 6-, 8-, 10-, 20-, 50-, 100-, 150-, or more fold). Encapsulation of the engineered proteins in a suitable delivery vehicle (e.g., polymeric microparticles or implantable devices) may increase the efficiency of delivery.
- a suitable delivery vehicle e.g., polymeric microparticles or implantable devices
- dosage may vary based on the condition to be treated.
- One of ordinary skill in the art wishing to use an engineered protein of the present invention can obtain information and guidance regarding dosage from currently available antibody therapeutics.
- cetuxamab when used for the treatment of colorectal cancer in adults is delivered IV at 400 mg/m 2 as an initial loading dose administered as a 120-min infusion (max rate of infusion, 10 mg/min).
- the weekly maintenance dose is 250 mg/m 2 infused over 60 min (max rate of infusion, 10 mg/min) until disease progression or unacceptable toxicity.
- the recommended delivery for cetuxamab is IV in combination with radiation therapy.
- the recommended dose is 400 mg/m 2 as a loading dose given as a 120-min infusion (max infusion rate, 10 mg/min) 1 wk prior to initiation of a course of radiation therapy.
- the recommended weekly maintenance dose is 250 mg/m 2 infused over 60 min (max infusion rate, 10 mg/min) weekly for the duration of radiation therapy (6 to 7 wk). Complete administration 1 h prior to radiation therapy.
- the recommended initial dose is 400 mg/m 2 followed by 250 mg/m 2 weekly (max infusion rate, 10 mg/min) until disease progression or unacceptable toxicity.
- the engineered proteins described herein may be beneficially administered using the same or similar regimes.
- a potential advantage of the present engineered proteins is that their multispecific (e.g., heterobivalent) nature combines the efficacy of multiple compounds into a single drug, and this may reduce the total required drug dosage and facilitate administration while allowing for complementary mechanisms to synergize.
- the duration of treatment with any composition provided herein can be any length of time from as short as one day to as long as the life span of the host (e.g., many years).
- an engineered protein can be administered once a week (for, for example, 4 weeks to many months or years); once a month (for, for example, three to twelve months or for many years); or once a year for a period of 5 years, ten years, or longer.
- the frequency of treatment can be variable.
- the present engineered proteins can be administered once (or twice, three times, etc.) daily, weekly, monthly, or yearly.
- an effective amount of any composition provided herein can be administered to an individual in need of treatment.
- the term "effective" as used herein refers to any amount that induces a desired response while not inducing significant toxicity in the patient. Such an amount can be determined by assessing a patient's response after administration of a known amount of a particular composition.
- the level of toxicity if any, can be determined by assessing a patient's clinical symptoms before and after administering a known amount of a particular composition. It is noted that the effective amount of a particular composition administered to a patient can be adjusted according to a desired outcome as well as the patient's response and level of toxicity. Significant toxicity can vary for each particular patient and depends on multiple factors including, without limitation, the patient's disease state, age, and tolerance to side effects.
- Any method known to those in the art can be used to determine if a particular response is induced.
- Clinical methods that can assess the degree of a particular disease state can be used to determine if a response is induced.
- the particular methods used to evaluate a response will depend upon the nature of the patient's disorder, the patient's age, and sex, other drugs being administered, and the judgment of the attending clinician.
- the engineered proteins can also be used as delivery agents to deliver cargo (e.g., a therapeutic agent) to a particular cell type.
- the cargo can be internalized by virtue of internalization of the engineered protein and its target molecule.
- the cargo can be a cytotoxic agent, which refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. Cytotoxic agents include radioactive isotopes (e.g., 131 1, 125 I 5 90 Y and 186 Re), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin or synthetic toxins, or fragments thereof.
- the agents can also be non- cytotoxic, in which case they will not inhibit or prevent the function of cells and/or will not cause destruction of cells.
- a non-cytotoxic agent may include an agent that can be activated to be cytotoxic.
- a non-cytotoxic agent may include a bead, liposome, matrix or particle (see, e.g., U.S. Patent Publications 2003/0028071 and 2003/0032995 which are hereby incorporated by reference herein in their entireties).
- Such agents may be conjugated, coupled, linked or otherwise associated with an engineered protein disclosed herein.
- Kits and other compositions The engineered proteins, domains thereof, nucleic acids, including vector constructs that can be used to produce them, and any of the other compositions of the invention can be packaged in various combinations as a kit, together with instructions for use.
- Nucleic acid sequences encoding representative Fn3-Fn3 and Ab-Fn3 fusions are shown in Figures 6 and 13, respectively. These sequences and sequences that are identical to one or more defined portions therein are within the scope of the present invention. The beginnings and ends of the sequences presented in these figures are marked. For example, Fn3ioi is demarkated in Figure 6 and Fn Clone D and 225HC. Accordingly, the invention encompasses nucleic acid constructs comprising one or more of Clone A, Clone B, Clone C, Clone D, or Clone E or biologically active fragments or other variants (e.g. , substitution mutants) thereof. Other constructs can comprise the linker or leader sequences shown.
- the invention encompasses nucleic acid constructs that include a sequence encoding a leader sequence (e.g., ATG ... GCT of gWiz 225 HN-D), a sequence encoding a genetically modified Fn domain (e.g. , Clone D (GTT ...CAG of gWiz 225 HN-D)), a sequence encoding a linker (e.g., (GIy 4 Se ⁇ 2 ), and a sequence encoding a target-specific protein scaffold (e.g., 225 HC (CAG ... GCT of gWiz 225 HN-D).
- a leader sequence e.g., ATG ... GCT of gWiz 225 HN-D
- a genetically modified Fn domain e.g. , Clone D (GTT ...CAG of gWiz 225 HN-D)
- a linker e.g., (GIy 4 Se ⁇ 2
- nucleic acids shown in Figures 6 and 13 are degenerate variants and codon optimized variants of the nucleic acids shown in Figures 6 and 13. Also within the scope of the invention are constructs comprising nucleic acid sequences that exhibit a certain degree of identity to the sequences shown in Figure 6 or Figure 13 (e.g., sequences that are at least 85% (e.g., 90%, 95%, or 98%) identical to a sequence shown in Figure 6 or Figure 13) and that encode proteins that retain sufficient biological activity to be useful in one or more of the methods described herein.
- Proteins encoded by the nucleic acid sequences shown in Figure 6 or Figure 13, and biologically active fragments or other variants thereof are also within the scope of the present invention.
- the nucleic acid sequences described herein can be incorporated into a vector (e.g. , an expression vector such as a plasmid or a cosmid or other viral vector) using methods known in the art.
- the nucleic acids and/or vectors that contain them can similarly be transfected into cells (e.g., cells in tissue culture), and such cells are within the scope of the present invention.
- binders to lysozyme, carcinoembryonic antigen, goat IgG, and rabbit IgG were engineered during platform development.
- EGFR binders were incorporated into both a novel bispecific format, where the engineered proteins feature two genetically modified Fn3 domains, and into an Fn3-Ab fusion.
- Selective non-competitive heterobivalent constructs are capable of receptor downregulation. Select constructs inhibit cell proliferation and migration, particularly in combination with a ligand-competitive antibody, and therefore have strong therapeutic potential.
- destabilization decreases the tolerance to mutation, which decreases the capacity for evolution (Bloom et al, Proc. Natl. Acad. ScL USA, 103:5869-5874, 2006).
- the potentially resultant flexibility may diminish the free energy change upon binding because of entropic effects.
- conservation at structurally critical positions enables diversity to be focused on positions that are more likely to contribute to the binding interaction yielding a more efficient search of sequence space. In our work, we use stability, structural, and sequence analyses to identify conservation sites that may benefit library design.
- a tailored antibody library with elevated tyrosine, glycine, and serine and low levels of all other amino acids except cysteine was superior to a tyrosine/serine library (Fellouse et al, J. MoI Biol, 373:924-940, 2007).
- a similarly biased library was used with the Fn3 scaffold to yield a 6 nM binder to maltose binding protein (Gilbreth et al, J. MoI Biol, 381:407-418, 2008) and a novel 'affinity clamp' for peptide recognition (Huang et al, Proc. Natl. Acad. Sci. USA, 2008).
- Fn3 Stability We used yeast surface display for efficient stability analysis of Fn3 clones. It has been demonstrated that the number of displayed single-chain T-cell receptors per yeast cell correlates to receptor stability (Shusta et al, J. MoI Biol, 292:949-956 (1999)). To validate this correlation for Fn3, we created yeast surface display vectors of binders to vascular endothelial growth factor receptor 2 spanning a range of stabilities: free energies of unfolding from 3.8 to 7.5 kcal/mol and midpoints of thermal denaturation of 42 to 84° (Parker et al, Protein Engineering Design and Selection, j_8:435-444 (2005)).
- Fn domains useful in the presently engineered proteins include those in which one or more of the residues at positions 23, 24, 25, 29, 52, 56, 77, 78, 79, 84, and 85 of SEQ ID NO:1 are conserved.
- Solvent Accessible Surface Area The solvent accessible surface area of each potentially diversified position was calculated using GetArea (Fraczkiewicz and Braun, J. Computational Chemistry, (1998)) for wild-type Fn3 (solution structure ITTG (Main et al, Cell, 71:671-678 (1992)) and crystal structures IFNA (Dickinson et al, J. MoI. Biol, 236:1079-1092 (1994))) and an engineered binder (2OBG (Koide et al, Proc. Natl Acad. Sci. USA, 104:6632-6637 (2007))).
- Tyrosine has demonstrated unique utility in molecular recognition (Fellouse et al, Proc. Natl. Acad. Sci. USA, 101:12467-12472, 2004; Fellouse et al, J. MoI. Biol, 348:1153- 1162, 2005; Fellouse et al, J. MoI Bio., 357:100-114, 2006).
- Glycine provides conformational flexibility. Serine and alanine are valuable as small, neutral side chains. Acidic residues, arginine, and lysine provide charge although the utility is unclear (Birtalan et al, J.
- trimer phosphoramidite library construction enables precise creation of unique amino acid distributions, this approach is expensive with the inclusion of multiple specialty codon mixtures.
- standard oligonucleotide synthesis was employed using custom mixtures of skewed nucleotides at each position.
- the optimal set of three nucleotide mixtures was determined for each codon as follows. All possible sets of nucleotide mixtures with each component at 5% increments were filtered to select only those that closely match the desired levels of wild-type and tyrosine and reasonably match glycine, serine, aspartic acid, alanine, and arginine; these amino acids are the most frequent in antibody CDR-H3 and are functionally diverse.
- Sample protein libraries were then produced in silico from the amino acid probability distributions resulting from the sets of nucleotide mixtures.
- the library calculated to be most likely to be produced from the intended distribution (i.e., the antibody repertoire with the appropriate wild-type bias) was selected as optimal. This process was repeated for each position in the library.
- these skewed nucleotide mixtures provide good matches to the desired amino acid distributions ( Figure 2).
- the two exceptions are decreased levels of glycine and elevated cysteine. Since the latter two positions in a cysteine codon (TGT or TGC) are shared by glycine (GGN), it is not possible to create high levels of glycine without also yielding high cysteine unless TNN codons are depleted, which depletes tyrosine. Thus, a compromise is reached with 6% glycine and 10% cysteine.
- Fn3 genes were constructed by overlap extension PCR of partially degenerate oligonucleotides. Transformation into yeast by electroporation with homologous recombination yielded 2.5xlO 8 transformants. Sequencing and flow cytometry analysis indicate 60% of clones encode for full-length Fn3 resulting in 1.5xlO 8 Fn3 clones.
- the library is termed G4, as it is the fourth generation Fn3 library created in our laboratory after the two-loop, single- length BF 14 library (Lipovsek et al, J. MoI Biol, 368:1024-1041, 2007), the three-loop, length- diversified NNB library (Hackel et al, J. MoI Biol, 381:1238-1252, 2008), and the three-loop, DE-conserved tyrosine/serine library YS (Hackel and Wittrup, submitted).
- Loop Diversity indicates the library of codons included at positions without wild-type bias.
- Biased Positions indcates positions within the diversified loops (23-31, 52-56, 77-86) that are biased towards wild-type.
- Full-length Fn3s indicates the library size ⁇ i.e., the number of yeast transformants that encode for full-length Fn3 domains).
- the libraries were pooled for comparison and tested for their ability to generate binders to seven targets: human A33, mouse A33, epidermal growth factor receptor (EGFR), Fc ⁇ receptors HA and IIIA (Fc ⁇ RIIA and Fc ⁇ RIIIA), mouse immunoglobulin G (mlgG), and human serum albumin (HSA).
- the na ⁇ ve library was sorted by magnetic bead selections (Ackerman et al, Biotechnol Prog., 25:774-783 (2009)), and lead clones were diversified by error-prone PCR on the full Fn3 gene and shuffling of mutagenized Fn3 loops. Multiple rounds of selection and diversification were performed to yield binders to each target.
- a single clone has four cysteines.
- six of the seven two-cysteine clones contain cysteine residues in identical or adjacent loops at proximal positions suggesting feasible disulfide bonding, which can stabilize the domain (Lipovsek et al, J. MoI. Biol, 368:1024-1041, 2007).
- both wild-type bias and tailored diversity were effective in producing an effective library. Additional engineering campaigns and sequence analysis will improve the statistical significance of these trends and guide further library improvement.
- the impact of wild-type bias and tailored diversity on domain stability was analyzed.
- the NNB and G4 libraries were each induced for yeast surface display at elevated temperature (37°C).
- the G4 library exhibits 43 ⁇ 9% higher average display than the NNB library indicating higher average stability; clones from G4 are substantially more stable than those from NNB.
- the libraries were then sorted by FACS to identify clones of low stability and high stability. About 50 clones were sequenced from each resultant population and the amino acid frequencies in low and high stability clones were compared ⁇ see the Table of Figure 23).
- the biased positions in the BC loop were not critical to stability in this analysis except position 29. As observed in binder sequence analysis, the small side chain alanine is preferred whereas the larger side chain leucine is destabilizing.
- Wild-type amino acids at the four biased positions in the DE loop are stabilizing, especially S53 and S55. While G77 is perhaps mildly stabilizing, G79 is present at substantially higher frequency in stable clones. The complete conservation of S85 in the G4 library is justified by the preferential occurrence of S85 in stable clones from the NNB library. At positions without wild-type bias, none of the preferred amino acids are substantially destabilizing thereby validating their inclusion at elevated levels.
- wild-type bias is also an important element of the G4 library design. This bias increases the frequency of functional clones both by enabling diversity to be used at positions with more impact on binding and by reducing the number of non- functional clones that result from detrimental mutation of a structurally critical residue. Moreover, the improved stability of G4 clones improves evolvability (Bloom et al, Proc. Natl. Acad. Sci. USA,
- binders generated provides useful reagents for a variety of applications from tumor targeting (EGFR, human A33, and mouse A33) to biotechnology (HSA and mouse IgG) to immunology (Fc ⁇ RIIa and Fc ⁇ RIIIa).
- binders to tumor vasculature target CD276 were engineered solely from the G4 library.
- Yeast surface display plasmids were created for six Fn3 domains of previously published stabilities: wild-type, 159, 159(wt DE), 159(Q8L), 159(A56E), and 159(Q8L,A56E) (Parker et al, Protein Engineering Design and Selection, 18:435-444 (2005)). Genes were constructed by overlap extension PCR of eight oligonucleotides and transformed into EBYlOO yeast as described (Hackel et al, J. MoI. Biol, 381:1238-1252 (2008)). Gene construction was verified by DNA sequencing.
- SEQ ID NO: were diversified using NNB codons.
- the library was constructed by overlap extension PCR of eight oligonucleotides and transformed into EBYlOO yeast. Fourteen similar libraries were constructed with identical design except a single codon of interest was maintained as wild-type within the otherwise diversified regions. Separate libraries were constructed for D23, A24, P25, A26, V27, T28, V29, G52, T56, G77, R78, G79, S84, and S85; in addition, a library was constructed that maintained D23, A24, P25, and V29. These libraries, as well as wild-type Fn3, were grown at 30 0 C and induced at 37°; Fn3 expression was analyzed by flow cytometry as indicated above. The fractional improvement in display was calculated as the mean phycoerythrin fluorescence of the singly-conserved library minus that of the fully-diversified library and normalized to the fully-diversified fluorescence.
- Solvent-Accessible Surface Area The relative solvent accessible surface area of positions 22-32, 51-57, and 76-87 were calculated for wild-type Fn3 (solution structure ITTG (Main et al, Cell, 71:671-678, 1992) and crystal structures IFNA (Dickinson et al, J. MoI. Biol, 236:1079-1092, 1994) and an engineered binder (2OBG (Koide et al, Proc. Natl Acad. Sci. USA, 104:6632-6637, 2007).
- Fn3 solution structure ITTG (Main et al, Cell, 71:671-678, 1992) and crystal structures IFNA (Dickinson et al, J. MoI. Biol, 236:1079-1092, 1994) and an engineered binder (2OBG (Koide et al, Proc. Natl Acad. Sci. USA, 104:6632-6637, 2007).
- the area accessible to a 1.4A sphere was determined for each side chain in each structure and compared to the accessible area in a G-X-G random coiled peptide using GetArea (Fraczkiewicz and Braun, J. Computational Chemistry, 1998).
- Phylogenetic Sequence Alignment The following fibronectin sequences were used: chimpanzee (XP 516072), cow (P07589), dog, (XP 536059), horse (XP OO 1489154), human (NP 997647), mouse (NP 034363), opossum (XP OO 1368449), platypus (XP OO 1509150), rat (NP 062016), and rhesus monkey (XP OO 1083548). The sequences were aligned using
- Engineered Fn3 domain sequences were aligned (sequences as in: Hackel and Wittrup, submitted; Gilbreth et al, J. MoI Biol, 381:407-418, 2008; Huang et al, Proc. Natl. Acad. Sci. USA, 2008; Parker et al, Protein Engineering Design and Selection, 18:435-444, 2005; Koide et al, Proc. Natl. Acad. Sci. USA, 104:6632-6637, 2007; Hackel et al, J. MoI Biol, 381:1238-1252, 2008; Lipovsek et al, J. MoI,.
- oligonucleotides were designed to provide the desired amino acid distribution at each position. All three-site combinations of skewed nucleotide mixtures within 5% increments were considered (e.g., 20% A, 5% C, 35% G, 40% T at the first position, 15% A, 45% C, 10% G, 30% T at the second position, and 35% A, 25% C, 30% G, 10% T at the third position).
- the amino acid probability distribution of each set of nucleotides mixtures was calculated from the genetic code. The sets were filtered to identify those with good tyrosine matching and reasonable matching of alanine, aspartic acid, glycine, arginine, and serine.
- tyrosine was required to occur at 0.5-2x the intended frequency; alanine, aspartic acid, glycine, arginine, and serine were required to occur at 0.33-3x the intended frequency.
- the sets that fulfilled these criteria were then used to produce numerous in silico protein libraries based on their amino acid probability distribution. For each clone, the probability of occurrence from a library that precisely matched the desired distribution was calculated. The sum of probabilities for each sample library was used as a metric of library fitness.
- the skewed nucleotide designs were selected based on fitness and the ability to use identical mixtures at multiple sites ⁇ e.g., 45% C, 10% G, 45% T at the wobble position of multiple codons). Nucleotide designs are included in the Table of Figure 24.
- oligonucleotides were synthesized with skewed nucleotides at diversified positions and nucleotides encoding wild-type Fn3 at fully-conserved positions.
- the library design summarized in the Table of Figure 21, includes four, three, and four loop lengths in the BC, DE, and FG loops. Separate oligonucleotides were synthesized to yield each length.
- Overlap extension PCR of eight oligonucleotides was performed to construct complete Fn3 genes. Separate reactions were conducted for each loop length to avoid bias towards shorter loops.
- the gene libraries were transformed into yeast by homologous recombination with linearized yeast surface display vector, which includes the Aga2p protein fusion, N-terminal HA epitope, and C-terminal c-myc epitope.
- the fraction of clones that produce full-length Fn3 was determined by flow cytometry as the fraction displaying the N-terminal HA tag that also contained the C-terminal c-myc epitope; these results were corroborated by sequence analysis.
- Binder Selections Human and mouse A33 extracellular domains were both produced with His ⁇ epitope tags in human embryonic kidney cells and purified by metal affinity chromatography. Protein was biotinylated either on free amines using the sulfo-NHS
- EGFR mutant 404SG (Kim et al., Proteins, 62:1026-1035 (2006)) was produced in Saccharomyces cerevisiae yeast, purified by metal affinity chromatography and anti-EGFR antibody affinity chromatography, and biotinylated on free amines using the sulfo-NHS biotinylation kit.
- Biotinylated mlgG was purchased from Rockland Immunochemicals. Human serum albumin (Sigma) was biotinylated using the sulfo-NHS biotinylation kit. The NNB, YS, and G4 libraries were pooled for direct competition.
- the libraries were sorted for binding to the seven protein targets and affinity matured as described (Hackel and Wittrup, submitted). Yeast were grown and induced to display Fn3. Binders to streptavidin-coated magnetic Dynabeads were removed (Ackerman et ah, Biotechnol. Prog., 25:774-783 (2009)). Biotinylated protein was loaded on streptavidin-coated magnetic Dynabeads and incubated with the remaining yeast. The beads were washed with PBSA and the beads with attached cells were grown for further selection.
- full- length Fn3 clones were selected by fluorescence-activated cell sorting using the C-terminal c- myc epitope for identification of full-length clones.
- Plasmid DNA was zymoprepped from the cells and mutagenized by error-prone PCR of the entire Fn3 gene or the BC, DE, and FG loops. Mutants were transformed into yeast by electroporation with homologous recombination and requisite shuffling of the loop mutants. The lead clones and their mutants were pooled for further cycles of selection and mutagenesis. Once significant binder enrichment was observed during magnetic bead sorts, fluorescence activated cell sorting was used.
- Yeast displaying Fn3 were incubated with biotinylated target protein and anti-c-myc antibody (clone 9E10 or chicken anti-c-myc, Invitrogen). Cells were washed and incubated with AlexaFluor488-, phycoerythrin-, or AlexaFluor647-conjugated streptavidin and fluorophore-conjugated anti-mouse or anti- chicken antibody. Cells were washed and cells with the highest target to c-myc labeling ratio were selected on a FACS Aria or MoFIo flow cytometer. Plasmids from binding populations were zymoprepped and transformed into E. coli; transformants were grown, miniprepped, and sequenced.
- biotinylated target protein and anti-c-myc antibody clone 9E10 or chicken anti-c-myc, Invitrogen. Cells were washed and incubated with AlexaFluor488
- NNB and G4 libraries were independently grown at 30 0 C and induced at 37°.
- Yeast were labeled with mouse anti-HA antibody (clone 16B12, Covance) and chicken anti-c-myc antibody to label the N- and C-terminal epitopes.
- Cells were washed, incubated with phycoerythrin-conjugated goat anti-mouse antibody and AlexaFluor488- conjugated goat anti-chicken antibody, and sorted by flow cytometry. Only cells were comparable signals for each epitope were considered to avoid selecting epitope mutants. The lowest and highest displaying cells were collected and grown for an additional induction and selection.
- Plasmids were isolated and transformed into E. coli. About 50 clones from each resultant population (both low and high stability for both NNB and G4) were miniprepped and sequenced. Sequences were aligned and the amino acid frequencies at each position were determined.
- An alternative mode of therapy is substantial receptor downregulation to reduce or eliminate the detrimental effects of receptor activation on tumor formation, proliferation, and migration.
- a previously demonstrated means of receptor downregulation is administration of non-competitive pairs of antibodies.
- Antibodies 528 and 806 downregulate EGFR and synergistically inhibit tumor xenografts (Perera et al., Clin. Cancer Res., JJ_:6390-6399, 2005).
- Non-competitive antibody pairs 111 + 565 and 143 + 565 downregulate EGFR whereas the competitors 111 + 143 do not (Friedman et al, Proc. Natl. Acad. ScL USA, 102,: 1915-1920, 2005).
- non-competitive anti-HER2 antibodies downregulate HER2 and inhibit tumor growth (Friedman et al, Proc. Natl. Acad. ScL USA, 102,: 1915-1920, 2005; Ben-Kasus et al, Proc. Natl. Acad. ScL USA, 106,:3294-32999, 2009).
- these approaches require dosing two molecules, which complicates regulatory and clinical procedures.
- decoupled pharmacokinetics could reduce synergy.
- Fn3 domains provide a good system for bispecific constructs because their single- domain architecture enables simple head-to-tail fusion, which is the natural state of Fn3 domains within complete fibronectin protein.
- Binder Engineering Multiple high affinity binders to distinct epitopes of EGFR ectodomain were desired.
- the NNB, YS, and G4 libraries were pooled and sorted for binding to biotinylated EGFR ectodomain mutant 404SG (Kim et ah, Proteins, 62:1026-1035, 2006). Two clones dominated the selection.
- Competition against existing anti-EGFR antibodies revealed that clone E4.2.2 is competitive with ICRlO, a domain I binder, and clone E4.2.1 is competitive with 528, a domain III binder.
- To identify additional binders intermediate populations were sorted for binding to EGFR ectodomain in the presence of ICRlO or 528.
- affinity of each clone was determined by titration of biotinylated Fn3 binding to A431 (on ice to prevent internalization); affinities ranged from 250 pM to 30 nM (the Table of Figure 25).
- A431 cells were incubated with 0.01, 0.1, 1 or 10 nM of biotinylated E6.2.6 or E13.4.3, then washed, labeled with streptavidin-R-phycoerythrin, and analyzed by flow cytometry.
- EGFR ectodomain mutant 404SG was displayed on the yeast surface. Cells were incubated at 8O 0 C for 30 minutes to denature the EGFR. Cells were labeled with biotinylated Fn3 and mouse anti-c-myc antibody followed by streptavidin-R-phycoerythrin and
- AlexaFluor488-conjugated anti-mouse antibody Fluorescence was quantified by flow cytometry.
- Binders were tested for the ability to compete with other clones as well as with antibodies 225, 528, and ICRlO (Figure ).
- Clone A is competitive solely with ICRlO, a known domain I binder (Cochran et ah, Journal of Immunological Methods, 287:147-158 (2004)). This result was corroborated by the ability of clone A to bind the EGFR ectodomain fragment comprising amino acids 1-176 displayed on the yeast surface.
- Clone D is not competitive with the other Fn3s or antibodies tested. It is able to bind ectodomain fragments 294-543 and 302- 503, thereby localizing the binding to domain III and the beginning of domain IV.
- Clones B, C, E, EI3.4.2, and EI 1.4.1 compete with each other as well as antibodies 225 and 528, EGF- competitive domain III binders (except for three untested combinations; see Figure 4).
- A431 cells (for 225 and EGF competition) were incubated on ice with the indicated Fn3 clone or PBSA control. AlexaFluor488-conjugates of 225 or EGF were added and cells were analyzed by flow cytometry.
- yeast displaying EGFR ectodomain were incubated with Fn3 clone 528 or ICRlO followed by biotinylated Fn3, which was detected by streptavidin-R- phycoerythrin and flow cytometry.
- the black boxes indicate competition and the white boxes indicate no competition, "nd" indicates samples that were not determined.
- Clones A-E, as well as E6.2.10 compete with EGF for binding to A431 cells.
- Clones B, C, E, and E6.2.10 all bind domain III on the portion closer to domain II, which is consistent with complementary Fn3 competition as well as EGF competition.
- Antibody 225 competition is reasonable for clones B, C, and E given their proximity to the cetuximab (a 225 chimera) interface.
- the lack of E6.2.10 competition with 225 binding is also acceptable given their disparate, though proximal, epitopes.
- Clone D binds near the interface of domains III and IV, which is consistent with its fragment labeling and lack of competition against 225 and clones B, C, and E.
- the ability of clone D to compete with EGF cannot readily be explained by direct steric inhibition given their distal binding epitopes.
- binders At least three classes of binders have been engineered: clone A binds to domain I; clones B, C, and E bind domain III and are competitive with each other and antibodies 225 and 528 (as well as EIl.4.1 and EB .4.2); clone D binds to the C-terminal portion of domain III and the N-terminal portion of domain IV and does not compete with antibodies 225 and 528 nor clones B, C, E, EI 1,4.1, or EB.4.2.
- combinations of non-competitive clones in a heterobivalent construct downregulate surface EGFR, though the D-D homobivalent does moderately reduce receptor levels. Moreover, some orders work best. For example, A-D downregulates whereas D-A does not.
- EGFR-expressing cells were cultured in 96-well plates, serum starved, and treated with 20 nM D-B and D-C constructs for 10 hours.
- Surface EGFR was measured at 2, 4, 6, 8, and 10 hours after treatment, quantitated by flow cytometry and normalized to PBSA-treated control.
- D-B and D-C downregulated EGFR in these A431 cells with half-times of 1.1 and 1.4 hours, respectively.
- Downregulation in HeLa cells is slightly faster at 0.44, 0.59, and 1.3 hours for D-B, D-C, and D-E.
- the genetically modified Fn3 domains of the present invention and engineered proteins containing them may effect receptor (or target)
- Heterobivalent D-C and D-E constructs were created with three different lengths of the linker between the Fn3 domains; in addition to the native EIDKPSQ sequence (SEQ ID NO ), glycine-rich linkers of four, 15, or 27 amino acids were included.
- the constructs were tested for downregulation of EGFR in HT29, U87, HeLa, hMEC, CHO, and A431 cells. The cells were cultured in 96-well plates, serum starved, and treated with 20 nM of the D-C or D-E bivalent constructs for eight hours. Surface EGFR was quantified by flow cytometry and normalized to PBSA-treated control. Although results vary by cell line and by heterobivalent construct, the longer linkers were always the least effective (although still capable of receptor downregulation) and the shortest linker was often the most effective.
- bispecific format An alternative bispecific format was tested in which monovalent Fn3 domains were biotinylated and combinations of clones were immobilized on AlexaFluor488-conjugated streptavidin.
- A, C, D, E, EI1.4.1, and EI3.4.2 no downregulation is observed in HT29 or U87 cells transfected to overexpress EGFR.
- bispecific format appears critical for efficacy.
- internalized AlexaFluor488 signal at 37° correlates with surface labeling at 4° (which restricts internalization) suggestive of passive internalization for all combinations.
- HEK human embryonic kidney
- D- B and D-C heterobivalents are able to downregulate transfected EGFR.
- the activity of the transfected EGFR is validated by a strong correlation between the fraction of cells transfected and the downregulation of native EGF; thus, the presence of overexpressing transfected cells reduces the EGF -based downregulation of non-transfected cells possibly through ligand depletion or competition.
- EGFR mutants with point mutations in their intracellular domains were tested for their ability to be downregulated. All eight mutants (T654A, T669A, K721R, Y845F, S1046A/S1047A, Y1068F, Y1148F, Y1173F; all of which are within the scope of the present invention) exhibit downregulation on par with wild-type EGFR in the presence of D-B and D-C.
- heterobivalents on EGFR phosphorylation was analyzed at eight sites: T654, T669, Y845, S1046, Y1068, Y1086, Yl 148, and Yl 173.
- Heterobivalent D-C (20 nM), PBSA, or EGF was added to serum starved A431 cells for 5,15, 60, or 240 minutes, and receptor phosphorylation was quantified by in-cell Western blot. The cells were fixed, permeabilized, labeled with rabbit anti-phospho-(S/T/Y) antibody followed by anti-rabbit-800CW and ToPro3 (to stain DNA), and imaged.
- Receptor agonism by D-C is consistently lower than that by EGF with the lone exception of T669 at early times. In fact, receptor agonism is often non-distinct from background.
- the genetically modified Fn domains of the invention may exhibit a general lack of agonism for a target such as the EGFR.
- EGFR trafficking model is shown in Appendix B of the provisional application filed August 13, 2009. EGFR trafficking can be examined with a model consisting of four simple mechanisms: synthesis, endocytosis, degradation, and recycling. Constitutive synthesis produces surface receptor (S) at rate ksyn. Surface receptor is internalized to endosome (E) at rate kendoS. Endosomal receptor is degraded at rate kdegE or recycled to the surface at rate krecE.
- S surface receptor
- E endosome
- Endosomal receptor is degraded at rate kdegE or recycled to the surface at rate krecE.
- A431 cells were cultured in 24-well plates, serum starved, and treated with 20 nM agent for 6 hours. The cells were then treated with 1 nM EGF for 15 minutes. Cell lysates were separated by SDS-PAGE, blotted to nitrocellulose, and labeled with rabbit antiphosphoERKl/2 Y202/Y204 antibody followed by peroxidase-conjugated anti- rabbit antibody and imaged.
- the downregulating bivalents A-D, D-B, D-C, and D-E inhibit EGF-induced ERK phosphorylation at tyrosines 202 and/or 204 whereas non-downregulating B- B homobivalent has no effect.
- the monovalent EGF competitor clone D is also antagonistic. While the genetically modified Fn domains useful in the present engineered proteins are not limited to domains that work through any particular cellular mechanism, they may include those that inhibit EGF-induced ERK phosphorylation.
- hMEC+ECT or hMEC+TCT a membrane-bound EGF ligand with an EGF or TGF ⁇ cytoplasmic tail
- the cells were cultured in 96- well plates and treated with 20 nM of the indicated agent(s). Additional ligand was added after 48 hours. Viability was quantified using AlamarBlue and normalized independently for each time point relative to PBSA-treated cells.
- the engineered EGFR binders both in monovalent and bivalent formats, are effective intracellular delivery agents.
- Fn3 and Fn3-Fn3 constructs were conjugated to
- DyLight633 readily accumulated intracellularly for EGFR binding clones but not for wild-type Fn3.
- Biotinylated Fn3 domains loaded onto streptavidin conjugated to AlexaFluor488 and 1.4 nm NanoGold spheres were effectively delivered to EGFR-expressing cells but not EGFR negative cells.
- the panel of binders should provide useful reagents for a variety of applications.
- the small size should provide rapid clearance for in vivo imaging applications and close proximity of binding site and fluorophore for F ⁇ rster resonance energy transfer studies.
- the engineered domains are cysteine-free with primary amines located distal to the presumed binding site with two exceptions: EI1.4.1 contains a cysteine and lysine in the FG loop and clone D contains adjacent cysteines in the FG loop.
- EI1.4.1 contains a cysteine and lysine in the FG loop
- clone D contains adjacent cysteines in the FG loop.
- the domains are amenable to thiol and amine chemical conjugation to fluorophores, nanoparticles, drug payloads and chemically modified surfaces for drug delivery, diagnostic, and biotechnology applications.
- the single- domain architecture readily enables protein fusion such as the bivalents discussed herein and immunotoxins (Chris Pirie, unpublished data).
- the picomolar to low nanomolar binding of these domains is beneficial for most applications.
- the breadth of epitopes targeted is useful for biophysical studies and dual binding such as for receptor clustering or sandwich immunoassays.
- Non-competitive heterobivalent constructs can form receptor clusters because of the ability to bind two heterobivalents to a single receptor thereby propagating receptor linkages whereas homobivalents or competitive heterobivalents can only form two-receptor complexes. Meanwhile, the reduced efficacy of some non-competitive heterobivalents may arise from the inability to simultaneously bind two receptors given the distance and steric constraints of the epitopes targeted and the length and composition of the bivalent linker.
- EGF perhaps fails because of a saturation of the cellular machinery, but regardless the mechanism of downregulation is clearly different for EGF and Fn3-Fn3.
- multiple receptor mutants including kinase inactive K721R, are downregulated to the same extent as wild-type receptor. Mutation of neither T669 nor S 1046, whose phosphorylation is implicated in receptor internalization (Countaway et al, J. Biol. Chem., 267:1129-1140 (1992); Winograd-Katz and Levitzki, Oncogene, 25:7381-90 (2006)), nor T654, whose phosphorylation either inhibits ubiquitination or accelerates recycling (Bao et al, J. Biol.
- a simple mathematical model of receptor trafficking indicates that downregulation can be expected to arise from enhanced degradation/recycling ratio, enhanced receptor
- agonism counters the hypothesis of enhanced receptor internalization although endocytosis could be accelerated by weak phosphorylation.
- the throughput of constitutive internalization could be enhanced via receptor clustering.
- receptor internalization is not sped as monovalent clone B and downregulating D-B exhibit equivalent intracellular accumulation.
- receptor internalization kinetics Preliminary measurements of receptor internalization indicate endocytic half-times of 0.3-0.8h (data not shown). Thus, although receptor internalization may be sped slightly, it does not appear to be the dominant source of downregulation. Enhanced degradation could conceivably result from the presence of receptor clusters that either inhibit recycling or drive degradation. In fact, AlexaFluor488-conjugated 225 antibody exhibits reduced recycling in the presence of downregulating heterobivalent A-D as compared to co-treatment with monomer A or non-do wnregulating C-B.
- Downregulation decreases the amount of receptor available for ligand binding, receptor homo- and hetero-dimerization, and constitutive activation, thereby decreasing the opportunity for receptor signaling. Downregulation is sufficient to inhibit ERK phosphorylation, a downstream signaling molecule on a pathway that leads to proliferation and migration.
- Downregulating heterobivalents are shown to inhibit proliferation and migration of a cell line with autocrine signaling, and this inhibitory activity can be augmented by combination treatment with ligand-competitive antibody 225. Further study can elucidate the relative impacts of receptor downregulation and ligand competition as well as the in vivo efficacy of the
- EGFR binders were engineered from the NNB, YS, and G4 pooled library comparison as outlined above.
- EGFR mutant 404SG Ref' (Kim et al, Proteins, 62:1026- 1035 (2006)) was produced in Saccharomyces cerevisiae yeast, purified by metal affinity chromatography and anti-EGFR antibody affinity chromatography, and biotinylated on free amines using the sulfo-NHS biotinylation kit.
- the Fn3 yeast surface display libraries were pooled, grown in SD-CAA medium at 30 0 C, 250 rpm and display of Fn3 was induced in SG- CAA medium at 30 0 C, 250 rpm.
- Binders to streptavidin-coated magnetic Dynabeads were removed.
- One million biotinylated EGFR ectodomains were loaded on each often million magnetic beads and incubated with the remaining yeast. Beads were washed once with PBSA at 4° and beads with attached cells were grown for further selection. Remaining sorts were conducted with five million beads coated with one to two million ectodomains. After two sorts, full-length Fn3 clones were selected by FACS using the C-terminal c-myc epitope. Plasmid DNA was zymoprepped from the cells and mutagenized by error-prone PCR of the entire Fn3 gene or the BC, DE, and FG loops.
- Mutants were transformed into yeast by electroporation with homologous recombination and requisite shuffling of the loop mutants.
- the lead clones and their mutants were pooled for further cycles of selection and mutagenesis.
- a single binding sort on magnetic beads was followed by a binding sort by FACS.
- the Fn3 gene was digested with Nhel and BamHI and transformed to a pET vector containing a HHHHHHKGSGK-encoding C-terminus (SEQ ID NO: ).
- the six histidines enable metal affinity purification, and the pentapeptide provides two additional amines for chemical conjugation.
- the plasmid was transformed into Rosetta (DE3) E. coli, which was grown in LB medium with 100 mg/L kanamycin and 34 mg/L chloramphenicol at 37°. Two hundred ⁇ L of overnight culture was added to 100 mL of LB medium, grown to an optical density of 0.2-1.5 units, and induced with 0.5 mM IPTG for 3-24 hours.
- lysis buffer 50 mM sodium phosphate, pH 8.0, 0.5M NaCl, 5% glycerol, 5 mM CHAPS, 25 mM imidazole, and Ix complete EDTA-free protease inhibitor cocktail
- the soluble fraction was clarified by centrifugation at 15,00Og for 10 min. and Fn3 was purified by metal affinity chromatography on TALON resin. Purified Fn3 was buffer exchanged into PBS and biotinylated with NHS-LC-biotin according to the manufacturer's instructions.
- An Fn3-linker-Fn3 construct was produced by standard molecular cloning techniques.
- the resultant vector encodes for FnS-EIDKPSQ-GSGGGSGGGKGGGGT-FnS-EIDKPSQ- ELRS-HHHHHH in which the N-terminal Fn3 is bracketed by Nhel and BamHI restriction sites and the C-terminal Fn3 is bracketed by Kpnl and Sad sites.
- the reduced linker encodes a GSGT linker.
- the extended linker is GSGGGSGGGK-GGGSGGGNGGGSGGGGT (SEQ ID NO_). Protein was produced as for Fn3.
- Affinity Titration A431 cells were washed in PBSA and incubated with various concentrations of biotinylated Fn3 on ice. The number of cells and sample volumes were selected to ensure excess Fn3 relative to EGFR. For some clones, this criterion necessitates very low cell density, which makes cell collection by centrifugation procedurally difficult. To obviate this difficulty, 'bare' yeast cells are added to the sample to enable effective cell pelleting during centrifugation. Cells were incubated on ice for sufficient time to ensure that the approach to equilibrium was at least 98% complete.
- Epitope Conformational Sensitivity Yeast were grown and induced to display EGFR ectodomain, incubated at 4°C or 80 0 C for 30 minutes, and chilled on ice for 10 minutes. Cells were labeled with 40 nM biotinylated Fn3 and 300 nM mouse anti-c-myc antibody followed by streptavidin-R-phycoerythrin and AlexaFluor488-conjugated anti-mouse antibody. Fluorescence was quantified by flow cytometry. Binding (R-phycoerythrin) was normalized to full-length display (AlexaFluor488).
- Yeast displaying EGFR ectodomain or A431 cells were washed and incubated with initial competitor Fn3 or antibody for 30 minutes.
- Alternative competitor Fn3, antibody, or AlexaFluor488-conjugated EGF was then added and incubated for 30 minutes. Cells were washed and secondary reagent was added to detect the alternative competitor:
- fluorescein-conjugated anti-His antibody streptavidin-R-phycoerythrin, R-phycoerythrin- conjugated anti-mouse antibody, and fluorescein-conjugated anti-rat antibody for Fn3, biotinylated Fn3, mouse antibodies, and rat ICRlO, respectively.
- Cells were washed and analyzed by flow cytometry. Samples with and without initial competitor were compared to determine competition.
- EGFR Fragment Labeling EGFR ectodomain fragments comprising amino acids 1-176, 294-543, and 302-503 were displayed on the yeast surface (Cochran et al, Journal of Immunological Methods, 287:147-158 (2004)). Cells were washed and incubated with 30 nM biotinylated Fn3 and mouse anti-c-myc antibody followed by streptavidin-R-phycoerythrin and AlexaFluor488-conjugated anti-mouse antibody. Cells were washed and analyzed by flow cytometry,
- Fine Epitope Mapping A low mutation library of EGFR ectodomain, produced by Ginger Chao as described (Chao et al, Journal of Molecular Biology, 342:539-550 (2004)), was grown and induced. Yeast were labeled with biotinylated Fn3 and mouse anti-c-myc antibody followed by AlexaFluor647-conjugated streptavidin and AlexaFluor488-conjugated anti-mouse antibody. Cells were washed and analyzed by flow cytometry.
- Cells were labeled with biotinylated Fn3 and mouse 199.12 (for clones A, E, and E6.2.10) or mouse 225 (for clone D) anti-EGFR antibody followed by AlexaFluor647-conjugated streptavidin and R-phycoerythrin-conjugated anti-mouse antibody. Cells were washed and analyzed by flow cytometry. Cells displaying folded ectodomain (AlexaFluor488 ) with reduced Fn3 binding (AlexaFluor647 weak ) relative to unmutated ectodomain were collected, grown, and induced.
- A431 cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
- DMEM Dulbecco's modified Eagle medium
- FBS fetal bovine serum
- CHO cells transfected with a vector to express EGFR-green fluorescent protein were cultured in DMEM with 10% FBS, 1% sodium pyruvate, 1% nonessential amino acids, and 0.2 g/L G418, HeLa cells were cultured in Eagle's minimal essential medium with 10% FBS.
- hMEC cells were cultured in supplemented HuMEC medium.
- HT29 cells were cultured in McCoy's medium with 10% FBS.
- U87 cells were cultured in DMEM with 10% FBS, 1% sodium pyruvate, and 1% non-essential amino acids. Cells were detached for subculture or assay use with 0.25% trypsin and 1 mM EDTA. For serum starvation, medium was removed by aspiration, cells were washed with warm PBS, and fresh serum-free medium was added.
- Downregulation Assays Cells were subcultured into 96-well plates, grown for 2 days, and serum starved for 12-18 h. Cells were treated with 20 nM Fn3-Fn3 or EGF for the indicated time. Medium was removed by aspiration and cells were washed with PBS, detached with trypsin/EDTA, and placed on ice for the remainder of the assay. Bound Fn3-Fn3 or ligand was removed by 5 min. acid strip with 0.2M acetic acid, 0.5 M NaCl. Cells were washed with PBSA and incubated in mouse 225 antibody followed by R-phycoerythrin-conjugated anti-mouse antibody. Cells were washed and analyzed by flow cytometry. Mean fluorescence was normalized to PBSA-treated control samples.
- HEK Transfectants An EGFR expression vector built on the pCDNA3 vector was used as wild-type or modified by site-directed mutagenesis to introduce T654A, T669A, K721R, Y845F, S1045A/S1046A, Y1068F, Yl 148F, or Yl 173F mutations. Mutation was verified by sequence analysis. HEK cells were grown to 1.2-1.5 million cells per mL and diluted to one million per mL. Miniprepped DNA and polyethyleneimine were independently diluted to 0.05 and 0.1 mg/mL in OptiPro medium and incubated at 22° for 15 min. Equal volumes of DNA and polyethyleneimine were mixed and incubated at 22° for 15 min.
- In-CeIl Western Blot A431 cells were cultured in 96-well plates, serum starved for 12- 24 h, and treated with 20 nM Fn3-Fn3 or EGF. Cells were fixed for 10 min. by addition of an equal volume of 4% formaldehyde. Cells were washed and permeabilized with four washes of PBS with 0.1% Triton XlOO and blocked in Odyssey blocking buffer for 2h at 22° or overnight at 4°. Cells were incubated in 10 nM rabbit anti-phospho(S/T/Y) for 2h at 22° or overnight at 4°.
- A431 cells were cultured in 24-well plates and serum starved for 16h.
- agonism assay cells were treated with 20 nM Fn3-Fn3, antibody, or EGF for 15 min.
- antagonism assay cells were treated with Fn3, Fn3-Fn3, or antibody for 6 h followed by 1 nM EGF for 15 min.
- Medium was removed by aspiration and cells were washed twice with cold PBS and lysed for 5 min. in 50 ⁇ L of RIPA buffer with protease and phosphatase inhibitors and EDTA (Pierce).
- Lysates were clarified by centrifugation at 14,00Og for 15 min., separated by SDS-PAGE on a 12% BisTris gel, and blotted to nitrocellulose. Blots were blocked in 5% nonfat dry milk and labeled with 1 : 1000 anti-phosphoERKl/2 Y202/Y204 antibody (Cell Signaling, Danvers, MA) followed by peroxidase-conjugated anti-rabbit antibody. Blots were incubated in SuperSignal West Dura substrate and imaged. Blots were than washed extensively, labeled with rabbit anti-GAPDH antibody followed by peroxidase-conjugated anti-rabbit antibody, incubated with substrate and imaged. PhosphoERKl/2 Y202/Y204 labeling was normalized by GAPDH signal.
- Quantitative Phosphoproteomics A431 cells were cultured in 12-well plates, serum starved for 16 h, and treated with 20 nM Fn3-Fn3, Fn3 + Fn3, or EGF for 15 or 60 min. Medium was removed by aspiration and cells were washed with PBS and lysed in 8M urea with 1 mM Na 3 VO 4 . Phosphoproteomic analysis was performed by Jason Neil of the Forest White lab (MIT). Lysates are digested to form peptides and labeled with iTRAQ reagents.
- MIT Forest White lab
- Phosphotyrosine-containing peptides are isolated by immunoprecipitation with a pool of polyclonal anti-phosphotyrosine antibodies and phosphopeptides are enriched by immobilized metal affinity chromatography. Peptides are separated and analyzed by LC-MS/MS. Peptides are identified using MASCOT and relative abundance is determined by comparison of peak intensities.
- hMEC cells transfected with a vector for membrane -bound EGF ligand with a TGF ⁇ cytoplasmic tail (hMEC+TCT (Joslin et al, J. Cell ScL, 120:3688-99 (2007))) were obtained from Doug Lauffenburger (MIT). Eight thousand cells were plated into each well of a 96-well plate and incubated in 100 ⁇ L of medium with 20 nM agent for 48 h or 96 h. For 96 h samples, medium was supplemented with fresh agent at 48h. Cell viability was quantified using the AlamarBlue assay (Invitrogen) according the manufacturer's instructions and normalized to PBSA-treated control.
- hMEC, hMEC+ECT, or hMEC+TCT cells were cultured in 96-well plates to confluent monolayers. Wounds were scratched into the monolayer using a pipette tip, and cells were washed with fresh medium and imaged on a Nikon confocal microscope with robotic stage. Cells were treated with 20 nM agent in 100 ⁇ L of medium, incubated for 24 h or 48 h, and imaged at identical fields of view. Migration was quantified as the average reduction in separation across the wound and normalized to PBSA-treated control.
- Fn3 and Fn3-Fn3 were fluorophore-labeled on primary amines using
- DyLight633 NHS-ester (Pierce) according to the manufacturer's instructions and extensively desalted.
- HT29 cells were cultured in 96-well plates, serum starved, and incubated with 20 nM Fn3-(Fn3)-DyLight633 for 0-9 hours. Cells were detached using trypsin/EDTA, acid stripped in 0.2 M acetic acid, 0.5 M NaCl for 5 minutes and analyzed by flow cytometry.
- Biotinylated Fn3 was incubated with streptavidin-NanoGold(1.4 nM)-AlexaFluor488 (Nanoprobes, Yaphank, NY) at a 3:1 Fn3:streptavidin ratio.
- streptavidin-NanoGold(1.4 nM)-AlexaFluor488 Nemoprobes, Yaphank, NY
- A431, HT29, and SWl 222 cells were cultured in 96-well plates and treated with 20 nM complex for 12h. Cells were detached using trypsin/EDTA, acid stripped in 0.2M acetic acid, 0.5M NaCl, and analyzed by flow cytometry.
- FIG. 12 The modular constructs depicted in Figure 12, which have configurations that can be assumed by the engineered proteins of the present invention, were secreted from HEK 293 cells co-transfected with havy and light chain expression plasmids derived from the gWiz vector. Secretions were harvested after eight days, purified via protein A affinity chromatography and concentrated in phosphate buffered saline. Yields ranged from 100-4000 ⁇ g/L depending on the antibody format and the fibronectin clone used.
- the binding epitope of the 225 mAb from which the constructs were derived and the binding epitopes of various EGFR-binding fibronectins are shown in the Table below. Residues implicated in the binding of the EGFR targeted fibronectin clones were identified using yeast surface display based fine epitope mapping. The 225 epitope from the published crystal structure of the bound Fab fragment is also listed.
- the affinity of the Ab-Fn3 fusion is an order of magnitude greater than that of the unmodified 225 antibody, both at endosomal pH (6.0) and physiological pH (7.4).
- the unconjugated 225 antibody and the Ab-Fn3 fusion HN-D were titrated on the surface of A431 cells at pH 6.0 and pH 7.4.
- A431 cells express 2.8 x 10 6 EGFR per cell.
- the insensitivity of binding to pH reduction indicates that the engineered protein will remain bound to EGFR following internalization.
- the measured equilibrium dissociation constants for HN-D at pH 7.4 and 6.0 were 40 and 75 pM, respectively, compared to 370 and 1284 pM for mAb 225.
- FIG. 15 The advantage of targeting a cell-surface receptor such as EGFR with a multispecific (or heterobivalent) engineered protein is shown in Figure 15.
- EGFR cell-surface receptor
- Figure 15 The presence of two non-competitive EGFR binding moieties enables receptor clustering. Clustering has been shown to abrogate EGFR recycling, thereby decreasing surface receptor expression and activation of downstream signaling pathways.
- Deconvolution microscopy images show a dramatic change in receptor localization following Ab-Fn3 fusion treatment relative to 225 mAb treatment in two EGFR-expressing tumor cell lines, suggesting receptor clustering.
- A431 and HeLa cells were treated with fluorescently-labeled 225 or fluorescently-labeled HN Ab-Fn3 fusion (containing f ⁇ bronectin clone D) for 1, 2, 4, or 6 hours. Cells were then washed and imaged on a Delta Vision deconvolution microscope for comparison of EGFR localization. We observed a dramatic difference in receptor distribution following treatment with the multispecific construct compared to treatment with an unconjugated mAb (Figure 16).
- FIGS 17(A) and (B) The results of studies of surface EGFR downregulation are shown in Figures 17(A) and (B). Seven EGFR expressing cell lines (listed in increasing order of EGFR expression) were treated with 20 nM antibody or antibody- fibronectin fusions for 13 hours at 37 0 C, allowing receptors to reach a new steady state level. Cells were then acid stripped, labeled with anti- EGFR antibody and fluorophore-conjugated secondary antibody, and analyzed via flow cytometry to quantify remaining surface receptor. Results are shown for the Ab-Fn3 fusions versus 225 and the potent 225 + Hl 1 mAb combination.
- the HN-B downregulates the most potently of all the single Fn3 -containing fusions, but the bispecif ⁇ c compounds generally fail to potently downregulate receptor on EGFR-dense cell lines such as A431.
- Figure 7(B) the same seven EGFR expressing cell lines used in bispecif ⁇ c downregulation assays were treted with 20 nM antibody or antibody- f ⁇ bronectin fusion for 13 hours at 37 0 C, allowing receptors to reach a new steady state level. Cells were then acid stripped, labeled with an anti-EGFR antibody and fluorophore-conjugated secondary antibody, and analyzed via flow cytometry to quantify remaining surface receptor relative to untreated cells.
- Results are shown for the Ab-Fn3 fusions versus 225 and the potent 225 + Hl 1 mAb combination.
- the trispecif ⁇ c constructs downregulate more potently than the bispecif ⁇ c constructions showin in Figure 17(A) and that trispecif ⁇ c constructs with f ⁇ bronectin moieties on both chains downregulate more effectively than those with both f ⁇ bronectin moieties on the same chain.
- the most potent constructs HNA+LCD, HND+LCA, and HNB+LCD
- Serum-starved A431 cells were incubated with 225, HI l, the 225+H11 combination, and EGF at 37 0 C for 15 minutes or 60 minutes. EGF stimulation was held constant at 15 minutes for both screens. Cells were then lysed and relative protein phosphorylation was measured using an iTraq-based mass spectrometry screen.
- Relative migration was measured as fractional wound replensihment compared to that of the untreated control ( Figure 20).
- proliferation assays cells were treated with the specified mAbs for 72 hours at 37 0 C. Relative proliferation was assessed as viable cell abundance compared to that of untreated cells
- DMEM for A431, U87-MG, U87-MGSH, and CHO-EG cells
- McCoy's Modified 5A media for HT-29 cells
- EMEM for HeLa cells
- HuMEC Ready Medium Invitrogen, Carlsbad, CA
- U87-MG, U87-MGSH, and CHO-EG media were supplemented with 1 mM sodium pyruvate (Invitrogen) and 0.1 mM non-essential amino acids (Invitrogen) and transfected lines U87-MGSH and CHO-EG were selected with 0.3 mM Geneticin (Invitrogen).
- ATCC media was supplemented with 10% fetal bovine serum (FBS).
- FBS fetal bovine serum
- 225 was secreted from the hybridoma cell line (ATCC). Unless otherwise noted, all washes were conducted in PBS containing 0.1% BSA and all mAbs were used at a concentration of 40 nM for single treatment and 20 nM each for combination treatment. EGF (Sigma, St. Louis, MO) was dosed at 20 nM. Trypsin-EDTA (Invitrogen) contains 0.05% trypsin and 0.5 mM EDTA.
- HEK 293F cells (Invitrogen) were grown to 1.2 million cells per mL and diluted to one million per mL.
- Miniprepped DNA and polyethyleneimine (Sigma) were independently diluted to 0.05 and 0.1 mg/mL in OptiPro medium and incubated at 22°C for 15 minutes. Equal volumes of DNA and polyethyleneimine were mixed and incubated at 22°C for 15 minutes. 500 mL of cells and 20 mL of
- DNA/polyethyleneimine mixture were added to a 2 L roller bottle and incubated at 37°, 5% CO 2 on a roller bottle adapter for seven days.
- the cell secretions were then centrifuged for 30 minutes at 15,000xg and the supernatant was filtered through a 0.22 ⁇ m bottle-top filter and purified via affinity column chromatography using protein A resin (Thermo Fisher Scientific, Waltham, MA).
- the eluted constructs were concentrated and transferred to PBS and then characterized by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis. Affinity titrations.
- A431 cells were trypsinized, washed in PBSA, and incubated with various concentrations of Ab-Fn3 in a 96-well plate on ice. The number of cells and sample volumes were selected to ensure at least tenfold excess Ab-Fn3 relative to EGFR. Cells were incubated on ice for sufficient time to ensure that the approach to equilibrium was at least 99% complete. Cells were then washed and labeled with 66 nM PE-conjugated goat anti-human antibody (Rockland Immunochemicals, Gilbertsville, PA) for 20 min on ice.
- PE-conjugated goat anti-human antibody Rockland Immunochemicals, Gilbertsville, PA
- Receptor quantification Cells were serum starved for 12-16 h, washed, digested in trypsin-EDTA (20 min at 37°C), neutralized with complete medium, and labeled with 20 nM 225 for 1 h on ice. They were then washed, labeled with 66 nM phycoerythrin (PE)-conjugated goat anti-mouse antibody (Invitrogen) for 20 min on ice, washed again, and subjected to quantitative flow cytometry on an EPICS XL cytometer (Beckman Coulter, Fullerton, CA). Receptor density was calculated based on a curve of identically labeled anti-mouse IgG-coated beads (Bangs Laboratories, Fishers, IN).
- PE phycoerythrin
- mAb 225 and Ab-Fn3 fusion constructs were labeled with Alexa 488 using a fluorescent labeling kit (Invitrogen).
- A431 cells were plated at 50,000 per well in 8-well microscopy chambers and allowed to settle overnight. They were then incubated with the appropriate mAb or fusion construct for various time lengths at 37°, 5% CO 2 . Wells were then washed and cells were resuspended in phenol red- free medium for imaging on a Delta Vision inverted deconvolution microscope. Deconvolution of 0.15 ⁇ m z-slices and image analysis were performed using the Softworx software package.
- Receptor downregulation assays Cells were seeded at 5x10 4 per well in 96-well plates, serum starved for 12-16 h, treated with the indicated mAbs or Ab-Fn3 fusions in serum-free medium, and incubated at 37 0 C. At each time point, cells were washed and treated with trypsin- EDTA for 20 min at 37 0 C. Trypsin was neutralized with medium (10% FBS) and cells were transferred to v-bottom plates on ice. They were then washed, acid stripped (0.2 M acetic acid, 0.5 M NaCl, pH 2.5), and washed again prior to incubation with 20 nM 225 for 1 h on ice to label surface EGFR.
- A431 cells were seeded at 4x10 4 per well in 96-well plates and allowed to adhere for 24 hours. Following 12-16 hours of serum starvation, cells were treated with the designated mAbs in serum-free medium at 37 0 C for the specified time length. All subsequent incubations were performed at room temperature. Cells were fixed for 20 minutes (PBS, 4% formaldehyde), permeabilized via four 5 minute incubations (PBS, 0.1% triton), blocked for 1 hour in Odyssey blocking buffer (Licor Biosciences, Lincoln, NE), and labeled for 1 hour with 15 nM anti-phosphosite antibodies (Genscript, Piscataway, NJ) in blocking buffer.
- PBST PBS, 0.1% Tween-20
- 66 nM 800-conjugated goat anti-rabbit antibody Rockland Immunochemicals
- 400 nM TO-PRO-3 DNA stain Invitrogen
- Luminex phosphoprotein quantification assays A431 cells seeded in 96-well plates at 3x10 4 per well were allowed to settle for 24 hours prior to 12-16 h serum starvation. Cells were then incubated with the specified mAbs in serum-free medium at 37 0 C. At the indicated times, cells were lysed using the Bio-Plex cell lysis kit (Bio-Rad, Hercules, CA). Phosphorylated ERKl/2 abundance was quantified using the Luminex bead-based immunoassay, performed with the Bio-Plex Phospho-ERKl/2 (T202/Y204, T185/Y187) bead kit and the Bio-Plex
- Phosphopeptide enrichment by IMAC and analysis and quantification of eluted peptides were conducted via ESI LC/MS/MS on an LTQ-Orbitrap (Thermo Fisher Scientific). Phosphopeptides were identified using Mascot analysis software and spectra were manually validated. Signal intensities were normalized by total protein levels and compared to isotype control treatment.
- HMEC and ECT cells were seeded at 5x10 4 per well in 96-well plates and grown to confluence. Monolayers were wounded with a pipet tip, washed with PBS, and placed in complete medium with the indicated mAbs. Scratch area was measured immediately and after a 24 hour incubation at 37 0 C using Image J software analysis of images from a Nikon confocal microscope (Nikon Instruments, Melville, NY). Percent migration was calculated as the fractional reduction in scratch area in the treated wells divided by that of the untreated wells.
- HMEC and ECT cells were seeded at 5x10 3 per well in 96-well plates and allowed to adhere for 24 h. They were then treated with the indicated mAbs in complete medium and incubated at 37 0 C for 72 hours. Cell viability (relative to an untreated control) was assessed using the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay (Invitrogen).
- MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention features engineered proteins that can include a genetically modified Fn domain; two or more such domains joined to one another; or at least one genetically modified Fn domain joined to a target-specific protein scaffold. One or more accessory sequences can be included in or added to any of these configurations. Methods of use, including methods of treating cancer, with the engineered proteins are also disclosed.
Description
ENGINEERED PROTEINS INCLUDING MUTANT FIBRONECTIN DOMAINS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of the filing date of U.S. provisional application No. 61/233,820, filed August 13, 2009, and U.S. provisional application No. 61/370,377, filed August 3, 2010. For the purpose of any U.S. patent that may grant based on the present application, the content of these prior provisional applications is incorporated herein by reference in its entirety.
GOVERNMENT RIGHTS STATEMENT
This invention was made with government support awarded by the National Institutes of Health under Grant No. CA96504 and National Science Foundation Fellowship Stipend
2387941. The U.S. government has certain rights in this invention.
TECHNICAL FIELD
This invention relates to engineered proteins, and more particularly to engineered proteins that include at least one genetically modified fibronectin (Fn) domain. The proteins can specifically bind target molecules, such as cell surface receptors, and thereby affect cellular physiology (e.g., cellular proliferation, differentiation, or migration).
SUMMARY OF THE INVENTION
The present invention is based, in part, on our discovery of engineered proteins that include at least one genetically modified fibronectin (Fn) domain (e.g., a type III fibronectin domain (Fn3)). Where more than one domain is included, each domain may bind a different epitope on a given molecular target. For example, an engineered protein can include (a) a first genetically modified Fn domain that binds a first epitope on a molecular target (e.g., a cellular receptor) and (b) a second genetically modified Fn domain that binds a second epitope on the same target (e.g., the same cellular receptor).
In one embodiment, the engineered protein can include (a) one or more genetically modified Fn domains and (b) one or more heterologous amino acid sequences, which may contribute to the therapeutic activity of the engineered protein by, for example, binding an epitope on the molecular target. We may refer to such heterologous amino acid sequences as
target- specific protein scaffolds. While heterologous sequences (or target- specific protein scaffolds) are described further below, we note here that they can constitute an immunoglobulin or a biologically active fragment or other variant thereof (e.g., an scFv). More broadly, we use the term "heterologous" to indicate that the amino acid sequences that may contribute to therapeutic activity are distinct (e.g., distinct in their sequence or structure) from the genetically modified Fn domain to which they are joined.
Any of the engineered proteins can further include an amino acid sequence that: prolongs the circulating half-life of the engineered protein; facilitates its purification; facilitates conjugation; is a label, marker or tag (including an imaging agent) or serves as a linker (e.g., between a first and second genetically modified Fn domain or between a genetically modified Fn domain and a heterologous amino acid sequence such as an immunoglobulin). We may refer to these sequences as "accessory" sequences.
To summarize the embodiments described above, the engineered protein can be: a genetically modified Fn domain; two or more such domains joined to one another; or at least one genetically modified Fn domain joined to a target-specific protein scaffold. One or more accessory sequences can be included in or added to any of these configurations. While we discuss these proteins further below, we note here that where at least one genetically modified Fn domain is joined to a target-specific protein scaffold, the protein scaffold can be an
immunoglobulin (e.g., an IgG) that is joined (directly or via a linker) to one, two, or more genetically modified Fn domains. The Fn domains can be identical to one another or distinct, and they can be joined to either the amino or carboxy terminus of the target-specific protein scaffold. For example, where the protein scaffold is an IgG, one or more genetically modified Fn domains can be joined (e.g., fused) to the amino or carboxy terminus of a light chain (or chains), to the amino or carboxy terminal of a heavy chain (or chains), or to any combination of these positions. For example, a first genetically modified Fn domain can be joined to the amino terminus of one or both heavy chains and a second genetically modified Fn domain can be fused to the carboxy terminus of one or both light chains. The first and second Fn domains can be the same in their sequence and/or binding specificity (e.g., they may bind the same epitope on a molecular target) or they may differ from one another in their sequence and/or binding specificity (e.g., they may bind two different epitopes on the same or different molecular targets).
Where an engineered protein binds more than one epitope, we may refer to the engineered protein as "heterovalent" (e.g., heterobivalent where two different epitopes are bound; heterotrivaent where three different epitopes are bound; and so forth). Where an engineered protein binds two of the same epitope, we may refer to it as homobivalent. We may also refer to the binding as "specific" or "selective", as a genetically modified Fn domain or a target-specific protein scaffold (e.g. , an immunoglobulin) can bind an epitope on a molecular target to the substantial exclusion of other molecular targets or other epitopes within the same target.
We may refer to the engineered proteins described herein as "including" certain sequences. For example, we describe engineered proteins including first and second genetically modified fibronectin domains. We also describe proteins including first and second genetically modified fibronectin domains and a heterologous amino acid sequence. In all events, the engineered proteins described herein can include, consist of, or consist essentially of the recited sequences.
The engineered proteins, compositions containing them pharmaceutically acceptable preparations, stock solutions, kits, and the like), nucleic acids encoding them, and cells in which they are expressed (e.g., cells in tissue culture) are all within the scope of the present invention. Methods of making and methods of isolating or purifying the engineered proteins are also within the scope of the present invention. We may refer to an engineered protein as "isolated" or "purified" when it has been substantially separated from materials with which it was previously associated. For example, an engineered protein can be isolated or purified following chemical synthesis or expression in cell culture. Methods of using the engineered proteins to assess cells in vitro and to treat patients are also within the scope of the present invention. Production, isolation, formulation, screening, diagnostic and treatment methods are discussed further below.
The genetically modified Fn domains, heterologous sequences, and accessory sequences can be joined by various means, including by covalent bonds. For example, these sequences can be joined as a fusion protein (e.g., where amino acid residues are joined by peptide bonds) or as a chemical conjugate. As noted, the accessory sequence can be a polypeptide linker between two Fn domains or between a Fn domain and a heterologous sequence. For example, the engineered protein can consist of or include two genetically modified Fn domains that are fused to one another or conjugated to one another. In another embodiment, the engineered protein can consist
of or include one or more genetically modified Fn domains that are fused to or conjugated with an antibody targeting the same molecular target (or antigen) such as Erbitux® (cetuximab;
Imclone), Vectibix® (panitumumab; Amgen), EMD72000 (EMD Serono), antibody 806 (The Ludwig Institute for Cancer Research), or antibody 425 (Merck). A genetically modified Fn domain and a target-specific protein scaffold (e.g. , an immunoglobulin) target the same molecular target (or antigen) when they specifically bind the same molecular target (or antigen). For example, the genetically modified Fn domain and a target-specific protein scaffold to which it is joined can specifically bind the same cell-surface protein (e.g., a tyrosine kinase receptor). The genetically modified Fn domain and the target-specific protein scaffold may bind distinct (e.g. , non-overlapping) epitopes on the molecular target.
We may refer to antibodies such as those listed above, any of which can be incorporated into the present engineered proteins, as "ligand-competitive antibodies." While one or more genetically modified Fn domains can be joined to (e.g., fused to or conjugated with) a whole, complete, or full-length protein scaffold, the Fn domain(s) can also be joined to a biologically or therapeutically active fragment or other variant of a protein scaffold (e.g., an antibody or another target-specific protein scaffold, examples of which are provided below). Thus, fragments or other variants of the currently available antibodies listed above can also be incorporated into the engineered proteins of the present invention and are useful in the present methods so long as they retain biological activity (e.g., sufficient and selective binding to the molecular target).
Compositions in which two or more of the amino acid sequences described herein are included but not physically joined are also within the scope of the present invention. For example, the composition can be a pharmaceutically acceptable preparation including, in admixture, a genetically modified fibronectin domain and a heterologous amino acid sequence. For example, the composition can be a solution suitable for intravenous administration.
Similarly, cells and patients can be treated as described herein but with an admixture or similar formulation of two or more of the target-binding amino acid sequences of the engineered proteins described herein. For example, a pharmaceutical formulation can include, as separate entities, a genetically modified Fn domain and an immunoglobulin, including any of the currently available immunoglobulins that specifically bind a molecular target as described herein (e.g., cetuximab).
In other aspects, the invention features methods of making the engineered proteins described herein and compositions containing them (e.g. , stock solutions or pharmaceutically acceptable formulations). The methods of generating engineered proteins can be carried out using standard techniques known in the art. For example, one can use standard methods of protein expression (e.g., expression in cell culture with recombinant vectors) followed by purification from the expression system. In some circumstances (e.g. , to produce a given domain, linker, or tag), chemical synthesis can also be used. These methods can be used alone or in combination to produce engineered proteins having one or more of the sequences described in detail herein as well as engineered proteins that differ from those proteins but that have the structure and one or more functions of an engineered protein as described herein (e.g., the configuration and components described herein and an ability to specifically bind a molecular target).
In another aspect, the invention features screening methods in which one or more epitopes on a target are used to identify or construct engineered proteins (or domains thereof) that specifically bind that epitope or epitopes.
Among the process methods of the present invention are methods of creating
combinatorial libraries of fibronectin clones, taking into consideration the parameters specified in the Examples below. The libraries may include clones in which one or more of the amino acid residues in the otherwise diversified binding loops of a Fn domain are maintained as wild-type sequence or as preferentially biased toward wild-type sequence. The selection of these conserved or biased amino acid positions can be aided through identification of clones that stabilize the domain or are accessible to solvent based on structural analysis. The clones may also be present preferentially in Fn domains of various species, and the present methods can include a step in which an alignment is carried out as described in the Examples below. The library may be biased toward clones having amino acids that are better suited for molecular recognition (e.g., tyrosine, serine, and glycine). In particular, amino acids observed in natural binding repertoires may be used. These combinatorial libraries may be constructed from degenerate nucleotides that produce the desired amino acid bias. These libraries may contain a higher fraction of functional sequences than results from fully random library generation.
Libraries made by the methods described herein are within the scope of the present invention as
are methods of screening such libraries to identify clones that can be incorporated in an engineered protein.
To identify genetically modified Fn domains, one can diversify a domain by mutating the DNA encoding one or more residues in the BC, DE, and/or FG loops (as defined in the art; see, e.g., Ruoslahti, Ann. Rev. Biochem. 57:375-413, 1988). While useful Fn domains are described further below, we note here that they can be variants (e.g. , mutants) of a type III domain and, more specifically, of the tenth type III domain. Virtually any Fn domain may serve as the original source of the genetically modified Fn domain that becomes incorporated into the present proteins. For example, the Fn domain may have a sequence modified from a mammalian (e.g., human) Fn domain. The diversification process may also be combined with homologous recombination of mutated loop gene fragments in which the constant portion of the Fn gene is used as a homologous region for recombination. This approach may be used in parallel with mutation of the entire Fn gene including the constant region. These approaches enable the creation of broader sequence diversity including mutations to either or both of the constant and loop regions.
The engineered proteins are not limited to those that affect cellular physiology by any particular mechanism. Our work to date indicates that antibody-Fn fusions are able to cluster cellular receptors on the cell surface. For example, we have fused the clinically approved human monoclonal antibody (mAb) 225 (cetuximab) with variants of the tenth type III domain of human fibronectin that recognize the EGF receptor (EGFR) to establish multispecifϊc antibody- fibronectin fusions capable of clustering EGFR. These constructs induce receptor clustering and effectively downregulate EGFR in a number of cancerous cell lines without agonizing signaling. The engineered proteins of the present invention may, therefore, bring about this same downregulation. We have also concluded that the antibody constant domain can aid in the persistence of the proteins in the bloodstream and enhance immune cell recruitment. Thus, the amino acid sequence that prolongs the circulating half-life may be a part of the immunoglobulin portion of immunoglobulin- fibronectin fusions. The modular structure and design of the present proteins forms the basis for a new generation of therapeutics, including antibody-based therapeutics, that can bind to different (e.g., nonoverlapping) regions on molecular targets, including cell-surface targets (e.g., cellular receptors such as a receptor tyrosine kinase).
In use, for example when an engineered protein is brought into contact with a cell expressing a target molecule (e.g., a cell in vivo or in cell or tissue culture), the engineered protein may cause a substantial decrease in the amount of the target (e.g., an EGFR or other receptor tyrosine kinase) on the surface of the cell. We expect this downregulation to occur without prompting significant activation of the target. For example, where the molecular target is a cell surface receptor, the engineered protein can downregulate the receptor without activating the receptor's signaling cascade. As a result, one can bring about a desired change in cellular physiology. For example, an engineered protein targeting the EGFR may inhibit cellular proliferation or migration. As such, these proteins are therapeutically useful (e.g., in treating cancers involving EGF receptor-positive cells). Engineered proteins that target an EGFR (including a constitutive Iy active mutant such as EGFRvIII) can be used in treating any of the same cancers presently treated with EGFR antagonists. Specific cancers amenable to treatment with proteins that target the EGFR include breast cancer, bladder cancer, non-small-cell lung cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, ovarian cancer, cervical cancer, lung cancer, esophageal cancer, glioblastomas, and pancreatic cancer. By targeting other cell-surface proteins, one can treat other types of cancers. Those of ordinary skill in the art will appreciate which molecular targets are associated with which cancers or other diseases, disorders, or conditions.
In other methods, the engineered proteins can be used, due to their target specificity, to deliver cargo (e.g., a therapeutic agent) to a cell that expresses the target molecule. In this event, the target may or may not be a receptor; any cell-surface, cancer-specific protein can be targeted. Further, as the proteins can be internalized, the delivery can encompass an intracellular delivery of the cargo. The cargo can vary widely and includes nucleic acids (e.g., antisense
oligonucleotides, microRNAs, and any nucleic acid that mediates RNAi (e.g., an siRNA or shRNA)). The cargo can also be a conventional small molecule therapeutic agent, such as a chemotherapeutic agent or any agent that is toxic to the cell to which it is delivered (e.g., a radioisotope).
In any of the methods of treatment, the subject can be a human and the method can include a step of identifying a patient for treatment (e.g., by performing a diagnostic assay for a cancer). Further, one may obtain a biological sample from a patient and expose cancerous cells within the sample to one or more engineered proteins ex vivo to determine whether or to what
extent the engineered protein downregulates a target expressed by the cells or inhibits their proliferation or capacity for metastasis. Similarly, one may obtain a biological sample from a patient and expose cancerous cells within the sample to one or more of the present proteins that have been engineered to carry toxic cargo. Evaluating cell survival or other parameters (e.g., cellular proliferation or migration) can yield information that reflects how well a patient's cancer may respond to in vivo treatment with the engineered protein tested in culture.
While the engineered proteins can contain naturally occurring amino acid residues (and may consist of only naturally occurring amino acid residues), the invention is not so limited. The proteins can also include non-naturally occurring residues. Any of the engineered proteins may also vary (either from each other or from a wild-type protein from which they were derived) due to post-translational modifϊcation(s). For example, the glycosylation pattern may vary or there may be differences in amidation or phosphorylation.
Within a given engineered protein, the sequence of the first Fn domain and the sequence of the second Fn domain can vary from one another in the regions that confer epitope binding specificity but be otherwise identical or nearly identical (e.g., at least 90% identical). For example, the first domain and the second domain can be generated from a type III Fn domain (e.g. , a tenth type III Fn domain) and can vary from either one another or from the wild type sequence from which they were derived in one or more of the regions defining the BC loop, the DE loop, and the FG loop. Aside from the variability in these regions, the first Fn domain and the second Fn domain can be identical to one another or nearly identical (e.g., at least 90%, 95%, or 98% identical). In any event, the Fn domain engineered (e.g., mutated) can be a human or other mammalian Fn domain.
The variability (i.e., variability between one genetically modified Fn domain and another or between such a domain and the wild type sequence from which it was derived) can be generated by the addition, deletion or substitution of amino acid residues. A first genetically modified Fn domain and a second genetically modified Fn domain can be at least or about 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical. A genetically modified Fn domain and the wild-type sequence from which it was derived can be at least or about 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical.
More specifically, a Fn domain included in an engineered protein can be generated from the following wild-type fibronectin domain, where residues 23-31 (underlined) represent the BC
loop, residues 52-56 (also underlined) represent the DE loop, and residues 77-86 (also underlined) represent the FG loop. Residues within one or more of the loops can be engineered, and the remaining residues, which constitute the constant region, can be also varied or invariant: VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKSTATIS GLKPGVDYTITVYAVTGRGDSPASSKPISINYRT (SEQ ID NO:1)
As noted, residues within the loop regions can be altered to effect a change in epitope- binding specificity (specific mutations are described further below), and the constant region can remain unchanged or vary from one Fn domain to another as described herein.
Previously, receptor downregulation has been achieved using multiple receptor-targeted antibodies, but the current technology enables downregulation with a single agent. This may be advantageous for clinical development and efficacy. The present invention is exemplified by our work with the EGF receptor. As two EGFR-targeted antibodies are approved for clinical use in oncology, the EGFR has been validated as a therapeutic target.
The method of treatment claims included herein may be expressed in terms of "use." For example, the present invention features the use of the engineered proteins described herein in the treatment of cancer or in the manufacture of a medicament for the treatment of cancer.
The details of one or more embodiments of the invention are set forth in the
accompanying drawings, the description below, and/or the claims. Other features, objects, and advantages of the invention will be apparent from the drawings, descriptions, and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure l(A) and Figure l(B) depict the results of analyses of sequences within wild-type Fn3 domains (Panel A) and genetically modified Fn domains (Panel B). The "x" in the BC loop corresponds to an amino acid present in other domains that is not present in the human tenth type III domain. The outline around S81-S84 represents rare positions as most type III domains contain shorter FG loops. In Panel (B), the amino acid frequency at each position was compared to the frequency in the composite naϊve libraries.
Figure 2 is a bar graph mapping amino acid distributions. The frequencies of each amino acid in multiple distributions are presented. NNB refers to a degenerate codon with 25% of each nucleotide at the first two positions and 33% of C, T, and G at the third position. Tyr/Ser refers to an even mix of tyrosine and serine. CDR-H3 refers to the expressed human and mouse CDR-
H3 sequences. Skewed Design refers to the theoretical distribution attainable using skewed oligonucleotides. Skewed Sequence refers to the distribution attained experimentally using skewed nucleotides.
Figure 3 is a plot depicting library source probability. For each binding clone sequence, the probability of origination from each library was calculated based on library design. The relative preferences for G4 versus NNB (o) or G4 versus YS (x) are presented for each loop as well as the total domain. Each symbol indicates a sequenced clone.
Figure 4 illustrates the results of a binding competition performed with the indicated Fn clones, the antibody 225, and EGF for the EGFR expressed on A431 cells.
Figures 5(A), 5(B), and 5(C) are a series of schematics and graphical results related to EGFR downregulation. Panel (A) shows an Fn3-Fn3 heterobivalent protein with the wild-type FN3 structure from PDB ID ITTG and a flexible linker drawn approximately to scale (in cartoon form). Panel (B) is a representation of surface EGFR expression. Panel (C) is a bar graph depicting data from the expression study shown in Panel (B) for select constructs with A431 cells. Error bars indicate standard deviation of triplicate samples.
Figure 6 is a series of sequences including a portion of the pETh-Fn3-Fn3 vector. This construct is used for bacterial expression of Fn3-Fn3 bivalent domains with a C-terminal His6 tag. The Fn3 sequences shown in this vector construct can be replaced by any other genetically modified Fn3 domain, including clones A, B, C, D, and E. The nucleic acid sequence is shown as SEQ ID NO: , and the amino acid sequence, translated from the ATG in Ndel site onward, is shown as SEQ ID NO: . Figure 6 also includes nucleic acid and protein sequences for Fn3 domains engineered for binding to the indicated target. Sequence data is provided from Nhel to BamHl in both the nucleotide and amino acid formats. The engineered binders are designated as clones A-E, FG5, and U5.
Figure 7 is a bar graph illustrating the results of receptor downregulation studies in various cell lines (HT29, U87, HeLa, HMEC, CHO, and A431) with PBSA as a control, EGF, and the contructs D-C, D-B, and D-E. Values and error bars indicate the mean and standard deviation of triplicate samples. Parenthetical notations (e.g., (0.1 IM)) indicate the number of EGFR per cell in million (M).
Figure 8 is a schematic depicting the results of a global phorphorylation analysis. The top portion (above the bold line) represents the fifteen highest responders to EGF treatment, and the bottom portion represents the fifteen highest responders to heterobivalent treatment.
Figure 9 is a bar graph depicting the results of a study of relative viability of hMEC cells treated with the proteins and constructs indicated for 48 or 96 hours. Column and error bars represent mean and standard deviation of triplicate samples. * indicates data from a single sample.
Figure 10 is a diagram showing EGFR downregulation by the Fn3-Fn3 constructs indicated in A431, HeLa, and HT29 cells. The mean of triplicate samples is presented.
Figures H(A) and H(B) are a pair of bar graphs depicting the results of a study of cellular migration following treatment of the cell types indicated with the proteins indicated. + indicates addition of 225 antibody. * indicates that PBSA "wound" was completely healed, thus measurable migration was limited. Column and error bars represent mean and standard deviation of triplicate samples.
Figure 12 is a schematic of various engineered proteins comprising a genetically modified Fn domain and an immunoglobulin. The constant regions of the heavy chain are labeled CHl, CH2, and CH3, and the constant region of the light chain is labeled CL. The variable domains of the heavy and light chains are labeled VH and VL, respectively, and the genetically modified Fn3 domain is labled Fn3. The amino (N) and carboxy (C) termini of the heavy and light chains are also indicated. The immunoglobulins are assembled in vitro in two- to-two complexes of heavy and light chain moieties, linked by three disulfide bonds. In the engineered proteins illustrated, Fn3 is fused to the heavy or light chain at the N or C terminus with a flexible linker and the fusion constructs are named as indicated (HN where the Fn3 domain is fused to the N terminus of the heavy chain; HC where the Fn3 domain is fused to the C terminus of the heavy chain; LN where the Fn3 comain is fused to the N terminus of the light chain; and LC where the Fn3 domain is fused to the C terminus of the light chain).
Figure 13 is a series of sequences of representing Ab-Fn3 fusions.
Figure 14 is a line graph depicting the results of a study of multispecific antibody binding kinetics. Closed symbols represent the unconjugated 225 antibody and open symbols represent the Ab-Fn3 fusion HN-D. Nonlinear least squares regression fits are shown for 225 (solid lines)
and HN-D (dashed lines) at pH 6.0 (darker solid and dashed lines) and pH 7.4 (lighter solid and dashed lines).
Figure 15 is a schematic of multispecific antibody-induced clustering. Engineered proteins that are multispecific and bind two non-competitive epitopes on a target receptor may induce linear or circular chains of crosslinked receptor on the cell surface.
Figure 16 is a series of photomicrographs providing visual evidence of multispecific antibody-induced clustering. Scale bars = 30 μm.
Figures 17(A) and (B) are schematics representing the extent of EGFR downregulation in the cell types indicated with engineered proteins indicated.
Figure 18 is a line graph plotting surface EGFR (% untreated) over time following Ab- Fn3 treatment in A431 cells. The lighter line tracks receptor downregulation following treatment with the Ab-Fn3 fusion FIN-D, and the darker line tracks receptor downregulation following treatment with the mAb combination 225 + Hl 1. First-order kinetic curves were fit using nonlinear least squares regression.
Figures 19(A), (B), and (C) are a series of plots demonstrating that EGFR and its downstream effectors are not agonized by combination mAb treatment. In Figure 19(A), activation profiles are shown for EGF (■), 225 (o), Hl 1 (D), and 225 + Hl 1 (•). Phosphoprotein fluorescence was normalized by DNA fluorescence, and signal relative to that of untreated cells is plotted versus time (±SD; n=3). In Figure 19(B), normalized phosphoprotein signal is plotted for cells treated with EGF (■), 225 (o), Hl 1 (D), 225 + Hl 1 (•), and an antibody-free control (ύ) (±SD; n=3). In Figure 19(C), serum-starved A431 cells were incubated with 225, Hl 1, the 225 + Hl 1 combination, and EGF at 370C for 15 minutes (top) or 60 minutes (bottom).
Figure 20 is a pair of bar graphs plotting relative cell migration (left-hand graph) and proliferation (right-hand graph) of HMEC (dark gray) and autocrine EGF-secreting ECT (light gray) cells following combination mAb treatment. Relative migration is shown as fractional wound replenishment compared to that of an untreated control ((±SD; n=6). Relative
proliferation is presented as viable cell abundance compared to that of untreated cells (±SD; n=6). Asterisks denote P less than 0.01 for the 225 ± Hl 1 combination relative to either mAb alone.
Figure 21 is a Table summarizing Fn3 library design. "Pos." and "WT" are the amino acid position and residue in the human wild-type tenth type III domain. "Access." is the ratio of
solvent accessible surface area for the residue in the fϊbronectin domain compared to the residue in a random coiled peptide. "Stability" is the relative increase in yeast surface display level of a library with wild-type conservation at the position of interest. "Native" indicates the frequencies of the indicated amino acids in type III fϊbronectin domains often species. "Binders" indicates the enrichment of wild-type (or homo log as indicated) in engineered binders relative to the naϊve frequency. "Library Design" indicates the intended amino acid distribution in the new library. "Ab div." is the designed amino acid distribution that mimics antibody CDR-H3. * indicates the location of loop length variability.
Figure 22 is a Table summarizing engineered binder sequences. "Name" is the name of each clone. "Target" is the cognate protein bound by the Fn3 clone. "23" refers to the amino acid present at position 23, which is aspartic acid (D) in wild-type Fn3; all positions diversified in the naϊve library are likewise presented. "Framework" refers to amino acid mutations outside of the diversified loops. A dash (-) indicates no amino acid.
Figure 23 is a Table summarizing a stability analysis. The NNB and G4 libraries were independently sorted for clones of low stability and high stability. Sequences of about 50 clones from each sorted population were analyzed. "AA" indicates the wild-type amino acid at positions with wild-type bias or amino acids of elevated frequency at positions without wild-type bias. "G4 Design" indicates the designed frequency of the indicated amino acid. "NNB" and "G4" indicate the difference in amino acid frequency between the high and low stability populations from the indicated library.
Figure 24 is a Table regarding codon design. The nucleotide mixture used in synthesis at each diversified position is indicated.
Figure 25 is a Table regarding EGFR binders. "Kd" indicates equilibrium dissociation constant for binding to A431 cells on ice or yeast at 220C. "nb" indicates no detectable binding. A dash (-) indicates data not collected.
DETAILED DESCRIPTION
The present invention is based, in part, on our discovery of engineered proteins that include at least one genetically modified Fn domain. Where more than one domain is included, each domain may bind a different epitope on a molecular target, and the two epitopes may be non-overlapping. For example, in one embodiment, the engineered protein includes a first
genetically modified Fn domain that specifically binds a first epitope on a molecular target (e.g., a cellular receptor) and a second genetically modified Fn domain that specifically binds a second epitope on the same target or a distinct target. In another embodiment, the engineered protein includes a genetically modified Fn domain that specifically binds a first epitope on a molecular target and a heterologous protein that specifically binds a second epitope on the same target or a distinct target.
We may refer to the "engineered protein(s)" as (a) "binding reagent(s)" and, on occasion these terms may be abbreviated to simply "protein(s)" or "binder(s)." It is to be understood that the engineered proteins of the present invention are not naturally occurring proteins.
Accordingly, we may refer to the proteins generally or to a portion thereof (e.g., a Fn domain) as "genetically modified" to indicate that the protein is non-naturally occurring or is a mutant of a wild-type sequence.
As noted above, an engineered protein (or a portion thereof (e.g., a genetically modified Fn domain or target-specific protein scaffold)) may be purified or isolated, in which case it has been substantially separated from materials with which it was previously associated. For example, an engineered protein can be isolated or purified following chemical synthesis or expression in cell culture; the engineered proteins can be separated from the synthesis reagents or the cellular material of the expression system. An isolated or purified engineered protein (or a portion or domain thereof) may be at least or about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% pure. In the compositions of the invention, the engineered proteins may be present at high concentrations (in which case the compositions may be useful as stock solutions or in in vitro analysis) or at physiologically acceptable concentrations (in which case the compositions would be suitable for administration to a patient).
The Fn domain: The Fn domains included in the present proteins can be based on a type III Fn domain (Fn3), such as the tenth type III domain of human fibronectin. This scaffold is small (94 amino acids, -10 kDa), stable (7.5-9.4 kcal/mol, Tm = 900C; Cota and Clarke, Protein Sci., 9: 112-120, 2000; Parker et al., Protein Engineering Design and Selection, 18:435- 444, 2005), soluble to 15 mg/mL, free of cysteines, and expressed at ~50 mg/L in E. coli (Xu et al., Chemistry & Biology, 9:933-942, 2002). Depending on the degree of modification, it is reasonable to expect low immunogenicity in vivo due to this domain's stability and natural abundance. The Fn3 domain occurs in ~2% of animal proteins (Bork and Doolittle, Proc. Natl.
Acad. Sci. USA, 89:8990-8994, 1992). In addition, both solution (Main et al, Cell, 71:671-688, 1992) and crystal (Dickinson et al, Journal of Molecular Biology, 236:1079-1092, 1994) structures of Fn3 have been determined, thus enabling rational elements of design. The scaffold contains three solvent-exposed loops on either side of parallel β-sheets, somewhat akin to the immunoglobulin fold. Significant evidence shows that Fn3 loops can tolerate diversity to potentially function in a manner analogous to complementarity-determining regions of antibodies. Sequence analyses reveal large variations in the BC and FG loops (Fn3 loops can be referenced by the two peripheral β-strands) with moderate variation in DE loop sequences.
NMR spectroscopy indicates significant flexibility of the FG loop as well as moderate flexibility of the BC loop (Carr et al., Structure, 5_:949-959, 1997). Moreover, elongation by insertion of four glycine residues is moderately well tolerated (1.2, 2.3, and 0.4 kcal/mol destabilization of BC, DE, and FG) (Batori et al, Protein Eng., 15:1015-1020, 2002)). The opposing loops, AB, CD, and EF, offer potential for a bispecific scaffold but are neither as well arranged nor as tolerable of insertion as the other loops. In short, we expect engineered proteins that include genetically modified Fn3 domains may have several biophysical advantages over antibodies, and we consider them an attractive scaffold for use in the proteins described herein.
Naturally occurring Fn3 domains can bind integrins, as the FG loop contains the Arg- Gly-Asp tripeptide (Pierschbacher et al, J. Cell Biochem., 28:115-126, 1985). In the initial use of the domain as a scaffold for molecular recognition, randomization of the BC loop and a shortened FG loop yielded micromolar binders to ubiquitin (Koide et al, The Journal of
Molecular Biology, 284:1141-1151, 1998). Thus, although Fn3 could accommodate mutations in loop residues without notable structural change and could acquire novel binding function, a reduced stability, reduced solubility, and non-specific, low affinity binding was also observed. Screening of a library with more extensive randomization of the BC, DE, and FG loops yielded binders to tumor necrosis factor α and vascular endothelial growth factor receptor 2 (VEGF-R2) of nanomolar affinity (Parker et al, Protein Engineering Design and Selection, 18:435-444, 2005; Xu et al, Chemistry & Biology, 9:933-942, 2002). Further maturation produced binders of sub-nanomolar affinity, demonstrating the potential for high affinity binding with Fn3.
Engineered Fn3 variants have been used intracellularly (Koide et al, Proc. Natl. Acad. Sci.
USA, 99:1253-1258, 2002) as inhibitors in cell culture (Richards et al, Journal of Molecular Biology, 326:1475-1488, 2003), in protein arrays (Xu et al, Chemistry & Biology, 9:933-942,
2002), and as labeling reagents in flow cytometry (Richards et ah, Journal of Molecular Biology, 326:1475-1488, 2003) and Western blots (Karatan et al, Chemistry & Biology, ϋ:835-844, 2004). An anti-VEGF-R2 Fn3 is progressing through clinical trials (and VEGF receptors can be targeted with the present engineered proteins, as described further below).
Where the engineered proteins include two genetically modified Fn domains, the orientation of the domains with respect to one another can be varied. For example, the first and second Fn domains can be arranged in a head-to-tail, head-to-head, or tail-to-tail configuration. This is also true where the engineered proteins include a linker or a heterologous amino acid sequence. For example, the first and second fibronectin domains can be fused, via a linker, in a head-to-tail orientation. Where a heterologous sequence is present, the first and second fibronectin domains can be fused to one another in a head-to-tail configuration (with or without a linker) and fused to the heterologous sequence (with or without a linker). Thus, a linker can be included between the Fn domains and the heterologous sequence, and the Fn domain(s) can be fused to the heterologous sequence at an amino-terminus, carboxy-terminus, or both. The orientation of the genetically modified Fn domain with respect to the heterologous amino acid sequence is discussed further below.
The genetically modified Fn domains used in the engineered proteins of the present invention can be characterized in several ways, including by the extent to which their amino acid sequence is identical to the amino acid sequence of a reference protein. We may refer to this similarity as "percent identity," and it can be readily determined by comparison of two sequences by eye and simple calculation or by submitting the two sequences (e.g. , a modified Fn3 sequence and a reference sequence to a sequence analysis program with the default parameters as defined therein. The reference sequence can be, for example, a corresponding wild-type sequence or a "parent" sequence into which one or more additional mutations were introduced. For example, the reference sequence for a genetically modified tenth Fn3 domain of human fibronectin can be the wild-type tenth Fn3 domain of human fibronectin.
As noted above, where two genetically modified Fn domains are included in an engineered protein, the two domains can be described as having a certain degree of identity as well. In any case, variability can be due to the addition, deletion or substitution of one or more amino acid residues, or to a combination of such changes. Where one residue is substituted for another (e.g., where a wild-type residue is changed), the substituted residue may represent a
conservative or non-conservative change. A first genetically modified Fn domain and a second genetically modified Fn domain can be at least or about 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical. A genetically modified Fn domain and a wild-type Fn domain can be at least or about 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical. Thus, the engineered proteins of the present invention can include a mutant of the tenth type III fibronectin domain that is at least 40% identical to the corresponding wild-type tenth type III fibronectin domain (e.g., a mammalian (e.g., human) Fn domain).
In the Examples presented below, we describe mutational flexibility at a number of positions within an Fn3 domain and within binder sequences. Figures l(A) and l(B) show the results of this analysis. Various sequences were aligned, and amino acid frequency at each position was evaluated. The results are presented based on an intensity scale; the more frequently a residue appears at a given position in the aligned sequences, the darker the box representing that residue in the plot. To analyze wild-type Fn3 domains, we aligned sequences from chimpanzee, cow, dog, horse, homan, mouse, opossum, platypus, rat, and rhesus monkey. As shown in Figure 1(A), we analyzed three sequences within the Fn3 domain that encompass the BC, DE, and FG loops. The peripheral residues W22, Y32, P51, A57, and P87 are well conserved while T76 is variable. Accordingly, the genetically modified Fn3 domains used in the present engineered proteins include those in which the wild-type residues corresponding to positions 22, 32, 51, 57, and 87 are not modified (e.g., deleted or replaced) but the residue at position 76 is mutated (e.g., deleted or replaced). Alternatively, amino acid residues that are highly conserved may be substituted conservatively. Other amino acid residues that, based on their conservation, may be retained or conservatively substituted are those at positions A24, P25, V29, G52, S53, S55, G77, G79, and S85. Conversely, the Y at position 31 in the BC loop and the central lysine in the DE loop can be varied more broadly. This conservation data guides protein library and mutant design to improve protein functionality; i.e., proteins with
conservation at some of the indicated positions will, on average, possess greater functionality than proteins without conservation.
Our sequence analysis of twenty binders from the G4 library indicates that the desirable biased amino acids (Y, S, G, D, and R) are maintained at high levels in binder sequences whereas undesirable biased amino acids (C and H) are slightly reduced. This supports the
hypothesis that Y, S, G, D, and R are indeed favorable whereas C and H are less favorable, which can guide protein library and mutant design.
Another way the genetically modified Fn domains used in the engineered proteins of the present invention can be characterized is by their affinity for the molecular target they were designed to specifically bind. For example, a genetically modified Fn domain (or one of the target-specific protein scaffolds described below) can bind a molecular target with an affinity in the pM to nM range (e.g., an affinity of less than or about 1 pM, 10 pM, 25 pM, 50 pM, 100 pM, 250 pM, 500 pM, 1 nM, 5 nM, 10 nM, 15 nM, 20 nM, 25 nM, 30 nM, 40 nM or 50 nM).
Genetically modified Fn domains can also be classified as having or lacking
conformational sensitivity. Such sensitivity is present when the genetically modified Fn domain specifically binds its molecular target in a naturally folded configuration but fails to do so (or does so with a greatly reduced affinity) when the target is denatured.
In addition to these characteristics, any given genetically modified Fn domain (or any given heterologous sequence) can be characterized in terms of its ability to modify cell behavior (e.g. , cellular proliferation or migration) or to positively impact a symptom of a disease, disorder, condition, syndrome, or the like, associated with the expression or activity of the molecular target. For example, the genetically modified Fn domain can be one that inhibits the ability of cancerous cells to proliferate or migrate and/or improves a symptom in a patient having a cancer associated with aberrent expression of the molecular target. For example, the EGFR is associated with numerous cancers, and the modified Fn domain included in an engineered protein can be one that specifically binds the EGFR and inhibits cellular proliferation or migration in the bound EGFR-expressing cells. Similarly, the modified Fn domain included in an engineered protein can be one that specifically binds EGFR-expressing cancer cells in a patient and improves a symptom the patient is experiencing or provides some other clinical benefit. In other words, the modified Fn domain and an engineered protein of which it is a part can be used to treat a patient who is suffering from a disease (e.g., cancer) that is associated with aberrent expression of a molecule targeted by the modified Fn domain or engineered protein. While target specificity is a feature of the engineered proteins, we wish to stress that the compositions and methods of the invention are not limited to those that elicit any particular cellular response or work through any particular mechanism of action.
In vitro assays for assessing binding to a molecular target, cellular proliferation, and cellular migration are known in the art. For example, where the molecular target is an EGFR, binding, proliferation, and migration assays can be carried out using A431 epidermoid carcinoma cells, HeLa cervical carcinoma cells, and/or HT29 colorectal carcinoma cells. Other useful cells and cell lines will be known to those of ordinary skill in the art. For example, genetically modified Fn3 domains (and/or engineered proteins containing them) can be analyzed using U87 glioblastoma cells, hMEC cells (human mammary epithelial cells), or Chinese hamster ovary (CHO) cells. The molecular target can be expressed as a fluorescently tagged protein to facilitate analysis of an engineered protein's effect on the target. For example, the assays of the present invention can be carried out using a cell type as described above transfected with a construct expressing an EGFR-green fluorescent protein fusion. An engineered protein may inhibit cellular proliferation or migration by at least or about 30% {e.g., by at least or about 30%, 40%, 50%, 65%, 75%, 85%, 90%, 95% or more) relative to a control (e.g., relative to proliferation or migration in the absence of the engineered protein or a scrambled engineered protein).
Of course, the genetically modified Fn domains may be described as having a
combination of the characteristics described above. For example, a genetically modified Fn domain that exhibits a certain percentage of sequence identity to a reference sequence can also be a domain that exhibits an affinity for the target molecule in the pM to nM range and/or exhibits conformational sensitivity. Similarly, the genetically modified Fn domain can be at least or about 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to a reference sequence (e.g., the naturally occurring domain from which it was derived) and can inhibit the proliferation or migration of a cell expressing a molecular target to which the modified Fn domain specifically binds.
More specifically, a genetically modified Fn domain can have or can include the amino acid sequence of a Fn3 domain described herein as clone A, clone B, clone C, clone D, or clone E (see Figure 6). Further, an engineered protein can be or can include a pair of these clones, which may be fused to one another via a linker. For example, the engineered proteins can include a pair of genetically modified Fn domains that have or that include the sequence of clone A, clone B, clone C, clone D, or clone E. Useful bivalents for targeting and
downregulating an EGFR include D-B, D-C, D-D, D-E, A-D, B-D, C-D, and E-D. The domains may be linked in the order indicated. As noted, genetically modified Fn domains, including the
bivalents described here, can be fused, directly or via a linker, to a heterologous amino acid sequence such as an immunoglobulin. The amino terminal, carboxy terminal, or both, of either the heavy or light chain (e.g., in an IgG) can serve as the point of attachment, and specfϊc configurations are discussed further below.
Heterologous Amino Acid Sequences: The engineered proteins of the invention can include, in addition to a genetically modified Fn domain: (a) a target-specific protein scaffold, and/or (b) an accessory amino acid sequence.
The affinity of the target-specific protein scaffold for its target may be increased when the scaffold is joined to one or more genetically modified fibronectin domains (as described herein). For example, the affinity of an antibody for its molecular target may be at least or about an order of magnitude greater than the affinity of the antibody alone at either endosomal pH (6.0), physiological pH (7.4), or both.
The target-specific protein scaffold can be an immunoglobulin (e.g., an IgG or a biologically active (e.g., antigen-binding) portion or variant thereof (e.g., an scFv)), a designed ankyrin repeat protein, an anticalin, or an affibody. These scaffolds for molecular recognition are known in the art, as are residues that are generally diversified to generate novel binding function. Accordingly, where the engineered proteins include a heterologous amino acid sequence, that sequence can be (or can be derived from; a mutant of) an ankyrin repeat protein, an anticalin, an affibody, or an immunoglobulin, including a fragment or other variant therof (e.g., an scFv). One can use information regarding generally diversified residues to select residues for diversification to generate protein binders to the targets described herein. One can also subject these protein scaffolds to directed evolution as described herein for Fn domains in order to generate binders with improved specificity and affinity for a given molecular target.
We may use the term "immunoglobulin" synonymously with "antibody." An
immunoglobulin can be a tetramer (e.g., an antibody having two heavy chains and two light chains) or a single-chain immunoglobulin. Further, the immunoglobulin may be an intact immunoglobulin of type IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof (e.g. , IgGi, IgG2, IgG3, and IgG4)).
Examples of antigen-binding portions or fragments or other immunoglobulin variants that can be used in the present proteins include: (i) an Fab fragment, a monovalent fragment consisting of the VLC, VHC, CL and CHl domains; (ii) a F(ab')2 fragment, a bivalent fragment
comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VHC and CHl domains; (iv) a Fv fragment consisting of the VLC and VHC domains of a single arm of an antibody, (v) a dAb fragment (Ward et al, Nature 341 :544- 546, 1989), which consists of a VHC domain; and (vi) an isolated complementarity determining region (CDR) having sufficient framework to specifically bind, e.g. , an antigen binding portion of a variable region. An antigen-binding portion of a light chain variable region and an antigen binding portion of a heavy chain variable region, e.g., the two domains of the Fv fragment, VLC and VHC, can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VLC and VHC regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al, Science 242:423-426, 1988; and Huston et al., Proc. Natl. Acad. ScL USA 85:5879-5883, 1988). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody or as "a variant" of an antibody.
These antibody portions or fragments are obtained using conventional techniques known to those of ordinary skill in the art, and the portions are screened for utility in the same manner as are intact antibodies. An Fab fragment can result from cleavage of a tetrameric antibody with papain; Fab' and F(ab')2 fragments can be generated by cleavage with pepsin.
In summary, single chain immunoglobulins, and chimeric, humanized or CDR-grafted immunoglobulins, including those having polypeptides derived from different species, can be incorporated into the engineered proteins.
The various portions of these immunoglobulins can be joined together chemically by conventional techniques, or can be prepared as contiguous polypeptides using genetic
engineering techniques. For example, nucleic acids encoding a chimeric or humanized chain can be expressed to produce a contiguous polypeptide. See, e.g., Cabilly et al., U.S. Patent
No. 4,816,567; Cabilly et al., European Patent No. 0,125,023 Bl; Boss et al., U.S. Patent No. 4,816,397; Boss et al., European Patent No. 0,120,694 Bl; Neuberger, M. S. et al.,
WO 86/01533; Neuberger, M. S. et al, European Patent No. 0,194,276 Bl; Winter, U.S. Patent No. 5,225,539; and Winter, European Patent No. 0,239,400 Bl . See also, Newman et al, BioTechnology, 10:1455-1460,1992, regarding CDR-graft antibody, and Ladner et al, U.S. Patent No. 4,946,778 and Bird, R. E. et al, Science 242:423-426,1988 regarding single chain antibodies.
Accessory sequences: The accessory sequence can be one that prolongs the circulating half-life of the genetically modified Fn domain or an engineered protein of which it is a part, a polypeptide that facilitates isolation or purification of the engineered protein, an amino acid sequence that facilitates the bond (e.g., fusion or conjugation) between one part of the engineered protein and another or between the engineered protein and another moiety (e.g. , a therapeutic compound) , an amino acid sequence that serves as a label, marker, or tag (including imaging agents), or an amino acid sequence that is toxic.
The amino acid sequence that increases the circulating half- life can be an Fc region of an immunoglobulin, including an immunoglobulin that has a reduced binding affinity for an Fc receptor (such as those described in U.S. Patent Application No. 20090088561, the content of which is hereby incorporated by reference in its entirety). As the engineered proteins of the present invention can include immunoglobulin sequences, and as the Fc region can increase circulating half-life, where the engineered proteins include an immunoglobulin as the
heterologous, target- specific protein scaffold, the Fc region of the immunoglobulin can also serve to increase the protein's circulating half-life; the accessory sequence can be a part of the heterologous amino acid sequence.
Half- life can also be increased by the inclusion of an albumin (or a portion or other variant thereof that is large enough to have a desired effect on half- life). The albumin can be a serum albumin, such as a human or bovine serum albumin.
The Fn domain or another portion of the engineered protein can also be "pegylated" using standard procedures with poly(ethylene glycol). Engineered proteins that are pegylated may have an improved circulating half-life.
Where the engineered protein includes an accessory protein that facilitates isolation or purification, that protein can be a tag sequence designed to facilitate subsequent manipulations of the expressed nucleic acid sequence (e.g., purification or localization). Tag sequences, such as green fluorescent protein (GFP), glutathione S-transferase (GST), c-myc, hemagglutinin, β galactosidase, or Flag™ tag (Kodak) sequences are typically expressed as a fusion with the polypeptide encoded by the nucleic acid sequence. Such tags can be inserted in a nucleic acid sequence such that they are expressed anywhere along an encoded polypeptide including, for example, at either the carboxyl or amino termini. The type and combination of regulatory and
tag sequences can vary with each particular host, cloning or expression system, and desired outcome.
As noted, the engineered proteins can include linkers at various positions (e.g., between two genetically modified Fn domains or between a genetically modified Fn domain and a heterologous amino acid sequence). The linker can be an amino acid sequence that is joined by standard peptide bonds to the engineered protein. The length of the linker can vary including an essentially absent linker in which the proteins are directly fused and, where it is an amino acid sequence, can be at least three and up to about 300 amino acids long (e.g., about 4, 8, 12, 15, 20, 25, 50, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 250 or 300 amino acids long). Moreover, a non-peptide linker such as polyethylene glycol or an alternative polymer could be used. As with all other domains in the engineered proteins, the amino acid residues of the linker may be naturally occurring or non-naturally occurring. We have used a polypeptide linker having the sequence GSGGGSGGGKGGGGT (SEQ ID NO: ), and linkers comprising this sequence or functional variants thereof can be incorporated in the engineered proteins of the present invention. The linkers can be gly cine-rich (e.g., more than 50% of the residues in the linker can be glycine residues).
The amino acid sequence that serves as a label, marker, or tag can be essentially any detectable protein. It may be detectable by virtue of an intrinsic property, such as fluorescence, or because it mediates an enzymatic reaction that gives rise to a detectable product. The detectable protein may be one that is recognized by an antibody or other binding protein.
The engineered proteins can also be configured to carry imaging or contrast agents, many of which are known in the art and can be connected to an engineered protein using standard techniques.
Regarding the overall configuration of the engineered proteins that include one or more genetically modified Fn domains and a heterologous amino acid sequence, there can be considerable variation. Multiple genetically modified Fn domains can be included in the engineered proteins. For example, the proteins can include 1-16 (e.g., 1, 2, 4, 8, 12, or 16) genetically modified Fn domains. As noted, the Fn domains can be identical to one another or distinct; they can bind the same, similar, or distinct epitopes, including non-overlapping epitopes; and they can be joined to the amino terminus, the carboxy terminus, or both termini of the target-specific protein scaffold. At a given terminus, one can include a single genetically
modified Fn domain or a pair of these domains. Where the protein scaffold is an IgG, one or more genetically modified Fn domains can be joined (e.g., fused) to the amino or carboxy terminus of a light chain (or chains), to the amino or carboxy terminal of a heavy chain (or chains), or to any combination of these positions. In a specific embodiment, the engineered protein can include, as a heterologous sequence, an immunoglobulin (e.g., an IgG) and multiple genetically modified fibronectin domains fused, directly or via a linker, to the amino terminus of a heavy chain or an amino terminus of a light chain of the immunoglobulin. In another embodiment, the engineered protein can include, as a heterologous sequence, an immunoglobulin (e.g. , an IgG) and one or more genetically modified fibronectin domains fused, directly or via a linker, to the amino terminus of a heavy chain and one or more genetically modified fibronectin domains fused, directly or via a linker, to the carboxy terminus of the heavy chain of the immunoglobulin. In another embodiment, the engineered protein can include, as a heterologous sequence, an immunoglobulin (e.g. , an IgG) and one or more genetically modified fibronectin domains fused, directly or via a linker, to the amino terminus of a light chain and one or more genetically modified fibronectin domains fused, directly or via a linker, to the carboxy terminus of the light chain of the immunoglobulin. In another embodiment, the engineered protein can include, as a heterologous sequence, an immunoglobulin (e.g., an IgG) and one or more genetically modified fibronectin domains fused, directly or via a linker, to either the amino or carboxy terminus or to both termini of a heavy chain and one or more genetically modified fibronectin domains fused, directly or via a linker, to either the amino or carboxy terminus or to both termini of the light chain of the immunoglobulin.
Protein engineering: Screening and evolution of combinatorial libraries, using methods both known in the art and described in the Examples below, provides an effective way to generate binding proteins that can be used in the engineered proteins of the invention. The process can be described as involving three key elements: naϊve library design, selection of functional clones, and sequence diversification of lead clones. Accordingly, the present invention features methods of generating an engineered protein (or a domain thereof) by directed evolution. The steps of such methods can include providing a naϊve combinatorial library of protein clones, selecting or screening the library to identify lead clones, and diversifying the identified clones (e.g., by mutagenesis or informed library synthesis) to produce a next
generation library. The cycle of selection and diversification can be repeated (e.g., two to ten times) until the desired functionality (e.g. , selective binding to an identified target) is achieved.
Clones with the desired functionality can be identified from the library of protein variants with high throughput selection via linkage of genotype and phenotype. Though this linkage can be achieved through a multitude of display formats (Hoogenboom, Nat. Biotechnol, 23:1105- 1116, 2005) such as phage display and mRNA display, yeast surface display is preferred (Hackel and Wittrup, In Protein Engineering Handbook (Bronscheuer, Ed.), Vol. 1. Wiley- VCH, 2009). In vitro technologies tout high theoretical library sizes because of the absence of cellular transformation, which can limit library size. Yet in a recent comparison of yeast surface display and phage display using the same antibody, DNA library, and target antigen, yeast surface display identified three times more clones than did phage display and did not miss a single phage clone revealing that constructed size and functional size can differ substantially (Bowley et al, Protein Engineering Design and Selection, 20:81-90, 2007). Yeast surface display may also enable selection of stable clones because of the quality control apparatus of the eukaryotic secretory system (Shusta et al, Journal of Molecular Biology, 292:949-956, 1999).
Fluorescence-activated cell sorting of yeast allows quantitative discrimination of clone functionality (VanAntwerp and Wittrup, Biotechnol, Prog., 16:31-37, 2000).
In yeast surface display, tens of thousands of copies of Fn3 are tethered to the exterior of an individual Saccharomyces cerevisiae yeast cell while the genetic information for the Fn3 clone is maintained in the cell interior. The cell-protein linkage begins with the Agalp subunit of a-agglutinin, which anchors in the cell wall periphery via β-glucan covalent linkage (Lu et al, J. Cell. Biol., 128:333-340, 1995). The Aga2p subunit, secreted from the yeast cell as a fusion to Fn3, attaches to Agalp via two disulfide bonds. The peptide bond in the fusion protein thus completes the linkage resulting in "display" of Fn3 on the yeast cell. Aga2p and Fn3, linked by a (G4S)3 peptide, are followed by HA and c-myc epitopes, respectively, to enable analysis of the display of Aga2p and the full-length protein fusion. Display is achieved through transformation of DNA encoding for the Aga2p-Fn3 fusion followed by cell growth and induction of both Agalp and Aga2p-Fn3 protein expression using a galactose-inducible GAL promoter. The displayed clones can be screened for their ability to bind to a target of interest, including any of those described herein, using flow cytometry or captured by immobilized antigen.
Selected clones can be evolved through partial diversification of their sequence followed by selection for mutants that exhibit improved functionality. Error-prone PCR to introduce random mutations throughout the gene is the most common method of diversification. Yeast surface display also enables gene shuffling via homologous recombination (Swers et al, Nucleic Acids Research, 32:e36, 2004).
Once identified, whether through phage display, mRNA display, yeast surface display, or by any other mechanism, a protein can be incorporated into the engineered proteins described herein using standard recombinant techniques. These techniquies are well known in the art and are discussed further below.
Targets: A wide variety of molecular targets can be specifically bound and these include molecules expressed on the cell surface, such as receptors for growth factors, neurotransmitters, and the like. The receptor can be a tyrosine kinase receptor, and much of the work with the constructs described in the Examples has focused on the epidermal growth factor (EGF) receptor (EGFR). This receptor is a receptor tyrosine kinase in the ErbB family that comprises three regions: an extracellular region, a transmembrane domain, and an intracellular region that includes a juxtamembrane domain, kinase domain, and a C-terminal tail containing
phosphorylation sites. These domains and sites are understood in the art. The extracellular region consists of four domains of which domains I and III are leucine rich repeat folds and domains II and IV are cysteine-rich domains. The receptor is predominantly present in a tethered conformation on the cell surface. Binding of ligand, including epidermal growth factor, transforming growth factor α, epiregulin, amphiregulin, β-cellulin, and heparin-binding epidermal growth factor, stabilizes an open conformation of the receptor. Resultant dimerization enables kinase activation and phosphorylation of the intracellular domain. Phosphorylation sites enable docking of adaptor proteins that initiate signaling cascades such as the mitogen-activated protein kinase pathway activated by Ras and She, the Akt pathway activated by
phosphatidylinositol-3-OH kinase, and the protein kinase C pathway activated by phospho lipase Cγ. These pathways form a complex signaling network that impacts multiple cellular processes including differentiation, migration, and growth (Yarden and Sliwkowski, Nat. Rev. MoI. Cell. Biol., 2:127-137, 2001). Activated EGFR is endocytosed within several minutes and a fraction undergoes fast recycling from the early endosome. The alternate fraction persists to the late
endosome resulting in slower recycling or degradation (Sorkin and Goh, Experimental Cell Research., 315:683-696, 2009).
Dysregulation of EGFR-mediated signalling is observed in breast, bladder, head and neck, and non-small cell lung cancers (Yarden and Sliwkowski, Nat. Rev. MoI. Cell. Biol, 2:127- 137, 2001). Accordingly, engineered proteins that target the EGFR can be used to treat these cancers.
An analysis of 15 years of published literature on EGFR expression and cancer prognosis revealed that receptor overexpression is associated with reduced survival in 70% of head and neck, ovarian, cervical, bladder, and esophageal cancers (Nicholson et ah, Eur. J. Cancer, 37 Suppl. 4, S9-15, 2001). Autocrine production of transforming growth factor α and epidermal growth factor (EGF) correlate with reduced survival in lung cancer (Tateishi et al, Cancer Research, 50:7077-7080, 1990). Receptor mutation is also implicated in cancer. EGFRvIII, which lacks amino acids 6-273, is observed in glioblastoma, non- small cell lung cancer, and cancers of the breast and ovary (Pedersen et al., Ann. Oncol, 12:745-760, 2001). This mutant is unable to bind ligand yet is constitutively active, posing a unique therapeutic challenge, particularly for ligand blocking agents. Ectodomain point mutants in glioblastoma yield tumorigenicity (Lee et al, PLoS. Med., I:e485, 2006). Kinase domain mutations observed in non-small cell lung cancer hyperactivate kinase (Sharma et al, Nat. Rev. Cancer, 7:169-181, 2007).
As a result of the involvement of EGFR in cancer, there has been substantial effort spent developing receptor inhibitors as therapeutics. The U.S. Food and Drug Administration has approved two monoclonal antibodies and two tyrosine kinase inhibitors targeting EGFR.
Cetuximab (Erbitux, Bristol-Myers Squibb), approved for colorectal and head and neck cancer, and panitumumab (Vectibix, Amgen), approved for colorectal cancer, are antibodies that compete with EGF for receptor binding. However, the relative impact of ligand competition, receptor downregulation, and antibody-dependent cellular cytotoxicity is unknown (note that panitumumab is an immunoglobulin G (IgG) 2a molecule and thus incapable of triggering cellular cytotoxicity). Both antibodies exhibit modest efficacy. In treatment of metastatic colorectal cancer refractory to irinotecan tyrosine kinase inhibitor, only 11% of patients respond to cetuximab alone and only 23% respond to cetuximab and irinotecan in combination
(Cunningham et al, N. Engl. J. Med., 351 :337-345, 2004). In the treatment of head and neck
cancer, the addition of cetuximab to radiation extends median survival from 29 to 49 months yet only increases responsiveness from 45% to 55% and improvement is only evident for
oropharyngeal cancer but not hypopharyngeal or laryngeal cancers. Moreover, metastases were present at comparable amounts with and without antibody (Bonner et al, N. Engl. J. Med.,
354:567-578, 2006). In metastatic colorectal cancer, panitumumab extends progression-free survival from 64 days to 90 days; yet the overall response rate was only 8% and there was no improvement in overall survival (Messersmith and Hidalgo, Clinical Cancer Research, 13:664- 4666, 2007).
While this efficacy validates EGFR as a useful therapeutic target, it begs the search for improved understanding of receptor biology and the development of improved therapy. Potential causes of the modest efficacy include inability to effectively compete with ligand, especially in the presence of autocrine signaling; insufficient downregulation of receptor; lack of inhibition of constitutively active EGFRvIII; and mutational escape. Thus, novel binders capable of downregulation and/or inhibition via different modes of action would be beneficial. Small, monovalent binders would enable improved biophysical studies via specific inhibition or Forster resonance energy transfer. Such small binders could also be useful for in vivo imaging to study receptor localization and trafficking.
Other cancer-specific targets: In addition to the EGFR {e.g., a human EGFR) as a cancer target, the binding reagents can be directed to A33 (e.g., human A33 or mouse A33), and mouse CD276.
Other cancer-specific or receptor tyrosine kinase-specific targets: Other targets include receptors of the ErbB, insulin, PDGF, FGF, VEGF, HGF, Trk, Eph, AXL, LTK, TIE, ROR, DDR, RET, KLG, RYK, and MuSK receptor families. For example, the engineered proteins described herein that target a VEGF receptor {e.g., VEGF -R2) can be used in the treatment of multiple myeloma.
Immunological targets: Immunological targets include the Fcγ receptors Ha and Ilia, and biotechnological targets include mouse IgG and human serum albumin (HSA).
Biotechnological targets: In addition, binders to lysozyme, carcinoembryonic antigen, goat IgG, and rabbit IgG were engineered during platform development.
Nucleic acids, vector constructs, and expression systems: Nucleic acid (e.g., DNA) sequences coding for any of the polypeptides within the present engineered proteins are also
within the scope of the present invention as are methods of making the engineered proteins. For example, variable regions can be constructed using PCR mutagenesis methods to alter DNA sequences encoding an immunoglobulin chain, e.g., using methods employed to generate humanized immunoglobulins (see e.g., Kanunan, et al, Nucl. Acids Res. 12:5404,1989; Sato, et al, Cancer Research 53:851-856, 1993; Daugherty, et al, Nucleic Acids Res. !9(9):2471- 2476,1991; and Lewis and Crowe, Gene 101:297-302, 1991). Using these or other suitable methods, variants can also be readily produced. In one embodiment, cloned variable regions can be mutagenized, and sequences encoding variants with the desired specificity can be selected (e.g., from a phage library; see e.g., Krebber et al, U.S. Patent No. 5,514,548; Hoogenboom et al, WO 93/06213, published April 1, 1993)).
To produce a genetically modified Fn domain, a heterologous amino acid sequence, an accessory sequence, a linker, or any other component of the engineered proteins described herein, nucleic acid sequences encoding the engineered protein or a portion thereof can be ligated into an expression vector and used to transform a prokaryotic cell (e.g., bacteria) or transfect a eukaryotic (e.g., insect, yeast, or mammal) host cell. In general, nucleic acid constructs can include a regulatory sequence operably linked to a nucleic acid encoding the engineered protein or a protion thereof (see, e.g., Figures 6 and 13). Regulatory sequences (e.g., promoters, enhancers, polyadenylation signals, or terminators) can be included as needed or desired to affect the expression of a nucleic acid sequence. The transformed or transfected cells can then be used, for example, for large or small scale production of the engineered protein by methods well known in the art. In essence, such methods involve culturing the cells under conditions suitable for production of the engineered protein and isolating the protein from the cells or from the culture medium. Additional guidance can be obtained from the Examples presented below.
Pharmaceutical preparations and methods of treatment: The engineered proteins described herein can be administered directly to a mammal. Generally, the engineered proteins can be suspended in a pharmaceutically acceptable carrier (e.g. , physiological saline or a buffered saline solution) to facilitate their delivery. Encapsulation of the polypeptides in a suitable delivery vehicle (e.g., polymeric microparticles or implantable devices) may increase the efficiency of delivery. A composition can be made by combining any of the peptides provided herein with a pharmaceutically acceptable carrier. Such carriers can include, without limitation,
sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents include mineral oil, propylene glycol, polyethylene glycol, vegetable oils, and injectable organic esters. Aqueous carriers include, without limitation, water, alcohol, saline, and buffered solutions. Preservatives, flavorings, and other additives such as, for example, antimicrobials, anti-oxidants (e.g., propyl gallate), chelating agents, inert gases, and the like may also be present. It will be appreciated that any material described herein that is to be administered to a mammal can contain one or more pharmaceutically acceptable carriers.
Any composition described herein can be administered to any part of the host's body for subsequent delivery to a target cell. A composition can be delivered to, without limitation, the brain, the cerebrospinal fluid, joints, nasal mucosa, blood, lungs, intestines, muscle tissues, skin, or the peritoneal cavity of a mammal. In terms of routes of delivery, a composition can be administered by intravenous, intracranial, intraperitoneal, intramuscular, subcutaneous, intramuscular, intrarectal, intravaginal, intrathecal, intratracheal, intradermal, or transdermal injection, by oral or nasal administration, or by gradual perfusion over time. In a further example, an aerosol preparation of a composition can be given to a host by inhalation.
The dosage required will depend on the route of administration, the nature of the formulation, the nature of the patient's illness, the patient's size, weight, surface area, age, and sex, other drugs being administered, and the judgment of the attending clinician. Suitable dosages are in the range of 0.01-1,000 μg/kg. Wide variations in the needed dosage are to be expected in view of the variety of cellular targets and the differing efficiencies of various routes of administration. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art. Administrations can be single or multiple (e.g., 2- or 3-, 4-, 6-, 8-, 10-, 20-, 50-, 100-, 150-, or more fold). Encapsulation of the engineered proteins in a suitable delivery vehicle (e.g., polymeric microparticles or implantable devices) may increase the efficiency of delivery.
As is known in the art, dosage may vary based on the condition to be treated. One of ordinary skill in the art wishing to use an engineered protein of the present invention can obtain information and guidance regarding dosage from currently available antibody therapeutics. For example, cetuxamab, when used for the treatment of colorectal cancer in adults is delivered IV at 400 mg/m 2 as an initial loading dose administered as a 120-min infusion (max rate of infusion, 10 mg/min). The weekly maintenance dose is 250 mg/m 2 infused over 60 min (max rate of
infusion, 10 mg/min) until disease progression or unacceptable toxicity. For treatment of squamous cell carcinoma of the head and neck, in adults, the recommended delivery for cetuxamab is IV in combination with radiation therapy. The recommended dose is 400 mg/m 2 as a loading dose given as a 120-min infusion (max infusion rate, 10 mg/min) 1 wk prior to initiation of a course of radiation therapy. The recommended weekly maintenance dose is 250 mg/m 2 infused over 60 min (max infusion rate, 10 mg/min) weekly for the duration of radiation therapy (6 to 7 wk). Complete administration 1 h prior to radiation therapy. As a single agent, the recommended initial dose is 400 mg/m 2 followed by 250 mg/m 2 weekly (max infusion rate, 10 mg/min) until disease progression or unacceptable toxicity. We expect the engineered proteins described herein may be beneficially administered using the same or similar regimes.
A potential advantage of the present engineered proteins is that their multispecific (e.g., heterobivalent) nature combines the efficacy of multiple compounds into a single drug, and this may reduce the total required drug dosage and facilitate administration while allowing for complementary mechanisms to synergize.
The duration of treatment with any composition provided herein can be any length of time from as short as one day to as long as the life span of the host (e.g., many years). For example, an engineered protein can be administered once a week (for, for example, 4 weeks to many months or years); once a month (for, for example, three to twelve months or for many years); or once a year for a period of 5 years, ten years, or longer. It is also noted that the frequency of treatment can be variable. For example, the present engineered proteins can be administered once (or twice, three times, etc.) daily, weekly, monthly, or yearly.
An effective amount of any composition provided herein can be administered to an individual in need of treatment. The term "effective" as used herein refers to any amount that induces a desired response while not inducing significant toxicity in the patient. Such an amount can be determined by assessing a patient's response after administration of a known amount of a particular composition. In addition, the level of toxicity, if any, can be determined by assessing a patient's clinical symptoms before and after administering a known amount of a particular composition. It is noted that the effective amount of a particular composition administered to a patient can be adjusted according to a desired outcome as well as the patient's response and level
of toxicity. Significant toxicity can vary for each particular patient and depends on multiple factors including, without limitation, the patient's disease state, age, and tolerance to side effects.
Any method known to those in the art can be used to determine if a particular response is induced. Clinical methods that can assess the degree of a particular disease state can be used to determine if a response is induced. The particular methods used to evaluate a response will depend upon the nature of the patient's disorder, the patient's age, and sex, other drugs being administered, and the judgment of the attending clinician.
As noted above, the engineered proteins can also be used as delivery agents to deliver cargo (e.g., a therapeutic agent) to a particular cell type. The cargo can be internalized by virtue of internalization of the engineered protein and its target molecule. The cargo can be a cytotoxic agent, which refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. Cytotoxic agents include radioactive isotopes (e.g., 1311, 125I5 90Y and 186Re), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin or synthetic toxins, or fragments thereof. The agents can also be non- cytotoxic, in which case they will not inhibit or prevent the function of cells and/or will not cause destruction of cells. A non-cytotoxic agent may include an agent that can be activated to be cytotoxic. A non-cytotoxic agent may include a bead, liposome, matrix or particle (see, e.g., U.S. Patent Publications 2003/0028071 and 2003/0032995 which are hereby incorporated by reference herein in their entireties). Such agents may be conjugated, coupled, linked or otherwise associated with an engineered protein disclosed herein.
Kits and other compositions: The engineered proteins, domains thereof, nucleic acids, including vector constructs that can be used to produce them, and any of the other compositions of the invention can be packaged in various combinations as a kit, together with instructions for use.
Nucleic acid sequences encoding representative Fn3-Fn3 and Ab-Fn3 fusions are shown in Figures 6 and 13, respectively. These sequences and sequences that are identical to one or more defined portions therein are within the scope of the present invention. The beginnings and ends of the sequences presented in these figures are marked. For example, Fn3ioi is demarkated in Figure 6 and Fn Clone D and 225HC. Accordingly, the invention encompasses nucleic acid constructs comprising one or more of Clone A, Clone B, Clone C, Clone D, or Clone E or biologically active fragments or other variants (e.g. , substitution mutants) thereof. Other
constructs can comprise the linker or leader sequences shown. For example, the invention encompasses nucleic acid constructs that include a sequence encoding a leader sequence (e.g., ATG ... GCT of gWiz 225 HN-D), a sequence encoding a genetically modified Fn domain (e.g. , Clone D (GTT ...CAG of gWiz 225 HN-D)), a sequence encoding a linker (e.g., (GIy4Se^2), and a sequence encoding a target-specific protein scaffold (e.g., 225 HC (CAG ... GCT of gWiz 225 HN-D). Also within the scope of the invention are degenerate variants and codon optimized variants of the nucleic acids shown in Figures 6 and 13. Also within the scope of the invention are constructs comprising nucleic acid sequences that exhibit a certain degree of identity to the sequences shown in Figure 6 or Figure 13 (e.g., sequences that are at least 85% (e.g., 90%, 95%, or 98%) identical to a sequence shown in Figure 6 or Figure 13) and that encode proteins that retain sufficient biological activity to be useful in one or more of the methods described herein. Proteins encoded by the nucleic acid sequences shown in Figure 6 or Figure 13, and biologically active fragments or other variants thereof (e.g., proteins that are at least 85% (e.g., 90%, 95%, or 98%) identical to a protein encoded by a sequence shown in Figure 6 or Figure 13) are also within the scope of the present invention. The nucleic acid sequences described herein can be incorporated into a vector (e.g. , an expression vector such as a plasmid or a cosmid or other viral vector) using methods known in the art. The nucleic acids and/or vectors that contain them can similarly be transfected into cells (e.g., cells in tissue culture), and such cells are within the scope of the present invention.
The studies described in the examples below illustrate the compositions and methods of the invention without limitation.
EXAMPLES
In the work described below and elsewhere in this specification, we describe a platform for engineering fibronectin domains (e.g., Fn3 domains) as selective binding reagents and methods of assembling these domains, with or without heterologous amino acid sequences, to produce heterovalent proteins that specifically bind a variety of molecular targets. Several elements of protein engineering by directed evolution were improved to produce a platform enabling the identification of high affinity binders derived from the Fn3 scaffold. These technological developments are broadly applicable to the field of protein engineering.
In the studies below, we describe the production of engineered proteins that bind eight targets: the cancer targets human EGFR, human A33, mouse A33, and mouse CD276;
immunological targets Fcγ receptors Ha and Ilia; and biotechnological targets mouse IgG and human serum albumin (HSA). In addition, binders to lysozyme, carcinoembryonic antigen, goat IgG, and rabbit IgG were engineered during platform development. EGFR binders were incorporated into both a novel bispecific format, where the engineered proteins feature two genetically modified Fn3 domains, and into an Fn3-Ab fusion. Selective non-competitive heterobivalent constructs are capable of receptor downregulation. Select constructs inhibit cell proliferation and migration, particularly in combination with a ligand-competitive antibody, and therefore have strong therapeutic potential.
Example 1: Stability and Complementarity Bias Improve the Protein
Functionality Landscape
We sought to develop an improved Fn3 library design through incorporation of two key features: (a) wild-type conservation of residues that are (i) structurally important if not critical and/or (ii) conservation of residues that are less likely to contribute to the desired binding interaction and (b) tailored amino acid diversity biased to functional amino acids.
Despite their location in the BC/DE/FG loop region of Fn3, some residues may be critical to the conformational stability of the protein fold. As such, diversification of these positions may produce a library population with reduced average stability. Destabilization limits the robustness of binders in biotechnology applications such as the stringent washing steps of purification and detection. Instability can result in degradation and aggregation of in vivo diagnostics and therapeutics, which reduces potency and can elicit an immune response.
Moreover, destabilization decreases the tolerance to mutation, which decreases the capacity for evolution (Bloom et al, Proc. Natl. Acad. ScL USA, 103:5869-5874, 2006). Also, the potentially resultant flexibility may diminish the free energy change upon binding because of entropic effects. Moreover, conservation at structurally critical positions enables diversity to be focused on positions that are more likely to contribute to the binding interaction yielding a more efficient search of sequence space. In our work, we use stability, structural, and sequence analyses to identify conservation sites that may benefit library design.
Early library designs commonly used NNB or NNS/NNK randomized codons to approximate an equal distribution of all amino acids. Yet, because not all amino acids are
equivalent in their ability to provide conformational and chemical complementarity for molecular recognition, a tailored distribution may be more effective. Sidhu and colleagues have investigated this hypothesis and demonstrated the utility of a tyrosine/serine library as well as the unique efficacy of tyrosine to mediate molecular recognition in antibody fragments (Fellouse et al, Proc. Natl. Acad. Sci. USA, 101:12467-12472 (2004); Fellouse et al, J. MoI. Biol,
348:1153-1162 (2005); Fellouse et al, J. MoI Bio., 357:100-114 (2006)). Direct competition of full diversity and tyrosine/serine diversity libraries in the Fn3 domain was dominated by the full diversity library for selection of high affinity binders to goat and rabbit immunoglobulin G (Hackel and Wittrup, submitted). Thus, though tyrosine/serine may provide ample diversity for binding, an expanded repertoire enables higher complementarity. The expanded repertoire can be effectively utilized with an efficient library design and/or affinity maturation scheme. A tailored antibody library with elevated tyrosine, glycine, and serine and low levels of all other amino acids except cysteine was superior to a tyrosine/serine library (Fellouse et al, J. MoI Biol, 373:924-940, 2007). A similarly biased library was used with the Fn3 scaffold to yield a 6 nM binder to maltose binding protein (Gilbreth et al, J. MoI Biol, 381:407-418, 2008) and a novel 'affinity clamp' for peptide recognition (Huang et al, Proc. Natl. Acad. Sci. USA, 2008). These biased distributions were created by oligonucleotide synthesis using custom trimer phosphoramidite mixtures. Our current work investigates the ability to create a desired distribution via inexpensive skewed nucleotide mixtures. In particular, the amino acid distribution in human and mouse CDR-H3 loops is effectively mimicked. We demonstrate that a new library incorporating selective conservation and tailored diversity is superior to both an unbiased library with approximately equal amino acid diversity and a tyrosine/serine binary code library. This library enabled the generation of binders to a multitude of targets with expected utility in research, biotechnology, and therapy.
Fn3 Stability: We used yeast surface display for efficient stability analysis of Fn3 clones. It has been demonstrated that the number of displayed single-chain T-cell receptors per yeast cell correlates to receptor stability (Shusta et al, J. MoI Biol, 292:949-956 (1999)). To validate this correlation for Fn3, we created yeast surface display vectors of binders to vascular endothelial growth factor receptor 2 spanning a range of stabilities: free energies of unfolding from 3.8 to 7.5 kcal/mol and midpoints of thermal denaturation of 42 to 84° (Parker et al, Protein Engineering Design and Selection, j_8:435-444 (2005)). Clonal cultures of yeast were grown at 300C, Fn3
expression was induced at 37°C, and the amount of displayed Fn3 was quantified by flow cytometry. The clones exhibit a positive relationship between display and stability spanning a substantial display range between the least and most stable clones, thereby validating this technique for stability comparison.
This validated approach was used to explore domain stabilization via single-site wild- type conservation in the context of a diverse library. To quantify this impact, a series of libraries were constructed: one library with fully diversified BC, DE, and FG loops and multiple libraries of the same design except for wild-type conservation at a single position of interest. The libraries were transformed into a yeast surface display system and the amount of Fn3 displayed upon induction at 37°C was quantified by flow cytometry. Eleven of fourteen positions studied, as well as a multisite library, exhibit improved display with wild-type conservation. A26, V27, and T28 have increased display but not of statistical significance. Accordingly, Fn domains useful in the presently engineered proteins include those in which one or more of the residues at positions 23, 24, 25, 29, 52, 56, 77, 78, 79, 84, and 85 of SEQ ID NO:1 are conserved.
Analogous positions in fibronectins from other species can be also be conserved.
Solvent Accessible Surface Area: The solvent accessible surface area of each potentially diversified position was calculated using GetArea (Fraczkiewicz and Braun, J. Computational Chemistry, (1998)) for wild-type Fn3 (solution structure ITTG (Main et al, Cell, 71:671-678 (1992)) and crystal structures IFNA (Dickinson et al, J. MoI. Biol, 236:1079-1092 (1994))) and an engineered binder (2OBG (Koide et al, Proc. Natl Acad. Sci. USA, 104:6632-6637 (2007))). Despite their presence in previously diversified loop regions, the side chains of D23, A24, P25, V29, G52, and S85 are relatively inaccessible; peripheral residues W22, Y32, A57, T76, and P87 are also buried. Conversely, the amino acids in the middle of each loop are relatively exposed, supporting the ability of these sites to be diversified while maintaining the correct fold.
Sequence Analysis: The mutational flexibility of each position was further explored through phylogenetic sequence analysis. The type III domains of fibronectin in chimpanzee, cow, dog, horse, human, mouse, opossum, platypus, rat, and rhesus monkey (any of which can serve as starting materials for an engineered protein as described herein) were aligned, and the relative frequency of each amino acid was determined (Figure 1(A)). The peripheral residues W22, Y32, P51, A57, and P87 are well conserved; however, T76 is variable. Other sites exhibiting conservation three-fold above random are A24 (22%), P25 (62%), V29 (25% as well
as 43% isoleucine), G52 (25%), S53 (23%), S55 (27%), G77 (21%), G79 (19%), and S85 (66%); also note that T56 is 12% conserved with 51% of the homolog serine. Thus, the BC loop exhibits conservation of its peripheral hydrophobic residues except Y31. The DE loop, except for the central lysine, is well-conserved. The FG loop has a trend towards glycine from G77 to G79 and two highly conserved sites near the C-terminus,
Published sequences of engineered binders were analyzed similarly. However, in this analysis, amino acid frequencies were compared to expected frequencies based on variable library designs (Figure 1(B)). Wild-type is present at least twice as often in binders as in the naϊve library at three positions: P25 (15% in binders versus 5% in libraries), G52 (26% v. 13%), and G79 (17% v. 5%). In addition, three positions yield substantial enrichment of homo logs: alanine at V29 (20% v. 6%), threonine at S55 (25% v. 6%), and serine at T56 (28% v. 11 %).
Library Design: The stability, accessibility, and sequence analyses (summarized in the Table of Figure 21) were used to determine the degree of diversification desired at each position. For example, proline at position 25 significantly stabilizes the library, is essentially inaccessible to solvent, and is highly conserved in the type III fibronectin domains of mammals. Thus, the new library will be heavily biased towards proline at this position. Conversely, the adjacent alanine at position 26 does not significantly stabilize the library, is highly accessible, and exhibits essentially no conservation. As a result, this position will be fully diversified in the new library design.
Along with conservation bias to maintain structural integrity and focus diversity on positions better suited for molecular recognition, it was desired to bias the diversity to functional amino acids. Tyrosine has demonstrated unique utility in molecular recognition (Fellouse et al, Proc. Natl. Acad. Sci. USA, 101:12467-12472, 2004; Fellouse et al, J. MoI. Biol, 348:1153- 1162, 2005; Fellouse et al, J. MoI Bio., 357:100-114, 2006). Glycine provides conformational flexibility. Serine and alanine are valuable as small, neutral side chains. Acidic residues, arginine, and lysine provide charge although the utility is unclear (Birtalan et al, J. MoI Biol, 377:1518-1528, 2008). Other side chains may provide ideal complementarity in less frequent situations. Thus, we propose the ideal diversity contains high tyrosine, glycine, and serine and/or alanine as well as small levels of all other amino acids. For the particular amino acid distribution we sought guidance from natural molecular recognition. The amino acid distribution in CDR-H3 matches the desired diversity and was used as the library design model (Figure 2). Each position
was designed to incorporate the desired level of wild-type conservation and to match the antibody CDR-H3 repertoire in the non-conserved portion of the distribution. The DE loop is a slight exception because a very similar design was previously validated as effective (Hackel and Wittrup, submitted). In this loop, G52, S53, S55, and T56 are highly conserved with wild-type at 50% frequency and unbiased distribution of all other amino acids. The lack of antibody-inspired bias in this loop is of limited detriment because of the high conservation of the wild-type amino acids. Multiple loop lengths, selected based on phylogenetic occurrence (Hackel et ah, J. MoI. Biol., 3jy_: 1238-1252, 2008), are included in each loop. The resultant library design is summarized in the Table of Figure 21.
Library Construction: Though trimer phosphoramidite library construction enables precise creation of unique amino acid distributions, this approach is expensive with the inclusion of multiple specialty codon mixtures. As an inexpensive alternative, standard oligonucleotide synthesis was employed using custom mixtures of skewed nucleotides at each position. The optimal set of three nucleotide mixtures was determined for each codon as follows. All possible sets of nucleotide mixtures with each component at 5% increments were filtered to select only those that closely match the desired levels of wild-type and tyrosine and reasonably match glycine, serine, aspartic acid, alanine, and arginine; these amino acids are the most frequent in antibody CDR-H3 and are functionally diverse. Sample protein libraries were then produced in silico from the amino acid probability distributions resulting from the sets of nucleotide mixtures. The library calculated to be most likely to be produced from the intended distribution (i.e., the antibody repertoire with the appropriate wild-type bias) was selected as optimal. This process was repeated for each position in the library.
In general, these skewed nucleotide mixtures provide good matches to the desired amino acid distributions (Figure 2). The two exceptions are decreased levels of glycine and elevated cysteine. Since the latter two positions in a cysteine codon (TGT or TGC) are shared by glycine (GGN), it is not possible to create high levels of glycine without also yielding high cysteine unless TNN codons are depleted, which depletes tyrosine. Thus, a compromise is reached with 6% glycine and 10% cysteine. Though this incorporates a relatively high level of cysteine, the library design still yields many cysteine-free clones; moreover, interloop disulfide bonds are a potentially advantageous element (Lipovsek et al, J. MoI. Biol., 368:1024-1041, 2007).
Fn3 genes were constructed by overlap extension PCR of partially degenerate oligonucleotides. Transformation into yeast by electroporation with homologous recombination yielded 2.5xlO8 transformants. Sequencing and flow cytometry analysis indicate 60% of clones encode for full-length Fn3 resulting in 1.5xlO8 Fn3 clones. Sequence analysis reveals that the skewed nucleotides accurately match their intended distribution (Figure 2). The library is termed G4, as it is the fourth generation Fn3 library created in our laboratory after the two-loop, single- length BF 14 library (Lipovsek et al, J. MoI Biol, 368:1024-1041, 2007), the three-loop, length- diversified NNB library (Hackel et al, J. MoI Biol, 381:1238-1252, 2008), and the three-loop, DE-conserved tyrosine/serine library YS (Hackel and Wittrup, submitted).
Library Comparison: The new G4 library design was compared to a non-conserved, full diversity library (NNB (Hackel et al, J. MoI Biol, 381:1238-1252, 2008)) and to a library with wild-type conservation in the DE loop only and tyrosine/serine diversity (YS (Hackel and Wittrup, submitted)) {see the Table below).
"Loop Diversity" indicates the library of codons included at positions without wild-type bias. "Biased Positions" indcates positions within the diversified loops (23-31, 52-56, 77-86) that are biased towards wild-type. "Full-length Fn3s" indicates the library size {i.e., the number of yeast transformants that encode for full-length Fn3 domains).
The libraries were pooled for comparison and tested for their ability to generate binders to seven targets: human A33, mouse A33, epidermal growth factor receptor (EGFR), Fcγ receptors HA and IIIA (FcγRIIA and FcγRIIIA), mouse immunoglobulin G (mlgG), and human serum albumin (HSA). The naϊve library was sorted by magnetic bead selections (Ackerman et al, Biotechnol Prog., 25:774-783 (2009)), and lead clones were diversified by error-prone PCR on the full Fn3 gene and shuffling of mutagenized Fn3 loops. Multiple rounds of selection and diversification were performed to yield binders to each target. Sequence analysis of each binding population revealed that 19 of 21 binders originated from the G4 library while two clones were likely of NNB origin and no YS clones were identified {see the Table of Figure 22 and Figure ). Given the comparable number of clones in the naϊve libraries, this result
indicates that G4 is a superior library design to both NNB and YS for the selection of protein binders.
Sequence analysis reveals that wild-type bias is approximately maintained or perhaps slightly reduced in the BC and FG loops of binders while the strong bias at G52, S55, and T56 is slightly reduced but still highly frequent. It is noteworthy that in addition to 20% occurrence at G79, glycine is present at 15% at position 80. At position 29, equal amounts of alanine, leucine, serine, and wild-type valine were included in the naϊve library; in binders, the smallest available side-chain, alanine, is present at 35% while the largest side-chain, leucine, occurs with only 10% frequency. Cumulative analysis of amino acid frequency at positions without wild-type bias indicates maintenance of the preferentially high levels of tyrosine, serine, glycine, aspartic acid, and arginine. Conversely, cysteine and histidine, which were included at higher frequency than intended because of their codon similarity to tyrosine, are present at reduced levels in binders. Eight of nineteen (42%) G4-based binders are cysteine-free as compared to 19% in the naϊve library. Interestingly, only three clones (16%) have a single cysteine as compared to a naϊve 33% whereas seven clones (37%) contain two cysteines (26% in naive library). A single clone has four cysteines. Thus, a strong selective pressure exists against unpaired cysteines. Of particular interest, six of the seven two-cysteine clones contain cysteine residues in identical or adjacent loops at proximal positions suggesting feasible disulfide bonding, which can stabilize the domain (Lipovsek et al, J. MoI. Biol, 368:1024-1041, 2007). Thus, both wild-type bias and tailored diversity were effective in producing an effective library. Additional engineering campaigns and sequence analysis will improve the statistical significance of these trends and guide further library improvement.
The impact of wild-type bias and tailored diversity on domain stability was analyzed. The NNB and G4 libraries were each induced for yeast surface display at elevated temperature (37°C). The G4 library exhibits 43±9% higher average display than the NNB library indicating higher average stability; clones from G4 are substantially more stable than those from NNB. The libraries were then sorted by FACS to identify clones of low stability and high stability. About 50 clones were sequenced from each resultant population and the amino acid frequencies in low and high stability clones were compared {see the Table of Figure 23). The biased positions in the BC loop were not critical to stability in this analysis except position 29. As observed in binder sequence analysis, the small side chain alanine is preferred whereas the larger side chain leucine
is destabilizing. Wild-type amino acids at the four biased positions in the DE loop are stabilizing, especially S53 and S55. While G77 is perhaps mildly stabilizing, G79 is present at substantially higher frequency in stable clones. The complete conservation of S85 in the G4 library is justified by the preferential occurrence of S85 in stable clones from the NNB library. At positions without wild-type bias, none of the preferred amino acids are substantially destabilizing thereby validating their inclusion at elevated levels.
Discussion: . The current work demonstrates that tailored diversity is superior to nearly fully random {e.g., NNB) or overly constrained {e.g., YS) diversity. This is evidenced by the dominant selection of clones from the G4 library as well as the maintenance of the favored amino acids in binder sequences (Figure 4.6(B)). Tailored diversity improves the search of sequence space by increasing the frequency of functional binders. This results both through improving the likelihood of beneficial contacts, largely by elevation of tyrosine, and reducing detrimental constraints. The latter element is achieved through reduction of hydrophobic isoleucine, leucine, methionine, proline, threonine, and valine as well as the large, positively charged arginine and lysine, in deference to small, neutral serine. Yet a binary code of tyrosine and serine constrains sequence space such that it often lacks high affinity binders. Thus, through modest incorporation of other amino acids in the library and a broad, yet efficient mutagenesis approach, tailored diversity yields a vastly improved hybrid of the two extremes of NNB and YS.
The inclusion of wild-type bias is also an important element of the G4 library design. This bias increases the frequency of functional clones both by enabling diversity to be used at positions with more impact on binding and by reducing the number of non- functional clones that result from detrimental mutation of a structurally critical residue. Moreover, the improved stability of G4 clones improves evolvability (Bloom et al, Proc. Natl. Acad. Sci. USA,
103:5869-5874, 2006) allowing otherwise unstable sequence motifs to be explored.
The methodology and techniques in the current work are directly applicable to any protein engineering effort. While the designed skewed nucleotide mixtures for particular sites are unique to Fn3, the antibody mimic mixture should be generally applicable to solvent-exposed loops in molecular recognition scaffolds. Moreover, the mixture design algorithm may be reapplied to any design distribution. The identification of positions most likely to benefit from wild-type bias can be readily applied to other scaffolds through high throughput stability analysis in the context of protein libraries, demonstrated here using yeast surface display. When
available, sequence and structural data provide additional avenues of analysis. The relative efficacy of each of these approaches will be elucidated as continued analyses expand the sequence data set and evolved library designs are tested.
Though the thrust of this work entails study of sequence/structure/function relationships and library design, the panel of binders generated provides useful reagents for a variety of applications from tumor targeting (EGFR, human A33, and mouse A33) to biotechnology (HSA and mouse IgG) to immunology (FcγRIIa and FcγRIIIa). In addition, binders to tumor vasculature target CD276 were engineered solely from the G4 library.
In the paragraphs that follow, we describe the materials and methods that were employed in more detail.
Stability-Display Relationship: Yeast surface display plasmids were created for six Fn3 domains of previously published stabilities: wild-type, 159, 159(wt DE), 159(Q8L), 159(A56E), and 159(Q8L,A56E) (Parker et al, Protein Engineering Design and Selection, 18:435-444 (2005)). Genes were constructed by overlap extension PCR of eight oligonucleotides and transformed into EBYlOO yeast as described (Hackel et al, J. MoI. Biol, 381:1238-1252 (2008)). Gene construction was verified by DNA sequencing. Clonal populations were grown at 300C in SD-CAA medium (0.07M sodium citrate pH 5.3, 6.7 g/L yeast nitrogen base, 5 g/L casamino acids, and 20 g/L glucose) and induced at 37° in SG-CAA (0.1M sodium phosphate, pH 6.0, 6.7 g/L yeast nitrogen base, 5 g/L casamino acids, 19 g/L galactose, and 1 g/L glucose). Yeast were labeled with mouse anti-c-myc antibody (clone 9E10) followed by phycoerythrin-conjugated goat anti-mouse antibody. Yeast were washed and phycoerythrin fluorescence was analyzed with an Epics XL flow cytometer (Beckman Coulter, Fullerton, CA).
Library Stability Analysis: A library was constructed in which positions 23-30
(DAPAVTVR (SEQ ID NO:_)), 52-55 (GSKST (SEQ ID NO:_)), and 77-86 (GRGDSP ASSK
(SEQ ID NO: ) were diversified using NNB codons. The library was constructed by overlap extension PCR of eight oligonucleotides and transformed into EBYlOO yeast. Fourteen similar libraries were constructed with identical design except a single codon of interest was maintained as wild-type within the otherwise diversified regions. Separate libraries were constructed for D23, A24, P25, A26, V27, T28, V29, G52, T56, G77, R78, G79, S84, and S85; in addition, a library was constructed that maintained D23, A24, P25, and V29. These libraries, as well as wild-type Fn3, were grown at 300C and induced at 37°; Fn3 expression was analyzed by flow
cytometry as indicated above. The fractional improvement in display was calculated as the mean phycoerythrin fluorescence of the singly-conserved library minus that of the fully-diversified library and normalized to the fully-diversified fluorescence.
Solvent-Accessible Surface Area: The relative solvent accessible surface area of positions 22-32, 51-57, and 76-87 were calculated for wild-type Fn3 (solution structure ITTG (Main et al, Cell, 71:671-678, 1992) and crystal structures IFNA (Dickinson et al, J. MoI. Biol, 236:1079-1092, 1994) and an engineered binder (2OBG (Koide et al, Proc. Natl Acad. Sci. USA, 104:6632-6637, 2007). The area accessible to a 1.4A sphere was determined for each side chain in each structure and compared to the accessible area in a G-X-G random coiled peptide using GetArea (Fraczkiewicz and Braun, J. Computational Chemistry, 1998).
Phylogenetic Sequence Alignment: The following fibronectin sequences were used: chimpanzee (XP 516072), cow (P07589), dog, (XP 536059), horse (XP OO 1489154), human (NP 997647), mouse (NP 034363), opossum (XP OO 1368449), platypus (XP OO 1509150), rat (NP 062016), and rhesus monkey (XP OO 1083548). The sequences were aligned using
ClustalW (Larkin et al, Bioinformatics, Version 2.0 (2007)). The relative frequency of each amino acid was calculated at each position.
A similar analysis was conducted using engineered binder sequences. Engineered Fn3 domain sequences were aligned (sequences as in: Hackel and Wittrup, submitted; Gilbreth et al, J. MoI Biol, 381:407-418, 2008; Huang et al, Proc. Natl. Acad. Sci. USA, 2008; Parker et al, Protein Engineering Design and Selection, 18:435-444, 2005; Koide et al, Proc. Natl. Acad. Sci. USA, 104:6632-6637, 2007; Hackel et al, J. MoI Biol, 381:1238-1252, 2008; Lipovsek et al, J. MoI,. Biol, 368:1024-1041, 2007; Koide et al, J. MoI Biol, 284:1141-1151, 1998; Koide et al, Proc. Natl. Acad. Sci. USA, 99:1253-1258, 2002; Xu et al, Chemistry & Biology, 9:933- 942, 2002; Karatan et al, Chemistry & Biology, U:835-844, 2004; Olson et al, ACS Chem. Biol, 3:480-485, 2008) were aligned; identical loop sequences in related clones were only counted once to avoid bias. The amino acid frequency at each position was calculated and compared to the expected amino acid frequency as determined from a weighted average of theoretical library designs (e.g., NNS, NNB, serine/tyrosine, etc.).
Library Construction: Degenerate oligonucleotides were designed to provide the desired amino acid distribution at each position. All three-site combinations of skewed nucleotide mixtures within 5% increments were considered (e.g., 20% A, 5% C, 35% G, 40% T at the first
position, 15% A, 45% C, 10% G, 30% T at the second position, and 35% A, 25% C, 30% G, 10% T at the third position). The amino acid probability distribution of each set of nucleotides mixtures was calculated from the genetic code. The sets were filtered to identify those with good tyrosine matching and reasonable matching of alanine, aspartic acid, glycine, arginine, and serine. Specifically, tyrosine was required to occur at 0.5-2x the intended frequency; alanine, aspartic acid, glycine, arginine, and serine were required to occur at 0.33-3x the intended frequency. The sets that fulfilled these criteria were then used to produce numerous in silico protein libraries based on their amino acid probability distribution. For each clone, the probability of occurrence from a library that precisely matched the desired distribution was calculated. The sum of probabilities for each sample library was used as a metric of library fitness. The skewed nucleotide designs were selected based on fitness and the ability to use identical mixtures at multiple sites {e.g., 45% C, 10% G, 45% T at the wobble position of multiple codons). Nucleotide designs are included in the Table of Figure 24.
Degenerate oligonucleotides were synthesized with skewed nucleotides at diversified positions and nucleotides encoding wild-type Fn3 at fully-conserved positions. The library design, summarized in the Table of Figure 21, includes four, three, and four loop lengths in the BC, DE, and FG loops. Separate oligonucleotides were synthesized to yield each length.
Overlap extension PCR of eight oligonucleotides was performed to construct complete Fn3 genes. Separate reactions were conducted for each loop length to avoid bias towards shorter loops. The gene libraries were transformed into yeast by homologous recombination with linearized yeast surface display vector, which includes the Aga2p protein fusion, N-terminal HA epitope, and C-terminal c-myc epitope. The fraction of clones that produce full-length Fn3 was determined by flow cytometry as the fraction displaying the N-terminal HA tag that also contained the C-terminal c-myc epitope; these results were corroborated by sequence analysis.
Binder Selections: Human and mouse A33 extracellular domains were both produced with Hisβ epitope tags in human embryonic kidney cells and purified by metal affinity chromatography. Protein was biotinylated either on free amines using the sulfo-NHS
biotinylation kit or by site-specific sortase-based conjugation of GGGGG-biotin to an LPETG C- terminal epitope (Parthasarathy et al, Bioconjug. Chem. j_8:469-476 (2007)). EGFR mutant 404SG (Kim et al., Proteins, 62:1026-1035 (2006)) was produced in Saccharomyces cerevisiae yeast, purified by metal affinity chromatography and anti-EGFR antibody affinity
chromatography, and biotinylated on free amines using the sulfo-NHS biotinylation kit.
Biotinylated FcγRIIA and FcγRIIIA were a kind gift from Jeffrey Ravetch (Rockefeller
University). Biotinylated mlgG was purchased from Rockland Immunochemicals. Human serum albumin (Sigma) was biotinylated using the sulfo-NHS biotinylation kit. The NNB, YS, and G4 libraries were pooled for direct competition.
The libraries were sorted for binding to the seven protein targets and affinity matured as described (Hackel and Wittrup, submitted). Yeast were grown and induced to display Fn3. Binders to streptavidin-coated magnetic Dynabeads were removed (Ackerman et ah, Biotechnol. Prog., 25:774-783 (2009)). Biotinylated protein was loaded on streptavidin-coated magnetic Dynabeads and incubated with the remaining yeast. The beads were washed with PBSA and the beads with attached cells were grown for further selection. After two magnetic bead sorts, full- length Fn3 clones were selected by fluorescence-activated cell sorting using the C-terminal c- myc epitope for identification of full-length clones. Plasmid DNA was zymoprepped from the cells and mutagenized by error-prone PCR of the entire Fn3 gene or the BC, DE, and FG loops. Mutants were transformed into yeast by electroporation with homologous recombination and requisite shuffling of the loop mutants. The lead clones and their mutants were pooled for further cycles of selection and mutagenesis. Once significant binder enrichment was observed during magnetic bead sorts, fluorescence activated cell sorting was used. Yeast displaying Fn3 were incubated with biotinylated target protein and anti-c-myc antibody (clone 9E10 or chicken anti-c-myc, Invitrogen). Cells were washed and incubated with AlexaFluor488-, phycoerythrin-, or AlexaFluor647-conjugated streptavidin and fluorophore-conjugated anti-mouse or anti- chicken antibody. Cells were washed and cells with the highest target to c-myc labeling ratio were selected on a FACS Aria or MoFIo flow cytometer. Plasmids from binding populations were zymoprepped and transformed into E. coli; transformants were grown, miniprepped, and sequenced.
Library Source Determination: For each clone, the probabilities that it originated from the NNB, YS, or G4 library were calculated using the designed nucleotide distributions at each position as well as the probability of mutation by error-prone PCR.
Library Stability Analysis: The NNB and G4 libraries were independently grown at 300C and induced at 37°. Yeast were labeled with mouse anti-HA antibody (clone 16B12, Covance) and chicken anti-c-myc antibody to label the N- and C-terminal epitopes. Cells were washed,
incubated with phycoerythrin-conjugated goat anti-mouse antibody and AlexaFluor488- conjugated goat anti-chicken antibody, and sorted by flow cytometry. Only cells were comparable signals for each epitope were considered to avoid selecting epitope mutants. The lowest and highest displaying cells were collected and grown for an additional induction and selection. Plasmids were isolated and transformed into E. coli. About 50 clones from each resultant population (both low and high stability for both NNB and G4) were miniprepped and sequenced. Sequences were aligned and the amino acid frequencies at each position were determined.
Example 2: Epidermal Growth Factor Receptor Downregulation with Bivalent
Fibronectin Constructs
An alternative mode of therapy is substantial receptor downregulation to reduce or eliminate the detrimental effects of receptor activation on tumor formation, proliferation, and migration. A previously demonstrated means of receptor downregulation is administration of non-competitive pairs of antibodies. Antibodies 528 and 806 downregulate EGFR and synergistically inhibit tumor xenografts (Perera et al., Clin. Cancer Res., JJ_:6390-6399, 2005). Non-competitive antibody pairs 111 + 565 and 143 + 565 downregulate EGFR whereas the competitors 111 + 143 do not (Friedman et al, Proc. Natl. Acad. ScL USA, 102,: 1915-1920, 2005). Also, non-competitive anti-HER2 antibodies downregulate HER2 and inhibit tumor growth (Friedman et al, Proc. Natl. Acad. ScL USA, 102,: 1915-1920, 2005; Ben-Kasus et al, Proc. Natl. Acad. ScL USA, 106,:3294-32999, 2009). However, these approaches require dosing two molecules, which complicates regulatory and clinical procedures. Moreover, decoupled pharmacokinetics could reduce synergy. We believe a bispecific molecule would alleviate these problems though the efficacy is uncertain given the lack of mechanistic detail in the published literature. Fn3 domains provide a good system for bispecific constructs because their single- domain architecture enables simple head-to-tail fusion, which is the natural state of Fn3 domains within complete fibronectin protein.
In the current work, we engineer a panel of small, single-domain EGFR binders to multiple identified receptor epitopes. Homo- and hetero-bivalent combinations of these binders, expressed as protein fusions (and all within the scope of the present invention), are tested for the ability to downregulate receptors in a variety of cell lines. Several molecules effectively reduce EGFR levels up to 80%. The impact of epitopes, receptor density, bivalent format, and avidity
are investigated. Phosphorylation, both of receptor and downstream molecules, is examined. Inhibition of proliferation and migration through downregulation is demonstrated.
Binder Engineering: Multiple high affinity binders to distinct epitopes of EGFR ectodomain were desired. The NNB, YS, and G4 libraries were pooled and sorted for binding to biotinylated EGFR ectodomain mutant 404SG (Kim et ah, Proteins, 62:1026-1035, 2006). Two clones dominated the selection. Competition against existing anti-EGFR antibodies revealed that clone E4.2.2 is competitive with ICRlO, a domain I binder, and clone E4.2.1 is competitive with 528, a domain III binder. To identify additional binders, intermediate populations were sorted for binding to EGFR ectodomain in the presence of ICRlO or 528. Five unique clones that bound ICRIO-blocked EGFR were identified: EI4.4.2, EB .4.3, EI3.4.2, EI2.4.6, and EIl.4.1. In addition, two further rounds of sorting with unblocked EGFR yielded an improved mutant of E4.2.2 named E6.2.6 and one additional clone, E6.2.10 (the Table of Figure 25). In addition to binding soluble EGFR ectodomain produced in yeast, these eight clones all bind EGFR- expressing human epidermoid carcinoma A431 cells. The affinity of each clone was determined by titration of biotinylated Fn3 binding to A431 (on ice to prevent internalization); affinities ranged from 250 pM to 30 nM (the Table of Figure 25). For our affinity titrations, A431 cells were incubated with 0.01, 0.1, 1 or 10 nM of biotinylated E6.2.6 or E13.4.3, then washed, labeled with streptavidin-R-phycoerythrin, and analyzed by flow cytometry.
Competition and Epitope Mapping: Clones A-E , EI3.4.2, and EI 1.4.1 bind
conformationally-sensitive epitopes as evidenced by their inability to bind EGFR ectodomain after thermal denaturation of receptor on the yeast surface. To demonstrate conformational sensitivity, EGFR ectodomain mutant 404SG was displayed on the yeast surface. Cells were incubated at 8O0C for 30 minutes to denature the EGFR. Cells were labeled with biotinylated Fn3 and mouse anti-c-myc antibody followed by streptavidin-R-phycoerythrin and
AlexaFluor488-conjugated anti-mouse antibody. Fluorescence was quantified by flow cytometry.
Binders were tested for the ability to compete with other clones as well as with antibodies 225, 528, and ICRlO (Figure ). Clone A is competitive solely with ICRlO, a known domain I binder (Cochran et ah, Journal of Immunological Methods, 287:147-158 (2004)). This result was corroborated by the ability of clone A to bind the EGFR ectodomain fragment comprising amino acids 1-176 displayed on the yeast surface. Clone D is not competitive with
the other Fn3s or antibodies tested. It is able to bind ectodomain fragments 294-543 and 302- 503, thereby localizing the binding to domain III and the beginning of domain IV. Clones B, C, E, EI3.4.2, and EI 1.4.1 compete with each other as well as antibodies 225 and 528, EGF- competitive domain III binders (except for three untested combinations; see Figure 4). A431 cells (for 225 and EGF competition) were incubated on ice with the indicated Fn3 clone or PBSA control. AlexaFluor488-conjugates of 225 or EGF were added and cells were analyzed by flow cytometry. For all other competitions, yeast displaying EGFR ectodomain were incubated with Fn3 clone 528 or ICRlO followed by biotinylated Fn3, which was detected by streptavidin-R- phycoerythrin and flow cytometry. The black boxes indicate competition and the white boxes indicate no competition, "nd" indicates samples that were not determined. Clones A-E, as well as E6.2.10, compete with EGF for binding to A431 cells.
Higher resolution epitope mapping was performed by high throughput identification of EGFR mutations that maintain foldedness but have reduced affinity for the clone of interest (Chao et al., Journal of Molecular Biology, 342:539-550, 2004). In agreement with competition and fragment labeling, clone A binds to domain I as evidenced by its reduced binding to mutants L14H, Q16R, Y45F, and H69(QRY). The specific location in domain I provides an explanation for EGF competition as the four sites identified for clone A binding are all within 4A of EGF in the EGF/EGFR crystal structure. Clones B, C, E, and E6.2.10 all bind domain III on the portion closer to domain II, which is consistent with complementary Fn3 competition as well as EGF competition. Antibody 225 competition is reasonable for clones B, C, and E given their proximity to the cetuximab (a 225 chimera) interface. The lack of E6.2.10 competition with 225 binding is also acceptable given their disparate, though proximal, epitopes. Clone D binds near the interface of domains III and IV, which is consistent with its fragment labeling and lack of competition against 225 and clones B, C, and E. The ability of clone D to compete with EGF cannot readily be explained by direct steric inhibition given their distal binding epitopes.
However, a reasonable hypothesis is that clone D binding inhibits receptor untethering that supports high affinity ligand binding. Though domains III and IV do not grossly change during untethering (Burgess et al., Molecular Cell, 12:541-552, 2003), subtle rearrangements at the domain III / domain IV interface exist. For example, amino acids 430 and 506, which are the sites identified in clone D epitope mapping, move from 19.7A apart in the tethered structure to 16.7 A in the dimer.
Thus, at least three classes of binders have been engineered: clone A binds to domain I; clones B, C, and E bind domain III and are competitive with each other and antibodies 225 and 528 (as well as EIl.4.1 and EB .4.2); clone D binds to the C-terminal portion of domain III and the N-terminal portion of domain IV and does not compete with antibodies 225 and 528 nor clones B, C, E, EI 1,4.1, or EB.4.2.
Downregulation by Heterobivalent Constructs: To investigate receptor downregulation via a single heterobivalent agent, Fn3 clones were linked as head-to-tail protein fusions with the native seven amino acid EIDKSPQ (SEQ ID NO ) as well as a flexible
GSGGGSGGGKGGGGT (SEQ ID NO: ) linker (Figure 5(A)). Thirty constructs comprising all possible bivalent combinations, in both orientations, as well as monomers for five clones (identified as A-E under Alias in the Table of Figure 25; bivalents are named N-C where N and C represent the N-terminal and C-terminal Fn3 clones) were tested. Three different EGFR- expressing human cell lines were tested: A431 epidermoid carcinoma, HeLa cervical carcinoma, and HT29 colorectal carcinoma. Cells were cultured, serum starved, and incubated with 20 nM Fn3 or Fn3-Fn3 for 6-8 hours. Cells were detached, bound agent was acid stripped, and surface EGFR was quantified by flow cytometry. Although some constructs did not modify surface EGFR levels relative to PBSA control, bivalents D-B, D-C, D-D, D-E, A-D, B-D, C-D, and E-D downregulate, yielding up to 80% reduction in surface EGFR; D-B, D-C, and D-E have the greatest effect (Figures 5(B) and 5(C)). Thus, we have demonstrated that particular
combinations of non-competitive clones in a heterobivalent construct downregulate surface EGFR, though the D-D homobivalent does moderately reduce receptor levels. Moreover, some orders work best. For example, A-D downregulates whereas D-A does not.
Multiple elements of downregulation were investigated. To further expand the generality of downregulation efficacy as well as to examine the impact of receptor density, three heterobivalents were tested on additional cell lines: U87 glioblastoma, hMEC (human mammary epithelial cells), and Chinese hamster ovary (CHO) cells transfected with a construct expressing an EGFR-green fluorescent protein fusion. The cells were cultured in 96-well plates, serum starved, and treated with 20 nM agent for 8 hours. Surface eGFR was quantified by flow cytometry and normalized to PBSA-treated control. Downregulation was observed in all six cell lines for D-B, D-C, and D-E (Figure 7). Interestingly, downregulation was reduced for D-C and D-E in the low-expressing cells HT29 and U87. Conversely, EGF downregulates receptor
most robustly in these low-expressing lines while exhibiting muted receptor reduction in the high-expressing CHO and A431 cells.
Downregulation kinetics were analyzed for two robust heterobivalent constructs. EGFR- expressing cells were cultured in 96-well plates, serum starved, and treated with 20 nM D-B and D-C constructs for 10 hours. Surface EGFR was measured at 2, 4, 6, 8, and 10 hours after treatment, quantitated by flow cytometry and normalized to PBSA-treated control. We found that both D-B and D-C downregulated EGFR in these A431 cells with half-times of 1.1 and 1.4 hours, respectively. Downregulation in HeLa cells is slightly faster at 0.44, 0.59, and 1.3 hours for D-B, D-C, and D-E. Thus, the genetically modified Fn3 domains of the present invention and engineered proteins containing them may effect receptor (or target)
downregulation on a scale consistent with these times (e.g., with half-times of about 0.3 - 2.0 hours).
Heterobivalent D-C and D-E constructs were created with three different lengths of the linker between the Fn3 domains; in addition to the native EIDKPSQ sequence (SEQ ID NO ), glycine-rich linkers of four, 15, or 27 amino acids were included. The constructs were tested for downregulation of EGFR in HT29, U87, HeLa, hMEC, CHO, and A431 cells. The cells were cultured in 96-well plates, serum starved, and treated with 20 nM of the D-C or D-E bivalent constructs for eight hours. Surface EGFR was quantified by flow cytometry and normalized to PBSA-treated control. Although results vary by cell line and by heterobivalent construct, the longer linkers were always the least effective (although still capable of receptor downregulation) and the shortest linker was often the most effective.
An alternative bispecific format was tested in which monovalent Fn3 domains were biotinylated and combinations of clones were immobilized on AlexaFluor488-conjugated streptavidin. In all bispecific and trispecific combinations of A, C, D, E, EI1.4.1, and EI3.4.2, no downregulation is observed in HT29 or U87 cells transfected to overexpress EGFR. Yet most combinations yield a substantial accumulation of internalized AlexaFluor488 signal suggestive of complex internalization without downregulation. Thus, bispecific format appears critical for efficacy. Of note, internalized AlexaFluor488 signal at 37° correlates with surface labeling at 4° (which restricts internalization) suggestive of passive internalization for all combinations.
Phosphorylation: To investigate the mechanisms of downregulation, an EGFR expression vector was transfected into human embryonic kidney (HEK) cells, which express low
levels of native EGFR. Though EGF robustly downregulates native HEK EGFR, trans fected cells with approximately 50-fold more EGFR are not effectively downregulated. Conversely, D- B and D-C heterobivalents are able to downregulate transfected EGFR. The activity of the transfected EGFR is validated by a strong correlation between the fraction of cells transfected and the downregulation of native EGF; thus, the presence of overexpressing transfected cells reduces the EGF -based downregulation of non-transfected cells possibly through ligand depletion or competition. These results indicate a divergence between the mechanisms of downregulation by EGF and Fn3-Fn3 heterobivalents.
To further explore the mechanism, eight EGFR mutants with point mutations in their intracellular domains were tested for their ability to be downregulated. All eight mutants (T654A, T669A, K721R, Y845F, S1046A/S1047A, Y1068F, Y1148F, Y1173F; all of which are within the scope of the present invention) exhibit downregulation on par with wild-type EGFR in the presence of D-B and D-C.
The impact of heterobivalents on EGFR phosphorylation was analyzed at eight sites: T654, T669, Y845, S1046, Y1068, Y1086, Yl 148, and Yl 173. Heterobivalent D-C (20 nM), PBSA, or EGF was added to serum starved A431 cells for 5,15, 60, or 240 minutes, and receptor phosphorylation was quantified by in-cell Western blot. The cells were fixed, permeabilized, labeled with rabbit anti-phospho-(S/T/Y) antibody followed by anti-rabbit-800CW and ToPro3 (to stain DNA), and imaged. Receptor agonism by D-C is consistently lower than that by EGF with the lone exception of T669 at early times. In fact, receptor agonism is often non-distinct from background. Thus, the genetically modified Fn domains of the invention may exhibit a general lack of agonism for a target such as the EGFR.
Likewise, standard Western blot analysis of cell lysates reveals that heterobivalents do not yield significant phosphorylation of extracellular signal-regulated kinase (ERKl/2) at Y202/Y204 upon 15 minute incubation whereas EGF is activating. To demonstrate ERK agonism, A431 cells were cultured in 24-well plates, serum starved, and treated with 20 nM agent for 15 minutes. Cell lysates were separated by SDS-PAGE, blotted to nitrocellulose, and labeled with rabbit anti-phosphoERKl/2 Y202/&204 antibody followed by peroxidase- conjugated anti-rabbit antibody and imaged.
This result is corroborated by global phosphorylation analysis of A431 cells upon addition of heterobivalent constructs for 15 or 60 minutes. The cells were treated with 20 nM
agent (control, EGF, D-B, D-C, or B + D) and phosphorylated tyrosine peptides were analyzed by iTRAQ LC-MS/MS. EGF yields substantially more phosphorylation than heterobivalents or a pair of monovalents (Figure 8).
Collectively, these data demonstrate that select Fn3-Fn3 heterobivalents substantially downregulate EGFR in a manner distinct from EGF and without significant receptor activation; there is a general lack of global agonism by the Fn-Fn constructs.
An EGFR trafficking model is shown in Appendix B of the provisional application filed August 13, 2009. EGFR trafficking can be examined with a model consisting of four simple mechanisms: synthesis, endocytosis, degradation, and recycling. Constitutive synthesis produces surface receptor (S) at rate ksyn. Surface receptor is internalized to endosome (E) at rate kendoS. Endosomal receptor is degraded at rate kdegE or recycled to the surface at rate krecE.
Efficacy. The ability of monovalent, homobivalent, and heterobivalent constructs to inhibit downstream signaling was examined. A431 cells were cultured in 24-well plates, serum starved, and treated with 20 nM agent for 6 hours. The cells were then treated with 1 nM EGF for 15 minutes. Cell lysates were separated by SDS-PAGE, blotted to nitrocellulose, and labeled with rabbit antiphosphoERKl/2 Y202/Y204 antibody followed by peroxidase-conjugated anti- rabbit antibody and imaged. The downregulating bivalents A-D, D-B, D-C, and D-E inhibit EGF-induced ERK phosphorylation at tyrosines 202 and/or 204 whereas non-downregulating B- B homobivalent has no effect. The monovalent EGF competitor clone D is also antagonistic. While the genetically modified Fn domains useful in the present engineered proteins are not limited to domains that work through any particular cellular mechanism, they may include those that inhibit EGF-induced ERK phosphorylation.
Beyond phosphorylation, the effect on cellular output was examined in terms of proliferation and migration. To test cellular output in a challenging tumor-like environment, an autocrine model system was used in which hMEC cells were transfected with a vector for a membrane-bound EGF ligand with an EGF or TGFα cytoplasmic tail (hMEC+ECT or hMEC+TCT (Joslin et al, J. Cell Sci, 120:3688-3699, 2007)). The cells were cultured in 96- well plates and treated with 20 nM of the indicated agent(s). Additional ligand was added after 48 hours. Viability was quantified using AlamarBlue and normalized independently for each time point relative to PBSA-treated cells. Treatment with downregulating heterobivalent Fn3- Fn3 significantly reduced the number of viable cells at 48 hours and 96 hours (Figure 9). In
addition, combination treatment of 225 antibody and heterobivalent A-D further reduces cell viability. Of note, clones A and D are not competitive with 225 and thus this combination treatment elicits strong downregulation (Figure 10). A431, HeLa, and HT29 cells were cultured, serum starved, and treated with 20 nM 225 and 20 nM of the indicated Fn3 or Fn3-Fn3 construct for 6-8 hours. Surface EGFR was quantified by flow cytometry and is presented on an intensity scale relative to PBSA-treated control. In Figure 10, black boxes signify no downregulation, and white boxes indicate complete downregulation.
Likewise, treatment with downregulating heterobivalent constructs strongly reduces cell migration in the autocrine cells as well as parental hMEC cells, and combination treatment further augments this inhibition (Figure H(A) and H(B)). Cells were cultured in 96-well plates to a confluent monolayers. A "wound" was then scratched into each monolayer to create a void of cells. Cells were treated with 20 nM of the indicated agent(s). Migration was analyzed by microscopy. Figure H(A) shows the results obtained (relative migration) for hMEC cells with autocrine EGF signaling (TCT), and Figure H(B) shows the relative micration of hMEC, ECT, and TCT cells.
Delivery: The engineered EGFR binders, both in monovalent and bivalent formats, are effective intracellular delivery agents. Fn3 and Fn3-Fn3 constructs were conjugated to
DyLight633 fluorophore via primary amines and incubated with HT29 cells. DyLight633 readily accumulated intracellularly for EGFR binding clones but not for wild-type Fn3.
Biotinylated Fn3 domains loaded onto streptavidin conjugated to AlexaFluor488 and 1.4 nm NanoGold spheres were effectively delivered to EGFR-expressing cells but not EGFR negative cells.
Discussion: The panel of binders should provide useful reagents for a variety of applications. The small size should provide rapid clearance for in vivo imaging applications and close proximity of binding site and fluorophore for Fόrster resonance energy transfer studies. The engineered domains are cysteine-free with primary amines located distal to the presumed binding site with two exceptions: EI1.4.1 contains a cysteine and lysine in the FG loop and clone D contains adjacent cysteines in the FG loop. Thus, the domains are amenable to thiol and amine chemical conjugation to fluorophores, nanoparticles, drug payloads and chemically modified surfaces for drug delivery, diagnostic, and biotechnology applications. The single- domain architecture readily enables protein fusion such as the bivalents discussed herein and
immunotoxins (Chris Pirie, unpublished data). The picomolar to low nanomolar binding of these domains is beneficial for most applications. The breadth of epitopes targeted is useful for biophysical studies and dual binding such as for receptor clustering or sandwich immunoassays.
The analysis of the combinations of monovalent and homo- and hetero-bivalent constructs provides a broad data set to assess the stringent criterion for downregulation. As expected, monovalent binding does not reduce EGFR levels. Homobivalents, aside from weak downregulation by D-D, also are ineffective. In fact, strong reduction in EGFR levels is only observed for select heterobivalents of non-competitive clones. Constructs D-B, D-C, and D-E yield the strongest downregulation while A-D, B-D, C-D, and E-D exhibit modest efficacy. Non-competitive heterobivalents including clone D are generally effective except for D-A. Noncompetitive heterobivalents including clone A are less consistent. C-A and A-B are weakly effective against all three cell types, A-C and A-E are weakly effective against only two cell types, and B-A and E-A are ineffective. Thus, a combination of non-competitive clones is necessary but not sufficient for strong downregulation. This criterion is consistent with the purported basis for downregulation: receptor clustering. Non-competitive heterobivalent constructs can form receptor clusters because of the ability to bind two heterobivalents to a single receptor thereby propagating receptor linkages whereas homobivalents or competitive heterobivalents can only form two-receptor complexes. Meanwhile, the reduced efficacy of some non-competitive heterobivalents may arise from the inability to simultaneously bind two receptors given the distance and steric constraints of the epitopes targeted and the length and composition of the bivalent linker.
This potential mechanism is also in agreement with the reduced downregulation observed for cells expressing low levels of EGFR as reduced receptor surface density decreases the likelihood of receptor crosslinking. The origin of improved efficacy with shorter linkers is unclear. Perhaps increased conformational flexibility of the Fn3-Fn3 construct reduces the effective local concentration of the unbound Fn3 after single-receptor binding thereby decreasing crosslinking. Alternatively, shorter linkers could increase interaction of clustered receptors though significant agonism is not observed. The heterobivalents exhibit a response that is grossly different than that elicited by EGF, This is perhaps most clearly demonstrated by the ability of heterobivalents to downregulate EGFR overexpressed in HEK cells, whereas EGF does not downregulate. EGF perhaps fails because of a saturation of the cellular machinery, but
regardless the mechanism of downregulation is clearly different for EGF and Fn3-Fn3. Also, multiple receptor mutants, including kinase inactive K721R, are downregulated to the same extent as wild-type receptor. Mutation of neither T669 nor S 1046, whose phosphorylation is implicated in receptor internalization (Countaway et al, J. Biol. Chem., 267:1129-1140 (1992); Winograd-Katz and Levitzki, Oncogene, 25:7381-90 (2006)), nor T654, whose phosphorylation either inhibits ubiquitination or accelerates recycling (Bao et al, J. Biol. Chem., 275:26178- 26186 (2000)), impacts downregulation. In addition, mutation of Y845, Y1068, Yl 148, or Yl 173, which are important in the ERK signaling pathway (Amos et al., J. Biol Chem.,
280:7729-7738 (2005); Biscardi et al., J. Biol. Chem., 274:8335-8343 (1999); Downward et al., J. Biol. Chem., 260:14538-46 (1985); Morandell et al., Proteomics, 8:4383-401 (2008); Wu et al, J. Biol. Chem., 277:24252-7 (2002); Yamauchi et al, Nature, 390:91-6 (1997)), has no effect. These results are corroborated by phosphorylation analyses. Of eight key sites studied on EGFR, heterobivalent D-C yielded significantly lower phosphorylation than that by EGF except at T669. Conversely, no phosphorylation is observed at T654, S1046, and Y1068. Y845, Y1086, Y1148, and Yl 173 exhibit no agonism at multiple time points and weak phosphorylation at one hour. Moreover, Western blot analysis demonstrates ERK phosphorylation upon treatment with EGF but not upon treatment with any of the heterobivalents tested. Global phosphoproteomic analysis also exhibits substantially more phosphorylation from EGF than D- B, D-C, or a combination of B and D monomers. Thus, unlike EGF, Fn3-Fn3 constructs achieve receptor downregulation without significant receptor agonism.
A simple mathematical model of receptor trafficking indicates that downregulation can be expected to arise from enhanced degradation/recycling ratio, enhanced receptor
internalization, or both. The lack of agonism counters the hypothesis of enhanced receptor internalization although endocytosis could be accelerated by weak phosphorylation.
Alternatively, the throughput of constitutive internalization could be enhanced via receptor clustering. Yet experimental data suggest that receptor internalization is not sped as monovalent clone B and downregulating D-B exhibit equivalent intracellular accumulation. Moreover, the kinetics of downregulation (iy2 = 0.4-1.4 h) are comparable to constitutive receptor
internalization kinetics. Preliminary measurements of receptor internalization indicate endocytic half-times of 0.3-0.8h (data not shown). Thus, although receptor internalization may be sped slightly, it does not appear to be the dominant source of downregulation. Enhanced degradation
could conceivably result from the presence of receptor clusters that either inhibit recycling or drive degradation. In fact, AlexaFluor488-conjugated 225 antibody exhibits reduced recycling in the presence of downregulating heterobivalent A-D as compared to co-treatment with monomer A or non-do wnregulating C-B.
Downregulation decreases the amount of receptor available for ligand binding, receptor homo- and hetero-dimerization, and constitutive activation, thereby decreasing the opportunity for receptor signaling. Downregulation is sufficient to inhibit ERK phosphorylation, a downstream signaling molecule on a pathway that leads to proliferation and migration.
Downregulating heterobivalents are shown to inhibit proliferation and migration of a cell line with autocrine signaling, and this inhibitory activity can be augmented by combination treatment with ligand-competitive antibody 225. Further study can elucidate the relative impacts of receptor downregulation and ligand competition as well as the in vivo efficacy of the
heterobivalent agents.
In the paragraphs that follow, we describe the materials and methods that were employed in more detail.
Binder Engineering: EGFR binders were engineered from the NNB, YS, and G4 pooled library comparison as outlined above. EGFR mutant 404SGRef' (Kim et al, Proteins, 62:1026- 1035 (2006)) was produced in Saccharomyces cerevisiae yeast, purified by metal affinity chromatography and anti-EGFR antibody affinity chromatography, and biotinylated on free amines using the sulfo-NHS biotinylation kit. The Fn3 yeast surface display libraries were pooled, grown in SD-CAA medium at 300C, 250 rpm and display of Fn3 was induced in SG- CAA medium at 300C, 250 rpm. Binders to streptavidin-coated magnetic Dynabeads were removed. One million biotinylated EGFR ectodomains were loaded on each often million magnetic beads and incubated with the remaining yeast. Beads were washed once with PBSA at 4° and beads with attached cells were grown for further selection. Remaining sorts were conducted with five million beads coated with one to two million ectodomains. After two sorts, full-length Fn3 clones were selected by FACS using the C-terminal c-myc epitope. Plasmid DNA was zymoprepped from the cells and mutagenized by error-prone PCR of the entire Fn3 gene or the BC, DE, and FG loops. Mutants were transformed into yeast by electroporation with homologous recombination and requisite shuffling of the loop mutants. The lead clones and their mutants were pooled for further cycles of selection and mutagenesis. Three rounds, each
consisting of two binding sorts on beads, full-length clone isolation by FACS, and mutagenesis, were performed. Selection stringency was increased by additional washing and elevated temperature. In the fourth round, a single binding sort on magnetic beads was followed by a binding sort by FACS. Cells were incubated in 10 nM biotinylated ectodomain and mouse anti- c-myc antibody followed by fluorescein-conjugated anti-biotin antibody and R-phycoerythrin- conjugated anti-mouse antibody. Cells with the highest fluorescein:R-phycoerythrin ratio were collected. Three additional rounds of sorting and mutagenesis were performed with decreasing ectodomain concentrations during selections. Plasmids from binding populations were zymoprepped arid transformed into E. coli; transformants were grown, miniprepped, and sequenced.
The relative dominance of E4.2.1 and E4.2.2, as well as very similar mutants, initiated a campaign to identify additional unique clones. Binding populations from rounds two through five were sorted twice for binding to ectodomain in the presence of either ICRlO, an antibody that competes with E4.2.2, or 528, an antibody that competes with E4.2.1. Unique clones were identified by sequence analysis.
Fn3 Production: The Fn3 gene was digested with Nhel and BamHI and transformed to a pET vector containing a HHHHHHKGSGK-encoding C-terminus (SEQ ID NO: ). The six histidines enable metal affinity purification, and the pentapeptide provides two additional amines for chemical conjugation. The plasmid was transformed into Rosetta (DE3) E. coli, which was grown in LB medium with 100 mg/L kanamycin and 34 mg/L chloramphenicol at 37°. Two hundred μL of overnight culture was added to 100 mL of LB medium, grown to an optical density of 0.2-1.5 units, and induced with 0.5 mM IPTG for 3-24 hours. Cells were pelleted, resuspended in lysis buffer (50 mM sodium phosphate, pH 8.0, 0.5M NaCl, 5% glycerol, 5 mM CHAPS, 25 mM imidazole, and Ix complete EDTA-free protease inhibitor cocktail), and exposed to four freeze-thaw cycles. The soluble fraction was clarified by centrifugation at 15,00Og for 10 min. and Fn3 was purified by metal affinity chromatography on TALON resin. Purified Fn3 was buffer exchanged into PBS and biotinylated with NHS-LC-biotin according to the manufacturer's instructions.
An Fn3-linker-Fn3 construct was produced by standard molecular cloning techniques. The resultant vector encodes for FnS-EIDKPSQ-GSGGGSGGGKGGGGT-FnS-EIDKPSQ- ELRS-HHHHHH in which the N-terminal Fn3 is bracketed by Nhel and BamHI restriction sites
and the C-terminal Fn3 is bracketed by Kpnl and Sad sites. The reduced linker encodes a GSGT linker. The extended linker is GSGGGSGGGK-GGGSGGGNGGGSGGGGT (SEQ ID NO_). Protein was produced as for Fn3.
Affinity Titration: A431 cells were washed in PBSA and incubated with various concentrations of biotinylated Fn3 on ice. The number of cells and sample volumes were selected to ensure excess Fn3 relative to EGFR. For some clones, this criterion necessitates very low cell density, which makes cell collection by centrifugation procedurally difficult. To obviate this difficulty, 'bare' yeast cells are added to the sample to enable effective cell pelleting during centrifugation. Cells were incubated on ice for sufficient time to ensure that the approach to equilibrium was at least 98% complete. Cells were then pelleted, washed with 1 mL PBSA, and incubated in PBSA with 10 mg/L streptavidin-R-phycoerythrin for 10-30 min. Cells were washed and resuspended with PBSA and analyzed by flow cytometry. The minimum and maximum fluorescence and the Kd value were determined by minimizing the sum of squared errors assuming a 1 : 1 binding interaction.
Epitope Conformational Sensitivity: Yeast were grown and induced to display EGFR ectodomain, incubated at 4°C or 800C for 30 minutes, and chilled on ice for 10 minutes. Cells were labeled with 40 nM biotinylated Fn3 and 300 nM mouse anti-c-myc antibody followed by streptavidin-R-phycoerythrin and AlexaFluor488-conjugated anti-mouse antibody. Fluorescence was quantified by flow cytometry. Binding (R-phycoerythrin) was normalized to full-length display (AlexaFluor488).
Competition: Yeast displaying EGFR ectodomain or A431 cells were washed and incubated with initial competitor Fn3 or antibody for 30 minutes. Alternative competitor Fn3, antibody, or AlexaFluor488-conjugated EGF was then added and incubated for 30 minutes. Cells were washed and secondary reagent was added to detect the alternative competitor:
fluorescein-conjugated anti-His antibody, streptavidin-R-phycoerythrin, R-phycoerythrin- conjugated anti-mouse antibody, and fluorescein-conjugated anti-rat antibody for Fn3, biotinylated Fn3, mouse antibodies, and rat ICRlO, respectively. Cells were washed and analyzed by flow cytometry. Samples with and without initial competitor were compared to determine competition.
EGFR Fragment Labeling: EGFR ectodomain fragments comprising amino acids 1-176, 294-543, and 302-503 were displayed on the yeast surface (Cochran et al, Journal of
Immunological Methods, 287:147-158 (2004)). Cells were washed and incubated with 30 nM biotinylated Fn3 and mouse anti-c-myc antibody followed by streptavidin-R-phycoerythrin and AlexaFluor488-conjugated anti-mouse antibody. Cells were washed and analyzed by flow cytometry,
Fine Epitope Mapping: A low mutation library of EGFR ectodomain, produced by Ginger Chao as described (Chao et al, Journal of Molecular Biology, 342:539-550 (2004)), was grown and induced. Yeast were labeled with biotinylated Fn3 and mouse anti-c-myc antibody followed by AlexaFluor647-conjugated streptavidin and AlexaFluor488-conjugated anti-mouse antibody. Cells were washed and analyzed by flow cytometry. Cells displaying full-length ectodomain (AlexaFluor488 ) with reduced Fn3 binding (AlexaFluor647weak) relative to unmutated ectodomain were collected, grown, and induced. Cells were then sorted twice for mutants of reduced binding with maintenance of foldedness as determined by binding to antibodies 199.12 or 225, which are conformationally sensitive (Cochran et al., Journal of Immunological Methods, 287:147-158 (2004)). Cells were labeled with biotinylated Fn3 and mouse 199.12 (for clones A, E, and E6.2.10) or mouse 225 (for clone D) anti-EGFR antibody followed by AlexaFluor647-conjugated streptavidin and R-phycoerythrin-conjugated anti-mouse antibody. Cells were washed and analyzed by flow cytometry. Cells displaying folded ectodomain (AlexaFluor488 ) with reduced Fn3 binding (AlexaFluor647weak) relative to unmutated ectodomain were collected, grown, and induced. Initial selections for clone C mapping yielded multiple glycine mutants and clones with multiple mutations. To improve the efficiency of folded mutants, analogous sorting was performed using the non-competitive domain III binder clone D for foldedness verification. Biotinylated clones C and D were independently complexed to AlexaFluor488- or AlexaFluor647-conjugated streptavidin and used to label the ectodomain library. Cells that exhibited binding to clone D but reduced clone C binding relative to wild-type ectodomain were collected. Selections for epitope mapping clone B yielded multiple mutants without a consistent location. The full-length ectodomains with reduced clone B binding were sorted for maintenance of clone D binding with a reduction in clone B binding.
Cell Culture: All cells were grown at 37°C, 5% CO2 in a humidified atmosphere. A431 cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). CHO cells transfected with a vector to express EGFR-green
fluorescent protein were cultured in DMEM with 10% FBS, 1% sodium pyruvate, 1% nonessential amino acids, and 0.2 g/L G418, HeLa cells were cultured in Eagle's minimal essential medium with 10% FBS. hMEC cells were cultured in supplemented HuMEC medium. HT29 cells were cultured in McCoy's medium with 10% FBS. U87 cells were cultured in DMEM with 10% FBS, 1% sodium pyruvate, and 1% non-essential amino acids. Cells were detached for subculture or assay use with 0.25% trypsin and 1 mM EDTA. For serum starvation, medium was removed by aspiration, cells were washed with warm PBS, and fresh serum-free medium was added.
Downregulation Assays: Cells were subcultured into 96-well plates, grown for 2 days, and serum starved for 12-18 h. Cells were treated with 20 nM Fn3-Fn3 or EGF for the indicated time. Medium was removed by aspiration and cells were washed with PBS, detached with trypsin/EDTA, and placed on ice for the remainder of the assay. Bound Fn3-Fn3 or ligand was removed by 5 min. acid strip with 0.2M acetic acid, 0.5 M NaCl. Cells were washed with PBSA and incubated in mouse 225 antibody followed by R-phycoerythrin-conjugated anti-mouse antibody. Cells were washed and analyzed by flow cytometry. Mean fluorescence was normalized to PBSA-treated control samples.
HEK Transfectants: An EGFR expression vector built on the pCDNA3 vector was used as wild-type or modified by site-directed mutagenesis to introduce T654A, T669A, K721R, Y845F, S1045A/S1046A, Y1068F, Yl 148F, or Yl 173F mutations. Mutation was verified by sequence analysis. HEK cells were grown to 1.2-1.5 million cells per mL and diluted to one million per mL. Miniprepped DNA and polyethyleneimine were independently diluted to 0.05 and 0.1 mg/mL in OptiPro medium and incubated at 22° for 15 min. Equal volumes of DNA and polyethyleneimine were mixed and incubated at 22° for 15 min. 1.2 mL of cells and 48 μL of DNA/polyethyleneimine mixture were added to a 24-well plate and incubated at 37°, 5% CO2 with shaking for 24 h. One hundred μL aliquots of each transfection were transferred to a 96- well plate and grown for 24 h. A downregulation assay was performed as described.
In-CeIl Western Blot: A431 cells were cultured in 96-well plates, serum starved for 12- 24 h, and treated with 20 nM Fn3-Fn3 or EGF. Cells were fixed for 10 min. by addition of an equal volume of 4% formaldehyde. Cells were washed and permeabilized with four washes of PBS with 0.1% Triton XlOO and blocked in Odyssey blocking buffer for 2h at 22° or overnight at 4°. Cells were incubated in 10 nM rabbit anti-phospho(S/T/Y) for 2h at 22° or overnight at 4°.
Four washes in PBS with 0.1% Tween20 were followed by 33 nM 800CW-conjugated anti- rabbit antibody and 180 nM ToPro3 and four additional washes. Plates were imaged at 700 nm and 800 nm. Antibody signal (800 nm) was normalized to DNA (700 nm) for each well.
Western Blot: A431 cells were cultured in 24-well plates and serum starved for 16h. For agonism assay, cells were treated with 20 nM Fn3-Fn3, antibody, or EGF for 15 min. For antagonism assay, cells were treated with Fn3, Fn3-Fn3, or antibody for 6 h followed by 1 nM EGF for 15 min. Medium was removed by aspiration and cells were washed twice with cold PBS and lysed for 5 min. in 50 μL of RIPA buffer with protease and phosphatase inhibitors and EDTA (Pierce). Lysates were clarified by centrifugation at 14,00Og for 15 min., separated by SDS-PAGE on a 12% BisTris gel, and blotted to nitrocellulose. Blots were blocked in 5% nonfat dry milk and labeled with 1 : 1000 anti-phosphoERKl/2 Y202/Y204 antibody (Cell Signaling, Danvers, MA) followed by peroxidase-conjugated anti-rabbit antibody. Blots were incubated in SuperSignal West Dura substrate and imaged. Blots were than washed extensively, labeled with rabbit anti-GAPDH antibody followed by peroxidase-conjugated anti-rabbit antibody, incubated with substrate and imaged. PhosphoERKl/2 Y202/Y204 labeling was normalized by GAPDH signal.
Quantitative Phosphoproteomics: A431 cells were cultured in 12-well plates, serum starved for 16 h, and treated with 20 nM Fn3-Fn3, Fn3 + Fn3, or EGF for 15 or 60 min. Medium was removed by aspiration and cells were washed with PBS and lysed in 8M urea with 1 mM Na3 VO4. Phosphoproteomic analysis was performed by Jason Neil of the Forest White lab (MIT). Lysates are digested to form peptides and labeled with iTRAQ reagents.
Phosphotyrosine-containing peptides are isolated by immunoprecipitation with a pool of polyclonal anti-phosphotyrosine antibodies and phosphopeptides are enriched by immobilized metal affinity chromatography. Peptides are separated and analyzed by LC-MS/MS. Peptides are identified using MASCOT and relative abundance is determined by comparison of peak intensities.
Proliferation: hMEC cells transfected with a vector for membrane -bound EGF ligand with a TGFα cytoplasmic tail (hMEC+TCT (Joslin et al, J. Cell ScL, 120:3688-99 (2007))) were obtained from Doug Lauffenburger (MIT). Eight thousand cells were plated into each well of a 96-well plate and incubated in 100 μL of medium with 20 nM agent for 48 h or 96 h. For 96 h samples, medium was supplemented with fresh agent at 48h. Cell viability was quantified using
the AlamarBlue assay (Invitrogen) according the manufacturer's instructions and normalized to PBSA-treated control.
Migration: hMEC, hMEC+ECT, or hMEC+TCT cells were cultured in 96-well plates to confluent monolayers. Wounds were scratched into the monolayer using a pipette tip, and cells were washed with fresh medium and imaged on a Nikon confocal microscope with robotic stage. Cells were treated with 20 nM agent in 100 μL of medium, incubated for 24 h or 48 h, and imaged at identical fields of view. Migration was quantified as the average reduction in separation across the wound and normalized to PBSA-treated control.
Delivery: Fn3 and Fn3-Fn3 were fluorophore-labeled on primary amines using
DyLight633 NHS-ester (Pierce) according to the manufacturer's instructions and extensively desalted. HT29 cells were cultured in 96-well plates, serum starved, and incubated with 20 nM Fn3-(Fn3)-DyLight633 for 0-9 hours. Cells were detached using trypsin/EDTA, acid stripped in 0.2 M acetic acid, 0.5 M NaCl for 5 minutes and analyzed by flow cytometry.
Biotinylated Fn3 was incubated with streptavidin-NanoGold(1.4 nM)-AlexaFluor488 (Nanoprobes, Yaphank, NY) at a 3:1 Fn3:streptavidin ratio. A431, HT29, and SWl 222 cells were cultured in 96-well plates and treated with 20 nM complex for 12h. Cells were detached using trypsin/EDTA, acid stripped in 0.2M acetic acid, 0.5M NaCl, and analyzed by flow cytometry.
Example 3: Production and Analysis of Ab-Fn3 Fusion Proteins
The modular constructs depicted in Figure 12, which have configurations that can be assumed by the engineered proteins of the present invention, were secreted from HEK 293 cells co-transfected with havy and light chain expression plasmids derived from the gWiz vector. Secretions were harvested after eight days, purified via protein A affinity chromatography and concentrated in phosphate buffered saline. Yields ranged from 100-4000 μg/L depending on the antibody format and the fibronectin clone used.
The binding epitope of the 225 mAb from which the constructs were derived and the binding epitopes of various EGFR-binding fibronectins are shown in the Table below. Residues implicated in the binding of the EGFR targeted fibronectin clones were identified using yeast surface display based fine epitope mapping. The 225 epitope from the published crystal structure of the bound Fab fragment is also listed.
The interaction between the particular Ab-Fn3 fusion HN-D and its target antigen, EGFR, was characterized on the surface of A431 cells. As shown in Figure 14, the affinity of the Ab-Fn3 fusion is an order of magnitude greater than that of the unmodified 225 antibody, both at endosomal pH (6.0) and physiological pH (7.4). The unconjugated 225 antibody and the Ab-Fn3 fusion HN-D were titrated on the surface of A431 cells at pH 6.0 and pH 7.4. A431 cells express 2.8 x 106 EGFR per cell. The insensitivity of binding to pH reduction indicates that the engineered protein will remain bound to EGFR following internalization. The measured equilibrium dissociation constants for HN-D at pH 7.4 and 6.0 were 40 and 75 pM, respectively, compared to 370 and 1284 pM for mAb 225.
The advantage of targeting a cell-surface receptor such as EGFR with a multispecific (or heterobivalent) engineered protein is shown in Figure 15. The presence of two non-competitive EGFR binding moieties enables receptor clustering. Clustering has been shown to abrogate EGFR recycling, thereby decreasing surface receptor expression and activation of downstream signaling pathways.
Deconvolution microscopy images show a dramatic change in receptor localization following Ab-Fn3 fusion treatment relative to 225 mAb treatment in two EGFR-expressing tumor cell lines, suggesting receptor clustering. To obtain visual evidence of multispecific antibody-induced clustering, A431 and HeLa cells were treated with fluorescently-labeled 225 or fluorescently-labeled HN Ab-Fn3 fusion (containing fϊbronectin clone D) for 1, 2, 4, or 6 hours. Cells were then washed and imaged on a Delta Vision deconvolution microscope for comparison of EGFR localization. We observed a dramatic difference in receptor distribution following treatment with the multispecific construct compared to treatment with an unconjugated mAb (Figure 16).
The results of studies of surface EGFR downregulation are shown in Figures 17(A) and (B). Seven EGFR expressing cell lines (listed in increasing order of EGFR expression) were treated with 20 nM antibody or antibody- fibronectin fusions for 13 hours at 370C, allowing
receptors to reach a new steady state level. Cells were then acid stripped, labeled with anti- EGFR antibody and fluorophore-conjugated secondary antibody, and analyzed via flow cytometry to quantify remaining surface receptor. Results are shown for the Ab-Fn3 fusions versus 225 and the potent 225 + Hl 1 mAb combination. The HN-B downregulates the most potently of all the single Fn3 -containing fusions, but the bispecifϊc compounds generally fail to potently downregulate receptor on EGFR-dense cell lines such as A431. In Figure 7(B), the same seven EGFR expressing cell lines used in bispecifϊc downregulation assays were treted with 20 nM antibody or antibody- fϊbronectin fusion for 13 hours at 370C, allowing receptors to reach a new steady state level. Cells were then acid stripped, labeled with an anti-EGFR antibody and fluorophore-conjugated secondary antibody, and analyzed via flow cytometry to quantify remaining surface receptor relative to untreated cells. Results are shown for the Ab-Fn3 fusions versus 225 and the potent 225 + Hl 1 mAb combination. The trispecifϊc constructs downregulate more potently than the bispecifϊc constructions showin in Figure 17(A) and that trispecifϊc constructs with fϊbronectin moieties on both chains downregulate more effectively than those with both fϊbronectin moieties on the same chain. The most potent constructs (HNA+LCD, HND+LCA, and HNB+LCD) consistently reduce surface EGFR by 60-80%, performing as well or better than the 225+H11 combination on all cell lines tested.
In other studies, we found that multispecifϊc engineered proteins reproducibly induce synergistic downregulation in a host of EGFR-expressing cell lines. Seven EGFR-expressing cell lines (HT-29, HeLa, U87, HMEC, CHO-EG, U87-MGSH, and A431) were treated with 20 nM antibody or antibody-Fn fusion proteins for 13 hours at 370C. They were then acid stripped, labeled with anti-EGFR antibody, and analyzed via flow cytometry to quantify the remaining surface receptor. The HN-D and LC-D constructs effectively downregulate EGFR nearly as effectively as the most potent combination of antibodies (225 + Hl 1) (Figure 18).
Further, in contrast to ligand stimulation, our engineered proteins reduced surface EGFR levels without activating EGFR or its downstream effectors. In-cell Western assays were performed on A431 cells for eight known EGFR phosphosites. Phosphoprotein fluorescence was normalized by DNA fluorescence and signal relative to that of untreated cells was plotted versus time (Figure 19A). The timecourse of ERK Vi activation in A431 cells following mAb or EGF treatment was measured via bead-based immunoassay. Normalized phosphoprotein signal was plotted for cells treated with EGF, mAb 225, HI l, and mAb 225 + Hl 1. An antibody-free
control was also assessed (Figure 19B). Serum-starved A431 cells were incubated with 225, HI l, the 225+H11 combination, and EGF at 370C for 15 minutes or 60 minutes. EGF stimulation was held constant at 15 minutes for both screens. Cells were then lysed and relative protein phosphorylation was measured using an iTraq-based mass spectrometry screen.
Phosphorylation levels were normalized by total protein content and signal strength relative to that in cells treated with an isotype control mAb is presented for MAPK and P13K pathway components. Repetition of the 60 minute screen yielded consistent results for proteins identified in both cohorts. Common downregulation profiles and receptor localization following combination mAb and Ab-Fn3 fusion treatment suggest that Ab-Fn3 constructs will not agonize EGFR signaling (Figure 19C) (Spangler et ah, Proc. Natl. Acad. ScL USA, 107:13252-13257, 2010).
With respect to cell behavior, our studies have shown that combination antibody treatment protein selectively and significantly reduces migration and proliferation of cells that secrete high amounts of autocrine ligand (ECT) compared to treatment with the Ab (225 mAb) alone. We infer that Ab-Fn3 fusion-induced downregulation operates through a similar clustering mechanism and would thus inhibit migration and proliferation of ECT cells. Cell migration and proliferation of HMEC and autocrine EGF-secreting ECT cells were assessed using the scratch and MTT assays, respectively. For migration assays, monolayers were wounded and subsequently incubated with mAb 225, HI l, and 225+H11 for 24 hours at 370C. A "no antibody" incubation was also performed as a control. Relative migration was measured as fractional wound replensihment compared to that of the untreated control (Figure 20). For proliferation assays, cells were treated with the specified mAbs for 72 hours at 370C. Relative proliferation was assessed as viable cell abundance compared to that of untreated cells
(Figure 20). From the similarities between EGFR responses to combination mAb and Ab-Fn3 fusion treatment, we predict that Ab-Fn3 fusions will evoke similar responses in HMEC and TCT cells (Spangler et ah, supra).
We are currently conducting pre-clinical studies of Ab-Fn3 fusions in mice with A431 tumor xenografts. In clinical trials, the patient population could include patients who are resistant to cetuximab therapy (and the present methods encompass methods of treatment for patients who are resistant to treatment with a target-specific protein scaffold alone).
Materials and methods used in the studies presented in Example 3 follow in the paragraphs below.
Cell lines and antibodies. The transfected CHO-EG, U87-MGSH, and ECT cell lines were established as described previously and all other lines were obtained from ATCC
(Manassas, VA). Cells were maintained in their respective growth media (from ATCC unless otherwise indicated): DMEM for A431, U87-MG, U87-MGSH, and CHO-EG cells, McCoy's Modified 5A media for HT-29 cells, EMEM for HeLa cells, and HuMEC Ready Medium (Invitrogen, Carlsbad, CA) for HMEC and ECT cells. U87-MG, U87-MGSH, and CHO-EG media were supplemented with 1 mM sodium pyruvate (Invitrogen) and 0.1 mM non-essential amino acids (Invitrogen) and transfected lines U87-MGSH and CHO-EG were selected with 0.3 mM Geneticin (Invitrogen). ATCC media was supplemented with 10% fetal bovine serum (FBS). 225 was secreted from the hybridoma cell line (ATCC). Unless otherwise noted, all washes were conducted in PBS containing 0.1% BSA and all mAbs were used at a concentration of 40 nM for single treatment and 20 nM each for combination treatment. EGF (Sigma, St. Louis, MO) was dosed at 20 nM. Trypsin-EDTA (Invitrogen) contains 0.05% trypsin and 0.5 mM EDTA.
Production of Ab-FnS fusions via HEK cell transfection: The human IgGl heavy and light chains of each Ab-Fn3 fusion were inserted into the gWiz mammalian expression vector (Genlantis). Constructs were verified by sequence analysis. HEK 293F cells (Invitrogen) were grown to 1.2 million cells per mL and diluted to one million per mL. Miniprepped DNA and polyethyleneimine (Sigma) were independently diluted to 0.05 and 0.1 mg/mL in OptiPro medium and incubated at 22°C for 15 minutes. Equal volumes of DNA and polyethyleneimine were mixed and incubated at 22°C for 15 minutes. 500 mL of cells and 20 mL of
DNA/polyethyleneimine mixture were added to a 2 L roller bottle and incubated at 37°, 5% CO2 on a roller bottle adapter for seven days. The cell secretions were then centrifuged for 30 minutes at 15,000xg and the supernatant was filtered through a 0.22 μm bottle-top filter and purified via affinity column chromatography using protein A resin (Thermo Fisher Scientific, Waltham, MA). The eluted constructs were concentrated and transferred to PBS and then characterized by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
Affinity titrations. To characterize Ab-Fn3 binding affinities, A431 cells were trypsinized, washed in PBSA, and incubated with various concentrations of Ab-Fn3 in a 96-well plate on ice. The number of cells and sample volumes were selected to ensure at least tenfold excess Ab-Fn3 relative to EGFR. Cells were incubated on ice for sufficient time to ensure that the approach to equilibrium was at least 99% complete. Cells were then washed and labeled with 66 nM PE-conjugated goat anti-human antibody (Rockland Immunochemicals, Gilbertsville, PA) for 20 min on ice. After a final wash, plates were analyzed on a FACS Calibur cytometer (BD Biosciences, San Jose, CA). Cell pelleting was conducted at lOOOxg. The minimum and maximum fluorescence and the Kd value were determined by minimizing the sum of squared errors assuming a 1 : 1 binding interaction (% Bound = [L]/([L]+Kd) where [L] is Ab-Fn3 concentration and IQ is the equilibrium dissociation constant of the Ab-Fn3 construct. Titrations were performed at both pH 6.0 (endosomal pH) and pH 7.4 (physiological pH).
Receptor quantification. Cells were serum starved for 12-16 h, washed, digested in trypsin-EDTA (20 min at 37°C), neutralized with complete medium, and labeled with 20 nM 225 for 1 h on ice. They were then washed, labeled with 66 nM phycoerythrin (PE)-conjugated goat anti-mouse antibody (Invitrogen) for 20 min on ice, washed again, and subjected to quantitative flow cytometry on an EPICS XL cytometer (Beckman Coulter, Fullerton, CA). Receptor density was calculated based on a curve of identically labeled anti-mouse IgG-coated beads (Bangs Laboratories, Fishers, IN).
Deconvolution microscopy. mAb 225 and Ab-Fn3 fusion constructs were labeled with Alexa 488 using a fluorescent labeling kit (Invitrogen). A431 cells were plated at 50,000 per well in 8-well microscopy chambers and allowed to settle overnight. They were then incubated with the appropriate mAb or fusion construct for various time lengths at 37°, 5% CO2. Wells were then washed and cells were resuspended in phenol red- free medium for imaging on a Delta Vision inverted deconvolution microscope. Deconvolution of 0.15 μm z-slices and image analysis were performed using the Softworx software package.
Receptor downregulation assays. Cells were seeded at 5x104 per well in 96-well plates, serum starved for 12-16 h, treated with the indicated mAbs or Ab-Fn3 fusions in serum-free medium, and incubated at 370C. At each time point, cells were washed and treated with trypsin- EDTA for 20 min at 370C. Trypsin was neutralized with medium (10% FBS) and cells were transferred to v-bottom plates on ice. They were then washed, acid stripped (0.2 M acetic acid,
0.5 M NaCl, pH 2.5), and washed again prior to incubation with 20 nM 225 for 1 h on ice to label surface EGFR. Cells were then washed and labeled with 66 nM PE-conjugated goat anti- mouse antibody (Invitrogen) for 20 minutes on ice. After a final wash, plates were analyzed on a FACS Calibur cytometer (BD Biosciences, San Jose, CA). Cell pelleting was conducted at lOOOxg.
In-cell western assays. A431 cells were seeded at 4x104 per well in 96-well plates and allowed to adhere for 24 hours. Following 12-16 hours of serum starvation, cells were treated with the designated mAbs in serum-free medium at 370C for the specified time length. All subsequent incubations were performed at room temperature. Cells were fixed for 20 minutes (PBS, 4% formaldehyde), permeabilized via four 5 minute incubations (PBS, 0.1% triton), blocked for 1 hour in Odyssey blocking buffer (Licor Biosciences, Lincoln, NE), and labeled for 1 hour with 15 nM anti-phosphosite antibodies (Genscript, Piscataway, NJ) in blocking buffer. Cells were then washed three times with PBST (PBS, 0.1% Tween-20) and labeled with 66 nM 800-conjugated goat anti-rabbit antibody (Rockland Immunochemicals) and 400 nM TO-PRO-3 DNA stain (Invitrogen) in blocking buffer for 30 min. After three final PBST washes, wells were aspirated dry for analysis on a Licor Odyssey Scanner (Licor Biosciences). Signal was normalized to cell abundance by dividing 800 (phosphoprotein) by 700 (TO-PRO-3) channel fluorescence.
Luminex phosphoprotein quantification assays. A431 cells seeded in 96-well plates at 3x104 per well were allowed to settle for 24 hours prior to 12-16 h serum starvation. Cells were then incubated with the specified mAbs in serum-free medium at 370C. At the indicated times, cells were lysed using the Bio-Plex cell lysis kit (Bio-Rad, Hercules, CA). Phosphorylated ERKl/2 abundance was quantified using the Luminex bead-based immunoassay, performed with the Bio-Plex Phospho-ERKl/2 (T202/Y204, T185/Y187) bead kit and the Bio-Plex
Phosphoprotein Detection Reagent kit on the Bio-Plex 200 platform (Bio-Rad).
Global phospho-mass spectrometry screens. 1x10 A431 cells per well were seeded in 6-well plates, grown to confluence, and incubated with the appropriate mAbs in serum-free medium at 370C for 15 or 60 minutes. Cells were washed once with chilled PBS and lysed at 40C (8 M urea, 1 mM Na3VO4). Protein concentration was measured via bicinchoninic acid assay (Pierce, Rockford, IL). Lysate reduction, alkylation, trypsin digestion, and peptide fractionation were performed as previously described. Samples were labeled separately with 8 isotopic
iTRAQ reagents (Applied Biosystems, Foster City, CA) for 2 hours at room temperature, combined, and concentrated. Immunoprecipitation with pooled anti-phosphotyrosine antibodies (4G10 (Millipore, Billerica, MA), pTyrlOO (Cell Signaling, Beverly, MA), and PT-66 (Sigma)) proceeded for 16 h at 40C using protein G agarose beads (Calbiochem, San Diego, CA) in IP buffer (100 mM Tris, 100 mM NaCl, 1% Nonidet P-40, pH 7.4). Phosphopeptide enrichment by IMAC and analysis and quantification of eluted peptides were conducted via ESI LC/MS/MS on an LTQ-Orbitrap (Thermo Fisher Scientific). Phosphopeptides were identified using Mascot analysis software and spectra were manually validated. Signal intensities were normalized by total protein levels and compared to isotype control treatment.
Migration assays. HMEC and ECT cells were seeded at 5x104 per well in 96-well plates and grown to confluence. Monolayers were wounded with a pipet tip, washed with PBS, and placed in complete medium with the indicated mAbs. Scratch area was measured immediately and after a 24 hour incubation at 370C using Image J software analysis of images from a Nikon confocal microscope (Nikon Instruments, Melville, NY). Percent migration was calculated as the fractional reduction in scratch area in the treated wells divided by that of the untreated wells.
Cell proliferation assays. HMEC and ECT cells were seeded at 5x103 per well in 96-well plates and allowed to adhere for 24 h. They were then treated with the indicated mAbs in complete medium and incubated at 370C for 72 hours. Cell viability (relative to an untreated control) was assessed using the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay (Invitrogen).
Statistical analysis. Heteroscedastic two-tailed student's t tests were performed on migration and proliferation assay results to compare combination and single mAb treatment.
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention.
WHAT IS CLAIMED IS:
Claims
1. An engineered protein comprising a first genetically modified fibronectin domain that binds a first epitope on a molecular target and a second genetically modified fibronectin domain that binds a second epitope on the target.
2. The engineered protein of claim 1, further comprising a linker between the first fibronectin domain and the second fibronectin domain.
3. The engineered protein of claim 2, wherein the linker is a polypeptide.
4. The engineered protein of claim 3, wherein the polypeptide is at least three but no more than 300 amino acids long.
5. The engineered protein of claim 4, wherein the first fibronectin domain and the second fibronectin domain are fused, via the linker, in a head-to-tail orientation.
6. The engineered protein of claim 1 or claim 2, further comprising a heterologous protein.
7. The engineered protein of claim 6, wherein the heterologous protein is a target- specific protein scaffold.
8. The engineered protein of claim 7, wherein the target-specific protein scaffold is an immunoglobulin or a biologically active fragment or other variant thereof.
9. The engineered protein of claim 8, wherein the immunoglobulin is the antibody cetuximab or the antibody panitumumab.
10. The engineered protein of claim 7, wherein the target-specific protein scaffold is a designed ankyrin repeat protein, an anticalin, or an affibody.
11. The engineered protein of claim 1 or claim 6, further comprising an accessory sequence
12. The engineered protein of claim 11, wherein the accessory sequence is an amino acid sequence that prolongs the circulating half- life of the genetically modified Fn domain or an engineered protein of which it is a part; an amino acid sequence that facilitates isolation or purification of the engineered protein; an amino acid sequence that facilitates the bond between one part of the engineered protein and another or between the engineered protein and another moiety; an imaging agent or an amino acid sequence that can be detected and thereby serves as a label, marker, or tag; or an amino acid sequence that is toxic.
13. The engineered protein of claim 12, wherein the amino acid sequence that prolongs the circulating half-life is an Fc region of an immunoglobulin, albumin, another plasma protein, or fragements or variants thereof of a length sufficient to prolong the circulating half-life of the engineered protein.
14. The engineered protein of claim 12, wherein the polypeptide that facilitates isolation or purification of the engineered protein is a green fluorescent protein (GFP), glutathione S- transferase (GST), c-myc, hemagglutinin, β galactosidase, or Flag™ tag (Kodak) sequence.
15. The engineered protein of claim 12, wherein the moiety is a therapeutic compound.
16. The engineered protein of claim 1, wherein the first fibronectin domain and the second fibronectin domain are identical within their constant regions.
17. The engineered protein of claim 1, wherein the first fibronectin domain and the second fibronectin domain are at least 80% identical.
18. The engineered protein of claim 1, wherein the first fibronectin domain and/or the second fibronectin domain is a tenth type III fibronectin domain.
19. The engineered protein of claim 1, wherein the first fibronectin domain and/or the second fibronectin domain comprises a human fibronectin sequence.
20. The engineered protein of claim 1, wherein the first fibronectin domain and/or the second fibronectin domain comprises clone A, clone B, clone C, clone D, or clone E.
21. The engineered protein of any of claims 1-20, wherein the target is a cellular receptor.
22. The engineered protein of claim 21, wherein the cellular receptor is a receptor tyrosine kinase of the ErbB, insulin, PDGF, FGF, VEGF, HGF, Trk, Eph, AXL, LTK, TIE, ROR, DDR, RET, KLG, RYK, or MuSK receptor family.
23. The engineered protein of claim 22, wherein the cellular receptor is an EGF receptor.
24. A nucleic acid comprising a sequence encoding the engineered protein of any of claims 1-23.
25. A vector comprising the nucleic acid sequence of claim 24.
26. The vector of claim 25, wherein the vector is a plasmid or a cosmid or other viral vector.
27. A cell ex vivo comprising the vector of claim 26.
28. A pharmaceutically acceptable composition comprising the engineered protein of any of claims 1-23 or the nucleic acid of claim 24.
29. A method of treating a patient who has cancer, the method comprising identifying a patient in need of treatment and administering to the patient a therapeutically effective amount of the pharmaceutically acceptable composition of claim 28, wherein the engineered protein specifically binds at least one epitope on a protein whose expression or activity is associated with the cancer.
30. An engineered protein comprising (a) a genetically modified fibronectin domain that specifically binds a first epitope on a receptor tyrosine kinase and (b) a heterologous protein that specifically binds a second epitope on the tyrosine kinase receptor.
31. The engineered protein of claim 30, wherein the first epitope and the second epitope are non-overlapping.
32. The engineered protein of claim 30, wherein the genetically modified fibronectin domain is a mutant of a type III fibronectin domain.
33. The engineered protein of claim 32, wherein the type III fibronectin domain is a tenth type III fibronectin domain.
34. The engineered protein of claim 32, wherein the mutant of the type III fibronectin domain is at least 40% identical to a corresponding wild-type type III fibronectin domain.
35. The engineered protein of any of claims 30-34, wherein the receptor tyrosine kinase is a receptor of the ErbB, insulin, PDGF, FGF, VEGF, HGF, Trk, Eph, AXL, LTK, TIE, ROR, DDR, RET, KLG, RYK, or MuSK receptor family.
36. The engineered protein of claim 35, wherein the receptor tyrosine kinase is an EGF receptor.
37. The engineered protein of claim 30, wherein the heterologous protein is a target- specific protein scaffold.
38. The engineered protein of claim 37, wherein the target-specific protein scaffold is an immunoglobulin or a biologically active fragment or other variant thereof.
39. The engineered protein of claim 38, wherein the immunoglobulin is the antibody cetuximab or the antibody panitumumab.
40. The engineered protein of claim 37, wherein the target-specific protein scaffold is a designed ankyrin repeat protein, an anticalin, or an affibody.
41. The engineered protein of claim 30 or claim 37, further comprising an accessory sequence.
42. The engineered protein of claim 41, wherein the accessory sequence is an amino acid sequence that prolongs the circulating half- life of the genetically modified Fn domain or an engineered protein of which it is a part; an amino acid sequence that facilitates isolation or purification of the engineered protein; an amino acid sequence that facilitates the bond between one part of the engineered protein and another or between the engineered protein and another moiety; an imaging agent or an amino acid sequence that can be detected and thereby serves as a label, marker, or tag; or an amino acid sequence that is toxic.
43. The engineered protein of claim 38, wherein multiple genetically modified
fibronectin domains are fused, directly or via a linker, to the amino terminus of a heavy chain or an amino terminus of a light chain of the immunoglobulin.
44. The engineered protein of claim 38, wherein one or more genetically modified fibronectin domains are fused, directly or via a linker, to the amino terminus of a heavy chain and one or more genetically modified fibronectin domains are fused, directly or via a linker, to the carboxy terminus of the heavy chain of the immunoglobulin.
45. The engineered protein of claim 38, wherein one or more genetically modified fibronectin domains are fused, directly or via a linker, to the amino terminus of a light chain and one or more genetically modified fibronectin domains are fused, directly or via a linker, to the carboxy terminus of the light chain of the immunoglobulin.
46. The engineered protein of claim 38, wherein one or more genetically modified fϊbronectin domains are fused, directly or via a linker, to either the amino or carboxy terminus or to both termini of a heavy chain and one or more genetically modified fibronectin domains are fused, directly or via a linker, to either the amino or carboxy terminus or to both termini of the light chain of the immunoglobulin.
47. The engineered protein of any of claims 38-46, wherein the immunoglobulin is of the IgG class.
48. A nucleic acid comprising a sequence encoding the engineered protein of any of claims 30-47.
49. A vector comprising the nucleic acid sequence of claim 48.
50. The vector of claim 44, wherein the vector is a plasmid or a cosmid or other viral vector.
51. A cell comprising the vector of claim 49 or claim 50.
52. A pharmaceutically acceptable composition comprising the engineered protein of any of claims 30-47.
53. A method of treating a patient who has cancer, the method comprising identifying a patient in need of treatment and administering to the patient a therapeutically effective amount of the pharmaceutically acceptable composition of claim 52, wherein the engineered protein
specifically binds at least one epitope on a protein whose expression or activity is associated with the cancer.
54. The method of claim 53, wherein the protein is an EGF receptor.
55. The method of claim 53, wherein the cancer is breast cancer, bladder cancer, non- small-cell lung cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, ovarian cancer, cervical cancer, lung cancer, esophageal cancer, glioblastomas, and pancreatic cancer.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10808832.9A EP2464663A4 (en) | 2009-08-13 | 2010-08-13 | Engineered proteins including mutant fibronectin domains |
US13/390,086 US20120270797A1 (en) | 2009-08-13 | 2010-08-13 | Engineered proteins including mutant fibronectin domains |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23382009P | 2009-08-13 | 2009-08-13 | |
US61/233,820 | 2009-08-13 | ||
US37037710P | 2010-08-03 | 2010-08-03 | |
US61/370,377 | 2010-08-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011020033A2 true WO2011020033A2 (en) | 2011-02-17 |
WO2011020033A3 WO2011020033A3 (en) | 2011-06-23 |
Family
ID=43586875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/045490 WO2011020033A2 (en) | 2009-08-13 | 2010-08-13 | Engineered proteins including mutant fibronectin domains |
Country Status (3)
Country | Link |
---|---|
US (1) | US20120270797A1 (en) |
EP (1) | EP2464663A4 (en) |
WO (1) | WO2011020033A2 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012024659A2 (en) * | 2010-08-20 | 2012-02-23 | Massachusetts Institute Of Technology | Antibody-based constructs directed against tyrosine kinase receptors |
EP2638916A1 (en) | 2012-03-16 | 2013-09-18 | Covagen AG | Novel binding molecules with antitumoral activity |
WO2013135588A1 (en) * | 2012-03-16 | 2013-09-19 | Covagen Ag | Novel binding molecules with antitumoral activity |
US8633297B2 (en) | 2007-10-31 | 2014-01-21 | Medimmune, Llc | Protein scaffolds |
US8728483B2 (en) | 2008-05-22 | 2014-05-20 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
WO2014126871A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
WO2014126884A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | High ph protein refolding methods |
US8853154B2 (en) | 2012-09-13 | 2014-10-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
US8969289B2 (en) | 2010-05-03 | 2015-03-03 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
US9017655B2 (en) | 2008-11-24 | 2015-04-28 | Bristol-Myers Squibb Company | Bispecific EGFR/IGFIR binding molecules |
WO2015143156A1 (en) | 2014-03-20 | 2015-09-24 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
US9212231B2 (en) | 2010-04-13 | 2015-12-15 | Medimmune, Llc | TRAIL R2-specific multimeric scaffolds |
US9234028B2 (en) | 2008-02-14 | 2016-01-12 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
US9328157B2 (en) | 2003-12-05 | 2016-05-03 | Bristol-Myers Squibb Company | Inhibitors of type 2 vascular endothelial growth factor receptors |
WO2016086036A2 (en) | 2014-11-25 | 2016-06-02 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of biologics |
US9416170B2 (en) | 2011-10-31 | 2016-08-16 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
US9469676B2 (en) | 2011-04-13 | 2016-10-18 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
US10221232B2 (en) | 2006-11-22 | 2019-03-05 | Bristol-Myers Squibb Company | Methods of treating cancer by administering IGF-IR binding molecules |
US10442851B2 (en) | 2014-03-20 | 2019-10-15 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type III domains |
US10766946B2 (en) | 2015-09-23 | 2020-09-08 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type III domains |
US10787498B2 (en) | 2013-02-06 | 2020-09-29 | Bristol-Myers Squibb Company | Fibronectin type III domain proteins with enhanced solubility |
US10898538B2 (en) | 2011-05-17 | 2021-01-26 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
WO2021174045A1 (en) | 2020-02-28 | 2021-09-02 | Bristol-Myers Squibb Company | Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof |
US11447538B2 (en) | 2013-02-01 | 2022-09-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
US11555062B2 (en) | 2011-10-11 | 2023-01-17 | Viela Bio, Inc. | Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer |
CN115976031A (en) * | 2022-07-18 | 2023-04-18 | 烟台市华昕生物医药科技有限公司 | Recombinant fibronectin and application thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9029513B2 (en) * | 2010-06-04 | 2015-05-12 | Toagosei Co. Ltd. | Anti-EGFR antibody and use thereof |
JP7104703B2 (en) | 2016-12-14 | 2022-07-21 | ヤンセン バイオテツク,インコーポレーテツド | CD8A-binding fibronectin type III domain |
EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
WO2018111976A1 (en) * | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
EP3728310A1 (en) * | 2017-12-18 | 2020-10-28 | VIIV Healthcare UK (No.5) Limited | Antigen binding polypeptides |
JP2022551204A (en) | 2019-10-14 | 2022-12-07 | アロ・バイオセラピューティクス・カンパニー | CD71-binding fibronectin type III domain |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030028071A1 (en) | 2001-07-25 | 2003-02-06 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US20030032995A1 (en) | 2001-07-25 | 2003-02-13 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2154535A1 (en) * | 1998-12-10 | 2010-02-17 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
US20050142539A1 (en) * | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
SG149004A1 (en) * | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
US20110009323A1 (en) * | 2007-06-15 | 2011-01-13 | Vasgene Therapeutics, Inc. | Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth |
WO2009018386A1 (en) * | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
WO2009102421A2 (en) * | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
PT2274331E (en) * | 2008-05-02 | 2014-02-27 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
PE20091931A1 (en) * | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | MULTIVALENT FIBRONECTIN-BASED FRAME DOMAIN PROTEINS |
CN103380143B (en) * | 2010-12-22 | 2016-01-06 | 百时美施贵宝公司 | In conjunction with the scaffold domains protein based on fibronectin of IL-23 |
-
2010
- 2010-08-13 EP EP10808832.9A patent/EP2464663A4/en not_active Withdrawn
- 2010-08-13 US US13/390,086 patent/US20120270797A1/en not_active Abandoned
- 2010-08-13 WO PCT/US2010/045490 patent/WO2011020033A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030028071A1 (en) | 2001-07-25 | 2003-02-06 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US20030032995A1 (en) | 2001-07-25 | 2003-02-13 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
Non-Patent Citations (8)
Title |
---|
BOWLEY ET AL., PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 20, 2007, pages 81 - 90 |
HACKEL ET AL., J. MOL. BIOL, vol. 381, 2008, pages 1238 - 1252 |
HACKEL; WITTRUP: "Protein Engineering Handbook", vol. I, 2009, WILEY-VCH |
HOOGENBOOM, NAT. BIOTECHNOL, vol. 23, 2005, pages 1105 - 1116 |
PARKER ET AL., PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 18, 2005, pages 435 - 444 |
See also references of EP2464663A4 |
SHUSTA ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 292, 1999, pages 949 - 956 |
VANANTWERP; WITTRUP, BIOTECHNOL, PROG., vol. 16, 2000, pages 31 - 37 |
Cited By (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9862758B2 (en) | 2003-12-05 | 2018-01-09 | Bristol-Myers Quibb Company | Inhibitors of type 2 vascular endothelial growth factor receptors |
US9328157B2 (en) | 2003-12-05 | 2016-05-03 | Bristol-Myers Squibb Company | Inhibitors of type 2 vascular endothelial growth factor receptors |
US10995131B2 (en) | 2003-12-05 | 2021-05-04 | Bristol-Myers Squibb Company | Libraries of modified fibronectin type III tenth domain-containing polypeptides |
US10221232B2 (en) | 2006-11-22 | 2019-03-05 | Bristol-Myers Squibb Company | Methods of treating cancer by administering IGF-IR binding molecules |
US11149077B2 (en) | 2006-11-22 | 2021-10-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
US8633297B2 (en) | 2007-10-31 | 2014-01-21 | Medimmune, Llc | Protein scaffolds |
US9176129B2 (en) | 2007-10-31 | 2015-11-03 | Medimmune, Llc | Protein scaffolds |
US10781247B2 (en) | 2008-02-14 | 2020-09-22 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
US9234028B2 (en) | 2008-02-14 | 2016-01-12 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
US9920108B2 (en) | 2008-02-14 | 2018-03-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
US9902762B2 (en) | 2008-05-22 | 2018-02-27 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
US10774130B2 (en) | 2008-05-22 | 2020-09-15 | Bristol-Myers Squibb Company | Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins |
US8728483B2 (en) | 2008-05-22 | 2014-05-20 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
US10183987B2 (en) | 2008-11-24 | 2019-01-22 | Bristol-Myers Squibb Company | Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules |
US9017655B2 (en) | 2008-11-24 | 2015-04-28 | Bristol-Myers Squibb Company | Bispecific EGFR/IGFIR binding molecules |
US9771411B2 (en) | 2008-11-24 | 2017-09-26 | Bristol-Myers Squibb Company | Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules |
US10954286B2 (en) | 2008-11-24 | 2021-03-23 | Bristol-Myers Squibb Company | Bispecific EGFR/IGFIR binding molecules |
US9212231B2 (en) | 2010-04-13 | 2015-12-15 | Medimmune, Llc | TRAIL R2-specific multimeric scaffolds |
US10934572B2 (en) | 2010-05-03 | 2021-03-02 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
US8969289B2 (en) | 2010-05-03 | 2015-03-03 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
US10221438B2 (en) | 2010-05-03 | 2019-03-05 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
US9540424B2 (en) | 2010-05-03 | 2017-01-10 | Bristol-Myers Squibb Company | Serum albumin binding molecules |
US10273286B2 (en) | 2010-05-26 | 2019-04-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
US11161893B2 (en) | 2010-05-26 | 2021-11-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
US9464136B2 (en) | 2010-08-20 | 2016-10-11 | Massachusetts Institute Of Technology | Antibody-based constructs directed against tyrosine kinase receptors |
WO2012024659A2 (en) * | 2010-08-20 | 2012-02-23 | Massachusetts Institute Of Technology | Antibody-based constructs directed against tyrosine kinase receptors |
WO2012024659A3 (en) * | 2010-08-20 | 2012-10-26 | Massachusetts Institute Of Technology | Antibody-based constructs directed against tyrosine kinase receptors |
US9469676B2 (en) | 2011-04-13 | 2016-10-18 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
US10214579B2 (en) | 2011-04-13 | 2019-02-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
US10898538B2 (en) | 2011-05-17 | 2021-01-26 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
US11555062B2 (en) | 2011-10-11 | 2023-01-17 | Viela Bio, Inc. | Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer |
US11408093B2 (en) | 2011-10-31 | 2022-08-09 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
US9522951B2 (en) | 2011-10-31 | 2016-12-20 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
US11279751B2 (en) | 2011-10-31 | 2022-03-22 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
US9765132B2 (en) | 2011-10-31 | 2017-09-19 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
US9416170B2 (en) | 2011-10-31 | 2016-08-16 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
US10604556B2 (en) | 2011-10-31 | 2020-03-31 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
US10464995B2 (en) | 2011-10-31 | 2019-11-05 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
JP2015516801A (en) * | 2012-03-16 | 2015-06-18 | コヴァジェン アクチェン ゲゼルシャフト | Novel binding molecules with antitumor activity |
US9593314B2 (en) | 2012-03-16 | 2017-03-14 | Covagen Ag | Binding molecules with antitumoral activity |
EP2638916A1 (en) | 2012-03-16 | 2013-09-18 | Covagen AG | Novel binding molecules with antitumoral activity |
WO2013135588A1 (en) * | 2012-03-16 | 2013-09-19 | Covagen Ag | Novel binding molecules with antitumoral activity |
US8993265B2 (en) | 2012-09-13 | 2015-03-31 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
US8933199B2 (en) | 2012-09-13 | 2015-01-13 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
US10406212B2 (en) | 2012-09-13 | 2019-09-10 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
US11813315B2 (en) | 2012-09-13 | 2023-11-14 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
US9493546B2 (en) | 2012-09-13 | 2016-11-15 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
US9662373B2 (en) | 2012-09-13 | 2017-05-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
US10245302B2 (en) | 2012-09-13 | 2019-04-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
US8853154B2 (en) | 2012-09-13 | 2014-10-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
US11447538B2 (en) | 2013-02-01 | 2022-09-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
US11512124B2 (en) | 2013-02-06 | 2022-11-29 | Bristol-Myers Squibb Company | Fibronectin type III domain proteins with enhanced solubility |
US10787498B2 (en) | 2013-02-06 | 2020-09-29 | Bristol-Myers Squibb Company | Fibronectin type III domain proteins with enhanced solubility |
EP3617220A1 (en) | 2013-02-12 | 2020-03-04 | Bristol-Myers Squibb Company | High ph protein refolding methods |
US10183967B2 (en) | 2013-02-12 | 2019-01-22 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
EP3744728A1 (en) | 2013-02-12 | 2020-12-02 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
US11345722B2 (en) | 2013-02-12 | 2022-05-31 | Bristol-Myers Squibb Company | High pH protein refolding methods |
WO2014126884A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | High ph protein refolding methods |
WO2014126871A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
US11053278B2 (en) | 2013-02-12 | 2021-07-06 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
EP3299378A1 (en) | 2013-02-12 | 2018-03-28 | Bristol-Myers Squibb Company | High ph protein refolding methods |
US10065987B2 (en) | 2013-02-12 | 2018-09-04 | Bristol-Myers Squibb Company | High pH protein refolding methods |
WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
US11407815B2 (en) | 2014-03-20 | 2022-08-09 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
US11203630B2 (en) | 2014-03-20 | 2021-12-21 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type III domains |
EP3647322A1 (en) | 2014-03-20 | 2020-05-06 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
WO2015143156A1 (en) | 2014-03-20 | 2015-09-24 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
US10450363B2 (en) | 2014-03-20 | 2019-10-22 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
US10442851B2 (en) | 2014-03-20 | 2019-10-15 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type III domains |
WO2016086036A2 (en) | 2014-11-25 | 2016-06-02 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of biologics |
EP4218832A2 (en) | 2014-11-25 | 2023-08-02 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain |
US10766946B2 (en) | 2015-09-23 | 2020-09-08 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type III domains |
US11434275B2 (en) | 2015-09-23 | 2022-09-06 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type III domains |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
WO2021174045A1 (en) | 2020-02-28 | 2021-09-02 | Bristol-Myers Squibb Company | Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof |
CN115976031A (en) * | 2022-07-18 | 2023-04-18 | 烟台市华昕生物医药科技有限公司 | Recombinant fibronectin and application thereof |
Also Published As
Publication number | Publication date |
---|---|
EP2464663A4 (en) | 2013-05-29 |
US20120270797A1 (en) | 2012-10-25 |
EP2464663A2 (en) | 2012-06-20 |
WO2011020033A3 (en) | 2011-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120270797A1 (en) | Engineered proteins including mutant fibronectin domains | |
US20220315652A1 (en) | Anti p2x7 receptor antibodies and fragments thereof | |
EP3218411B1 (en) | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use | |
JP6410724B2 (en) | Binding protein comprising at least two anti-HER2 repeat domains | |
JP5982698B2 (en) | Novel monoclonal antibody that specifically binds to DLL4 and use thereof | |
WO2011075789A1 (en) | Antibodies to non-functional oligomeric p2x7 receptors | |
CN111269315B (en) | Monoclonal antibodies against BCMA | |
KR102523150B1 (en) | Anti-tenascin c antibodies and uses thereof | |
KR20160130435A (en) | Insulin-like growth factor 1 receptor-specific antibodies and uses thereof | |
US20220119546A1 (en) | Plectin-1 binding antibodies and uses thereof | |
WO2021160138A1 (en) | Antigen binding protein of anti-epidermal growth factor receptor and application thereof | |
KR20190143826A (en) | Cell/tissue-specific cell-penetrating antibodies | |
WO2024012539A1 (en) | Anti-nectin-4 antibody and use thereof | |
CN111378040B (en) | Antibody for detecting multiple malignant tumor cells and application thereof | |
WO2019075392A1 (en) | Antigen-binding protein constructs and uses thereof | |
CN117700557B (en) | Antibody or antigen binding fragment specifically binding to folate receptor alpha | |
CN110291110B (en) | Antibodies that specifically bind to PAUF proteins and uses thereof | |
KR20140138533A (en) | A monoclonal antibody for IGF-1R and pharmaceutical composition comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10808832 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010808832 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010808832 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13390086 Country of ref document: US |